CA2356289A1 - Organophosphorous compounds and use thereof - Google Patents
Organophosphorous compounds and use thereof Download PDFInfo
- Publication number
- CA2356289A1 CA2356289A1 CA002356289A CA2356289A CA2356289A1 CA 2356289 A1 CA2356289 A1 CA 2356289A1 CA 002356289 A CA002356289 A CA 002356289A CA 2356289 A CA2356289 A CA 2356289A CA 2356289 A1 CA2356289 A1 CA 2356289A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- group
- unsubstituted
- alkyl
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000002903 organophosphorus compounds Chemical class 0.000 title claims abstract description 18
- 229940058344 antitrematodals organophosphorous compound Drugs 0.000 title 1
- 241000894006 Bacteria Species 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 239000002253 acid Substances 0.000 claims abstract description 23
- 241000700605 Viruses Species 0.000 claims abstract description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 21
- 125000001424 substituent group Chemical group 0.000 claims abstract description 21
- 244000045947 parasite Species 0.000 claims abstract description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 14
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims abstract description 11
- 208000015181 infectious disease Diseases 0.000 claims abstract description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 10
- 241000233866 Fungi Species 0.000 claims abstract description 9
- 238000011321 prophylaxis Methods 0.000 claims abstract description 6
- 125000004185 ester group Chemical group 0.000 claims abstract description 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 239000003899 bactericide agent Substances 0.000 claims abstract description 4
- 239000000417 fungicide Substances 0.000 claims abstract description 4
- 239000004009 herbicide Substances 0.000 claims abstract description 4
- -1 hydroxy, amino Chemical group 0.000 claims description 87
- 239000013543 active substance Substances 0.000 claims description 29
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical group 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- 125000004043 oxo group Chemical group O=* 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 150000003863 ammonium salts Chemical class 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 201000004792 malaria Diseases 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 6
- 230000000855 fungicidal effect Effects 0.000 claims description 6
- 125000004437 phosphorous atom Chemical group 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 208000000230 African Trypanosomiasis Diseases 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 5
- 150000003868 ammonium compounds Chemical class 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 208000029080 human African trypanosomiasis Diseases 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 230000000737 periodic effect Effects 0.000 claims description 5
- 201000002612 sleeping sickness Diseases 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 230000002363 herbicidal effect Effects 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 3
- 206010001986 Amoebic dysentery Diseases 0.000 claims description 3
- 208000024699 Chagas disease Diseases 0.000 claims description 3
- 208000003495 Coccidiosis Diseases 0.000 claims description 3
- 208000008953 Cryptosporidiosis Diseases 0.000 claims description 3
- 206010011502 Cryptosporidiosis infection Diseases 0.000 claims description 3
- 206010023076 Isosporiasis Diseases 0.000 claims description 3
- 208000004554 Leishmaniasis Diseases 0.000 claims description 3
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims description 3
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims description 3
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 3
- 208000005448 Trichomonas Infections Diseases 0.000 claims description 3
- 206010044620 Trichomoniasis Diseases 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 208000007456 balantidiasis Diseases 0.000 claims description 3
- 201000006592 giardiasis Diseases 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 3
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical class O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 claims description 3
- 201000000317 pneumocystosis Diseases 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000003367 polycyclic group Chemical group 0.000 claims description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 28
- 241000282414 Homo sapiens Species 0.000 abstract description 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 85
- 239000000243 solution Substances 0.000 description 67
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 239000003921 oil Substances 0.000 description 35
- 235000019198 oils Nutrition 0.000 description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 32
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 26
- 239000002904 solvent Substances 0.000 description 26
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 24
- 238000001816 cooling Methods 0.000 description 23
- 239000000126 substance Substances 0.000 description 22
- 241000282412 Homo Species 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 19
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 239000008346 aqueous phase Substances 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 229910052786 argon Inorganic materials 0.000 description 13
- 239000012043 crude product Substances 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 12
- 230000008029 eradication Effects 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 159000000000 sodium salts Chemical class 0.000 description 7
- 229960002317 succinimide Drugs 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 150000001335 aliphatic alkanes Chemical group 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- BVMUOARBOUMJBI-UHFFFAOYSA-N 5-(2-dimethoxyphosphorylethyl)pyrrolidin-2-one Chemical compound COP(=O)(OC)CCC1CCC(=O)N1 BVMUOARBOUMJBI-UHFFFAOYSA-N 0.000 description 4
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- LZKLEUSNFMFXEA-UHFFFAOYSA-N 1-(oxan-2-yloxy)-3-phenylpropan-2-amine Chemical compound C=1C=CC=CC=1CC(N)COC1CCCCO1 LZKLEUSNFMFXEA-UHFFFAOYSA-N 0.000 description 3
- 206010059313 Anogenital warts Diseases 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 3
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241001631646 Papillomaviridae Species 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 208000000260 Warts Diseases 0.000 description 3
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 3
- 150000003851 azoles Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229960000860 dapsone Drugs 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960003722 doxycycline Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000006747 infectious mononucleosis Diseases 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000003154 papilloma Diseases 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- JFLGQHWYBATIIT-UHFFFAOYSA-N 1-(2-trimethylsilylethoxy)pyrrolidin-2-one Chemical compound C[Si](CCON1C(CCC1)=O)(C)C JFLGQHWYBATIIT-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WHXCYZDDCFQVNR-UHFFFAOYSA-N 2-(2-dimethoxyphosphorylethyl)pyrrolidine Chemical compound COP(=O)(OC)CCC1CCCN1 WHXCYZDDCFQVNR-UHFFFAOYSA-N 0.000 description 2
- MWHJWRGVJKZREO-UHFFFAOYSA-N 2-(2-isocyano-3-phenylpropoxy)oxane Chemical compound C=1C=CC=CC=1CC([N+]#[C-])COC1CCCCO1 MWHJWRGVJKZREO-UHFFFAOYSA-N 0.000 description 2
- XGLVDUUYFKXKPL-UHFFFAOYSA-N 2-(2-methoxyethoxy)-n,n-bis[2-(2-methoxyethoxy)ethyl]ethanamine Chemical compound COCCOCCN(CCOCCOC)CCOCCOC XGLVDUUYFKXKPL-UHFFFAOYSA-N 0.000 description 2
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 2
- STVVMTBJNDTZBF-UHFFFAOYSA-N 2-amino-3-phenylpropan-1-ol Chemical compound OCC(N)CC1=CC=CC=C1 STVVMTBJNDTZBF-UHFFFAOYSA-N 0.000 description 2
- VGBKPOJELYHZDW-UHFFFAOYSA-N 3-(2-dimethoxyphosphorylethyl)-1-hydroxy-7-methylpurine-2,6-dione Chemical compound O=C1N(O)C(=O)N(CCP(=O)(OC)OC)C2=C1N(C)C=N2 VGBKPOJELYHZDW-UHFFFAOYSA-N 0.000 description 2
- VSNLUCYOJCLUDH-UHFFFAOYSA-N 3-(2-dimethoxyphosphorylethyl)-7-methylpurine-2,6-dione Chemical compound O=C1NC(=O)N(CCP(=O)(OC)OC)C2=C1N(C)C=N2 VSNLUCYOJCLUDH-UHFFFAOYSA-N 0.000 description 2
- NORGAQQNXXECPC-UHFFFAOYSA-N 3-(bromomethyl)-3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1=CC=C2C(=O)NC(CBr)CC2=C1 NORGAQQNXXECPC-UHFFFAOYSA-N 0.000 description 2
- CHTLYANSXRWMEV-UHFFFAOYSA-N 3-(hydroxymethyl)-3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1=CC=C2C(=O)NC(CO)CC2=C1 CHTLYANSXRWMEV-UHFFFAOYSA-N 0.000 description 2
- ZZEYQBNQZKUWKY-UHFFFAOYSA-N 4-Methyl-5H-furan-2-one Chemical compound CC1=CC(=O)OC1 ZZEYQBNQZKUWKY-UHFFFAOYSA-N 0.000 description 2
- 241000349731 Afzelia bipindensis Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical group [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 2
- 229930186147 Cephalosporin Chemical group 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 2
- 241000978750 Havardia Species 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000724675 Hepatitis E virus Species 0.000 description 2
- 208000037262 Hepatitis delta Diseases 0.000 description 2
- 241000724709 Hepatitis delta virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000588621 Moraxella Species 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229910021604 Rhodium(III) chloride Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000000078 anti-malarial effect Effects 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 150000001483 arginine derivatives Chemical class 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 2
- 229960004191 artemisinin Drugs 0.000 description 2
- 229930101531 artemisinin Natural products 0.000 description 2
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 2
- 229960003159 atovaquone Drugs 0.000 description 2
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 2
- 229960002326 bithionol Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical group O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical group 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 229960003324 clavulanic acid Drugs 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229960000285 ethambutol Drugs 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960003242 halofantrine Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960003439 mebendazole Drugs 0.000 description 2
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 2
- 229960001962 mefloquine Drugs 0.000 description 2
- 201000011475 meningoencephalitis Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960001952 metrifonate Drugs 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 2
- 229960001920 niclosamide Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940124588 oral cephalosporin Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229960000462 oxamniquine Drugs 0.000 description 2
- XCGYUJZMCCFSRP-UHFFFAOYSA-N oxamniquine Chemical compound OCC1=C([N+]([O-])=O)C=C2NC(CNC(C)C)CCC2=C1 XCGYUJZMCCFSRP-UHFFFAOYSA-N 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Chemical group O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 229960002292 piperacillin Drugs 0.000 description 2
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical group [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229960002957 praziquantel Drugs 0.000 description 2
- 229960005385 proguanil Drugs 0.000 description 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229960000918 protionamide Drugs 0.000 description 2
- 229960005134 pyrantel Drugs 0.000 description 2
- YSAUAVHXTIETRK-AATRIKPKSA-N pyrantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1 YSAUAVHXTIETRK-AATRIKPKSA-N 0.000 description 2
- 229960005206 pyrazinamide Drugs 0.000 description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 2
- 229960000611 pyrimethamine Drugs 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- SONJTKJMTWTJCT-UHFFFAOYSA-K rhodium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Rh+3] SONJTKJMTWTJCT-UHFFFAOYSA-K 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229960004673 sulfadoxine Drugs 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960005314 suramin Drugs 0.000 description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 229960004546 thiabendazole Drugs 0.000 description 2
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 2
- 229960004659 ticarcillin Drugs 0.000 description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical group C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 2
- 125000005425 toluyl group Chemical group 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 239000010937 tungsten Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- UQCJFKIZCSWJEH-UHFFFAOYSA-N (1-acetyloxy-2-oxopropyl) acetate Chemical compound CC(=O)OC(C(C)=O)OC(C)=O UQCJFKIZCSWJEH-UHFFFAOYSA-N 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-L (1R,2S)-epoxypropylphosphonate(2-) Chemical compound C[C@@H]1O[C@@H]1P([O-])([O-])=O YMDXZJFXQJVXBF-STHAYSLISA-L 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- PZVCVSQSQHGBNE-UHFFFAOYSA-N (3-acetyloxy-2-oxopropyl) acetate Chemical compound CC(=O)OCC(=O)COC(C)=O PZVCVSQSQHGBNE-UHFFFAOYSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- NCCJWSXETVVUHK-ZYSAIPPVSA-N (z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C1C(SCC\N=C/N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21.CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O NCCJWSXETVVUHK-ZYSAIPPVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ZOVDWTXRLXEPEV-UHFFFAOYSA-N 1-(2-dimethoxyphosphorylethyl)-3-hydroxy-7-methylpurine-2,6-dione Chemical compound O=C1N(CCP(=O)(OC)OC)C(=O)N(O)C2=C1N(C)C=N2 ZOVDWTXRLXEPEV-UHFFFAOYSA-N 0.000 description 1
- AKFBTNQCYMSUQF-UHFFFAOYSA-N 1-(2-dimethoxyphosphorylethyl)-7-methyl-3h-purine-2,6-dione Chemical compound O=C1N(CCP(=O)(OC)OC)C(=O)NC2=C1N(C)C=N2 AKFBTNQCYMSUQF-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- CJVHLUSZUITNOF-UHFFFAOYSA-N 2-(1-hydroxy-5-oxopyrrolidin-2-yl)ethylphosphonic acid Chemical compound ON1C(CCP(O)(O)=O)CCC1=O CJVHLUSZUITNOF-UHFFFAOYSA-N 0.000 description 1
- ZKHZWCCLBFAVIE-UHFFFAOYSA-N 2-(1-hydroxy-7-methyl-2,6-dioxopurin-3-yl)ethylphosphonic acid Chemical compound OP(=O)(O)CCN1C(=O)N(O)C(=O)C2=C1N=CN2C ZKHZWCCLBFAVIE-UHFFFAOYSA-N 0.000 description 1
- AMOYMEBHYUTMKJ-UHFFFAOYSA-N 2-(2-phenylethoxy)ethylbenzene Chemical compound C=1C=CC=CC=1CCOCCC1=CC=CC=C1 AMOYMEBHYUTMKJ-UHFFFAOYSA-N 0.000 description 1
- DHZZQJWGKRBEKT-UHFFFAOYSA-N 2-(iodomethyl)-1-phenylmethoxypyrrolidine Chemical compound ICC1CCCN1OCC1=CC=CC=C1 DHZZQJWGKRBEKT-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- PZSISEFPCYMBDL-UHFFFAOYSA-N 2-bromo-3-methylpyridine Chemical compound CC1=CC=CN=C1Br PZSISEFPCYMBDL-UHFFFAOYSA-N 0.000 description 1
- LSRDTCMNGSMEEI-UHFFFAOYSA-N 2-bromo-6-(bromomethyl)pyridine Chemical compound BrCC1=CC=CC(Br)=N1 LSRDTCMNGSMEEI-UHFFFAOYSA-N 0.000 description 1
- DADDHGFITKVJIW-UHFFFAOYSA-N 2-bromo-6-(dibromomethyl)pyridine Chemical compound BrC(Br)C1=CC=CC(Br)=N1 DADDHGFITKVJIW-UHFFFAOYSA-N 0.000 description 1
- SOHDPICLICFSOP-UHFFFAOYSA-N 2-bromo-6-methylpyridine Chemical compound CC1=CC=CC(Br)=N1 SOHDPICLICFSOP-UHFFFAOYSA-N 0.000 description 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- MBHPFOPIRFPBRT-UHFFFAOYSA-N 3-(2-diethoxyphosphorylethyl)-2-hydroxy-3,4-dihydroisoquinolin-1-one Chemical compound C1=CC=C2C(=O)N(O)C(CCP(=O)(OCC)OCC)CC2=C1 MBHPFOPIRFPBRT-UHFFFAOYSA-N 0.000 description 1
- LMRJQCOMFFQSHG-UHFFFAOYSA-N 3-(2-diethoxyphosphorylethyl)-3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1=CC=C2C(=O)NC(CCP(=O)(OCC)OCC)CC2=C1 LMRJQCOMFFQSHG-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- NLJVXZFCYKWXLH-DXTIXLATSA-N 3-[(3r,6s,9s,12s,15s,17s,20s,22r,25s,28s)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23,26-nonazabicyclo[26.3.0]hentriacontan Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 NLJVXZFCYKWXLH-DXTIXLATSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YZJCCPVCZMBTHQ-UHFFFAOYSA-N 3-methyl-1-(2-trimethylsilylethoxy)pyrrolidin-2-one Chemical compound CC1CCN(OCC[Si](C)(C)C)C1=O YZJCCPVCZMBTHQ-UHFFFAOYSA-N 0.000 description 1
- DFATXMYLKPCSCX-UHFFFAOYSA-N 3-methylsuccinic anhydride Chemical compound CC1CC(=O)OC1=O DFATXMYLKPCSCX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- WLFJDUQSOVLDSR-UHFFFAOYSA-N 4,6-diaminopyrimidine-2-sulfonamide Chemical compound NC1=CC(=NC(=N1)S(=O)(=O)N)N WLFJDUQSOVLDSR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- UAIJNOFAUOSLFK-UHFFFAOYSA-N 4-diphenylphosphoryl-3-hydroxy-1h-quinolin-2-one Chemical class C12=CC=CC=C2NC(=O)C(O)=C1P(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 UAIJNOFAUOSLFK-UHFFFAOYSA-N 0.000 description 1
- YVMBAUWDIGJRNY-BESUKNQGSA-N 4o8o7q7iu4 Chemical class C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YVMBAUWDIGJRNY-BESUKNQGSA-N 0.000 description 1
- GJOHLWZHWQUKAU-UHFFFAOYSA-N 5-azaniumylpentan-2-yl-(6-methoxyquinolin-8-yl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 GJOHLWZHWQUKAU-UHFFFAOYSA-N 0.000 description 1
- KAOCDZQOVPLMID-UHFFFAOYSA-N 5-ethoxy-3-methyl-5-oxopentanoic acid Chemical compound CCOC(=O)CC(C)CC(O)=O KAOCDZQOVPLMID-UHFFFAOYSA-N 0.000 description 1
- IDCUHOXUSMHTOK-OEQYQXMYSA-N 7-[(4as,7as)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid;hydrochloride Chemical compound Cl.C12=C(Cl)C(N3C[C@H]4NCCC[C@H]4C3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 IDCUHOXUSMHTOK-OEQYQXMYSA-N 0.000 description 1
- VTPFAXRTQXEVRD-UHFFFAOYSA-N 7-methyl-3H-purine-2,6-dione Chemical compound OC1=NC(=C2N(C=NC2=N1)C)O.CN1C=NC=2NC(NC(C12)=O)=O VTPFAXRTQXEVRD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000203716 Actinomycetaceae Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000607525 Aeromonas salmonicida Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000702419 Ambidensovirus Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 241000710189 Aphthovirus Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241000701802 Aviadenovirus Species 0.000 description 1
- 241001112741 Bacillaceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606662 Bartonellaceae Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000589874 Campylobacter fetus Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000606069 Chlamydiaceae Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000186225 Corynebacterium pseudotuberculosis Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000187831 Dermatophilus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- QGLBZNZGBLRJGS-UHFFFAOYSA-N Dihydro-3-methyl-2(3H)-furanone Chemical compound CC1CCOC1=O QGLBZNZGBLRJGS-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical group N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010019771 Hepatitis F Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 206010023849 Laryngeal papilloma Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589246 Legionellaceae Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000700563 Leporipoxvirus Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000589901 Leptospiraceae Species 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241000192017 Micrococcaceae Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000700560 Molluscum contagiosum virus Species 0.000 description 1
- 241000588622 Moraxella bovis Species 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000186360 Mycobacteriaceae Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241000204034 Mycoplasmataceae Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588656 Neisseriaceae Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- ARFHIAQFJWUCFH-IZZDOVSWSA-N Nifurtimox Chemical compound CC1CS(=O)(=O)CCN1\N=C\C1=CC=C([N+]([O-])=O)O1 ARFHIAQFJWUCFH-IZZDOVSWSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 206010031068 Orchitis mumps Diseases 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 241000700639 Parapoxvirus Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000026681 Paratuberculosis Diseases 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 241000606752 Pasteurellaceae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 241000607568 Photobacterium Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000607000 Plesiomonas Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241001430313 Propionibacteriaceae Species 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000947836 Pseudomonadaceae Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 206010068956 Respiratory tract inflammation Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000606683 Rickettsiaceae Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010041047 Slow virus infection Diseases 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 241000589971 Spirochaetaceae Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 241000194018 Streptococcaceae Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000024949 Swine Erysipelas Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010021006 Tyrothricin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 241000713152 Uukuniemi virus Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000544286 Vibrio anguillarum Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607493 Vibrionaceae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
- 241001148129 Yersinia ruckeri Species 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-O [(2s,3r,4r,5s,6r)-2-[[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-4-acetyloxy-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-3-hydroxy-5-[(2s,4r,5s,6s)-4-hydroxy-4,6-dimethyl-5-(3-methylbutanoyloxy)oxan-2-yl]oxy-6-met Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H]([NH+](C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-O 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229940024554 amdinocillin Drugs 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940058934 aminoquinoline antimalarials Drugs 0.000 description 1
- 150000005010 aminoquinolines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229960001444 amodiaquine Drugs 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940058936 antimalarials diaminopyrimidines Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- XMQVYNAURODYCQ-SLFBBCNNSA-N apalcillin Chemical group C1([C@@H](NC(=O)C=2C(=C3N=CC=CC3=NC=2)O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 XMQVYNAURODYCQ-SLFBBCNNSA-N 0.000 description 1
- 229950001979 apalcillin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000006196 aroyl alkyl group Chemical group 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 229960002970 artemotil Drugs 0.000 description 1
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 description 1
- 229960002521 artenimol Drugs 0.000 description 1
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical group N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- SWJXWSAKHXBQSY-UHFFFAOYSA-N benzo(c)cinnoline Chemical compound C1=CC=C2C3=CC=CC=C3N=NC2=C1 SWJXWSAKHXBQSY-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 229960003169 biapenem Drugs 0.000 description 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical group S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-O cefepime(1+) Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-O 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical group S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical group [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical group N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229950010227 cefotiam hexetil Drugs 0.000 description 1
- VVFDMWZLBPUKTD-ZKRNHDOASA-N cefotiam hexetil ester Chemical compound O=C([C@@H](NC(=O)CC=1N=C(N)SC=1)[C@H]1SCC=2CSC=3N(N=NN=3)CCN(C)C)N1C=2C(=O)OC(C)OC(=O)OC1CCCCC1 VVFDMWZLBPUKTD-ZKRNHDOASA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229960000466 cefpirome Drugs 0.000 description 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 1
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 description 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960003202 cefsulodin Drugs 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical group N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 229960002620 cefuroxime axetil Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical group N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- ISZNZKHCRKXXAU-UHFFFAOYSA-N chlorproguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C(Cl)=C1 ISZNZKHCRKXXAU-UHFFFAOYSA-N 0.000 description 1
- 229950000764 chlorproguanil Drugs 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 229960004375 ciclopirox olamine Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960005228 clioquinol Drugs 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- PBGGNZZGJIKBMJ-UHFFFAOYSA-N di(propan-2-yl)azanide Chemical compound CC(C)[N-]C(C)C PBGGNZZGJIKBMJ-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- 229960003974 diethylcarbamazine Drugs 0.000 description 1
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 1
- 229930016266 dihydroartemisinin Natural products 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- YWWZCHLUQSHMCL-UHFFFAOYSA-N diphenyl diselenide Chemical compound C=1C=CC=CC=1[Se][Se]C1=CC=CC=C1 YWWZCHLUQSHMCL-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940042400 direct acting antivirals phosphonic acid derivative Drugs 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- SDIXRDNYIMOKSG-UHFFFAOYSA-L disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 208000000292 ehrlichiosis Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 201000004306 epidermodysplasia verruciformis Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- 229960002878 flomoxef Drugs 0.000 description 1
- UHRBTBZOWWGKMK-DOMZBBRYSA-N flomoxef Chemical group O([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC(F)F)OC)CC=1CSC1=NN=NN1CCO UHRBTBZOWWGKMK-DOMZBBRYSA-N 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229940074076 glycerol formal Drugs 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000002271 gyrase inhibitor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001553 hepatotropic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 201000000089 larynx squamous papilloma Diseases 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001728 melarsoprol Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical group N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 229960002644 nifurtimox Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- ZDNNDTUAVSQNGB-UHFFFAOYSA-N o-(2-trimethylsilylethyl)hydroxylamine;hydrochloride Chemical compound Cl.C[Si](C)(C)CCON ZDNNDTUAVSQNGB-UHFFFAOYSA-N 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 150000003007 phosphonic acid derivatives Chemical class 0.000 description 1
- 150000003008 phosphonic acid esters Chemical class 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960005179 primaquine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- HVVNJUAVDAZWCB-UHFFFAOYSA-N prolinol Chemical compound OCC1CCCN1 HVVNJUAVDAZWCB-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 description 1
- DJUFPMUQJKWIJB-UHFFFAOYSA-N pyronaridine Chemical compound C12=NC(OC)=CC=C2N=C2C=C(Cl)C=CC2=C1NC(C=C(CN1CCCC1)C=1O)=CC=1CN1CCCC1 DJUFPMUQJKWIJB-UHFFFAOYSA-N 0.000 description 1
- 229950011262 pyronaridine Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- HMEYVGGHISAPJR-IAHYZSEUSA-N rolitetracycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCCC1 HMEYVGGHISAPJR-IAHYZSEUSA-N 0.000 description 1
- 229960005009 rolitetracycline Drugs 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 description 1
- 229960001567 sodium stibogluconate Drugs 0.000 description 1
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229960003865 tazobactam Drugs 0.000 description 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical group N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- ODKYYBOHSVLGNU-IAGONARPSA-N terizidone Chemical compound O=C1NOCC1\N=C\C(C=C1)=CC=C1\C=N\C1C(=O)NOC1 ODKYYBOHSVLGNU-IAGONARPSA-N 0.000 description 1
- 229960003457 terizidone Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- RYVBINGWVJJDPU-UHFFFAOYSA-M tributyl(hexadecyl)phosphanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[P+](CCCC)(CCCC)CCCC RYVBINGWVJJDPU-UHFFFAOYSA-M 0.000 description 1
- DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960003281 tyrothricin Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000007964 xanthones Chemical class 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
- A01N57/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds
- A01N57/24—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds containing heterocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention relates to organo-phosphorus compounds of formula (I), wherein A
is selected from the group consisting of a (C1-9) alkylene radical, -C-O-C-and -C-N-C- or A corresponds to formula (II), wherein one or more carbon atoms selected from the group consisting of C3, C4, C5 and their substituents can also be absent and at least one of the substituents of B1 to B10 is a C3-8-cycloalkyl-(C0-9)-alkyl group in which R1 is selected from the group consisting of five and six membered heterocycles having at least one nitrogen atom in the ring or polycyclic carbon atoms containing one of said heterocycles, wherein at least one of said nitrogen atoms belongs to a hydroxamic acid group or a hydroxamic acid ester group. The invention also relates to the utilization of the above-mentioned compounds in the therapeutic and prophylactic treatment of infections in human beings and animals caused by virus, bacteria, fungi and parasites and as fungicides, bactericides and herbicides in plants.
is selected from the group consisting of a (C1-9) alkylene radical, -C-O-C-and -C-N-C- or A corresponds to formula (II), wherein one or more carbon atoms selected from the group consisting of C3, C4, C5 and their substituents can also be absent and at least one of the substituents of B1 to B10 is a C3-8-cycloalkyl-(C0-9)-alkyl group in which R1 is selected from the group consisting of five and six membered heterocycles having at least one nitrogen atom in the ring or polycyclic carbon atoms containing one of said heterocycles, wherein at least one of said nitrogen atoms belongs to a hydroxamic acid group or a hydroxamic acid ester group. The invention also relates to the utilization of the above-mentioned compounds in the therapeutic and prophylactic treatment of infections in human beings and animals caused by virus, bacteria, fungi and parasites and as fungicides, bactericides and herbicides in plants.
Description
WO 00/37477 Amendments PCT/EP99/10274 Organophosphorus compounds and use thereof This invention relates to organophosphorus compounds, to the salts, esters and amides thereof and to the use thereof for the therapeutic and prophylactic treatment of infections in humans and animals which are caused by viruses, bacteria, fungi and parasites, to the use thereof as a fungicide, bactericide and herbicide in plants. According to the invention, the organophosphorus compounds comprise phosphinoyl derivatives, phosphinic acid derivatives and phosphonic acid derivatives.
3-Hydroxy-2-oxo-4-dimethylphosphono- and 3-hydroxy-2-oxo-4-diphenylphosphinyl-1,2-dihydroquinolines and the production thereof are described in Tetrahedron Letters, no. 38, 1972, pages 3979-3982.
N-Substituted alkylaminophosphates are described in Chemical Abstracts, vol.
093, no. 19, 10''' November 1989 and Curr. Chemother. Infect. Dis. Proc. Int. Congr.
Chemother., 11 ~';
1980; vol. 1; pages 355-8, in Chemical Abstracts, vol. 105, no. 19, 10'h November 1986 and JP 61 106504 A, in US-A-4206 156, in US-A-4 693 742 and in WO 99 525 15 A.
These compounds are described as suitable for the treatment of bacterial infections.
A furthermore describes the use thereof in viral, fungicidal and parasitic infections.
In order to widen the range of options for treating humans and animals, there is an urgent requirement to provide agents which are not only highly active but, unlike other pharmaceutical preparations, also exhibit reduced side-effects and thus constitute a reduced risk to human health.
The object of the present invention is accordingly to provide a substance which is universally usable in infections by viruses, bacteria, fungi and parasites in humans and animals and which meets the above-stated requirements.
This object is utterly surprisingly achieved by the group of substances defined in claim 1. This group of substances exhibits antiinfective action against viruses, bacteria, fungi and uni- and multicellular parasites. Fungicidal, bactericidal and herbicidal action has also been observed in plants.
WO 00/37477 Amendments PCT/EP99/10274 - la-The organophosphorus compounds according to the invention are of the general formula (I):
O
I I
R1_A_P_R3 C I ) I
wherein A is selected from the group which consists of a (C1_9) alkylene residue, which may comprise one or more double bonds and may be substituted with hydroxy, halogen, amino, oxo groups with branched or unbranched C1_9 alkyl groups and CZ_9 alkenyl groups, wherein the C1_9 alkyl groups and CZ_9 alkenyl groups may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, -C-O-C- and -C-N-C-, wherein the carbon atoms of -C-O-C-and -C-N-C- may be substituted with an alkyl having up to 7 carbon atoms or hydroxy groups, or in which A is of the following formula (II):
3-Hydroxy-2-oxo-4-dimethylphosphono- and 3-hydroxy-2-oxo-4-diphenylphosphinyl-1,2-dihydroquinolines and the production thereof are described in Tetrahedron Letters, no. 38, 1972, pages 3979-3982.
N-Substituted alkylaminophosphates are described in Chemical Abstracts, vol.
093, no. 19, 10''' November 1989 and Curr. Chemother. Infect. Dis. Proc. Int. Congr.
Chemother., 11 ~';
1980; vol. 1; pages 355-8, in Chemical Abstracts, vol. 105, no. 19, 10'h November 1986 and JP 61 106504 A, in US-A-4206 156, in US-A-4 693 742 and in WO 99 525 15 A.
These compounds are described as suitable for the treatment of bacterial infections.
A furthermore describes the use thereof in viral, fungicidal and parasitic infections.
In order to widen the range of options for treating humans and animals, there is an urgent requirement to provide agents which are not only highly active but, unlike other pharmaceutical preparations, also exhibit reduced side-effects and thus constitute a reduced risk to human health.
The object of the present invention is accordingly to provide a substance which is universally usable in infections by viruses, bacteria, fungi and parasites in humans and animals and which meets the above-stated requirements.
This object is utterly surprisingly achieved by the group of substances defined in claim 1. This group of substances exhibits antiinfective action against viruses, bacteria, fungi and uni- and multicellular parasites. Fungicidal, bactericidal and herbicidal action has also been observed in plants.
WO 00/37477 Amendments PCT/EP99/10274 - la-The organophosphorus compounds according to the invention are of the general formula (I):
O
I I
R1_A_P_R3 C I ) I
wherein A is selected from the group which consists of a (C1_9) alkylene residue, which may comprise one or more double bonds and may be substituted with hydroxy, halogen, amino, oxo groups with branched or unbranched C1_9 alkyl groups and CZ_9 alkenyl groups, wherein the C1_9 alkyl groups and CZ_9 alkenyl groups may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, -C-O-C- and -C-N-C-, wherein the carbon atoms of -C-O-C-and -C-N-C- may be substituted with an alkyl having up to 7 carbon atoms or hydroxy groups, or in which A is of the following formula (II):
-2-_~ 1_ ~2_ ~3_~ 4_~ 5_ (II) wherein one or more of the carbon atoms selected from the group C3, C4, C;, together with their substituents, may also be absent, and at least one substituent present in the range from B1 to Blo is a C3_g-cycloalkyl-(Co_9)-alkyl group, wherein both the C3_8 cycloalkyl group and the Co_9 alkyl group may comprise one or more double bonds and one or two carbon atoms of the cycloalkyl group may be replaced by nitrogen, oxygen or sulfur atoms, and wherein both the cycloalkyl group and the alkyl group may be substituted with hydroxy, halogen, amino, oxo groups with branched or unbranched C1_9 alkyl groups and Cz_9 alkenyl groups, wherein the C1_9 alkyl groups and Cz_9 alkenyl groups may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, and the remaining substituents B 1 to B to present are selected from the group which consists of hydrogen, hydroxy, halogen, amino groups, C1_zb alkyl residues, C,_zb alkoxy residues, C1_z6-alkoxy-C1_z6-alkyl residues or both substituents of a C atom together form an oxo group, wherein each C1_z6 alkyl residue and each Cl_z6 alkoxy residue may be branched or unbranched and be saturated or unsaturated with one or more double bonds and may be substituted with hydroxy, amino, halogen and oxo groups, in which R1 is selected from the group which consists of 5- and 6-membered heterocycles with at least one ring nitrogen atom or a polycyclic carbon with at least one of these heterocycles, wherein at least one of these nitrogen atoms belongs to a hydroxamic acid group or a hydroxamic acid ester group, and may be saturated or unsaturated with one or more double or triple bonds and may thus also be aromatic and may be substituted with hydroxy, halogen, amino, oxo groups and with branched or unbranched C1_9 alkyl groups and Cz_9 alkenyl groups, wherein the CI_9 alkyl groups and Cz_9 alkenyl groups may be saturated or unsaturated with one or more double or triple bonds and may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, wherein the nitrogen atom of the hydroxamic acid group or hydroxamic acid ester group is substituted with OR; and R; is selected from the group which consists of hydrogen, substituted and unsubstituted C1_9 alkyl, substituted and unsubstituted hydroxy-C1_9-alkyl, substituted and unsubstituted C1_9 alkenyl, substituted and unsubstituted C1_9 alkynyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic residue, in which R3 and R4 are identical or different and are selected from the group which consists of hydrogen, substituted and unsubstituted Gl_z6 alkyl, hydroxy-C1_z6-alkyl, substituted and
-3-unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted aralkyl, substituted and unsubstituted C,_26 alkenyl, substituted and unsubstituted C1_Z6 alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, halogen, OX3 and OXq, wherein X3 and X4 are identical or different and are selected from the group which consists of hydrogen, substituted and unsubstituted CI_26 alkyl, substituted and unsubstituted hydroxy-C1_ 26-alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted Ci_z6 alkenyl, substituted and unsubstituted Cl_26 alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, a silyl, a cation of an organic and inorganic base, in particular a metal of main groups I, II or III of the periodic system, ammonium, substituted ammonium and ammonium compounds derived from ethylenediamine or amino acids, and the pharmaceutically acceptable salts, esters and amides thereof and salts of the esters.
If two or more heteroatoms are present in the heterocycle R1, oxygen and sulfur atoms may be present.
The organophosphorus compounds are preferably of the formula (III) I I
R1-A-P-R3 ( I I I ) I
0Xq wherein R3 is preferably hydrogen, methyl, ethyl, an amide residue or OX3 and X4 is selected from the group which consists of hydrogen, sodium, potassium, methyl, ethyl, wherein X3 is defined as above and particularly preferably of the formula (IV) Ii R1-A-P-OX3 (IV) I
0Xq WO 00/37477 Amendments PCT/EP99/10274
If two or more heteroatoms are present in the heterocycle R1, oxygen and sulfur atoms may be present.
The organophosphorus compounds are preferably of the formula (III) I I
R1-A-P-R3 ( I I I ) I
0Xq wherein R3 is preferably hydrogen, methyl, ethyl, an amide residue or OX3 and X4 is selected from the group which consists of hydrogen, sodium, potassium, methyl, ethyl, wherein X3 is defined as above and particularly preferably of the formula (IV) Ii R1-A-P-OX3 (IV) I
0Xq WO 00/37477 Amendments PCT/EP99/10274
-4-wherein X3 and X4 are identical or different and are selected from the group which consists of hydrogen, a (C1_3) alkyl, a metal of main groups I, II or III of the periodic system, ammonium, substituted ammonium, or ammonium compounds derived from ethylenediamine or amino acids.
X3 and X4 are preferably a metal of main groups I, II or III of the periodic system, ammonium, substituted ammonium or ammonium compounds derived from ethylenediamine or amino acids. In other words, the salt compounds of the organophosphorus compounds are formed with organic or inorganic bases (for example sodium salt, potassium salt, calcium salt, aluminium salt, ammonium salt, magnesium salt, triethylamine salt, ethanolamine salt, dicyclohexylamine salt, ethylenediamine salt. N,N'-dibenzylethylenediamine salts) as well as salts with amino acids (for example arginine salt, aspartic acid salt, glutamic acid salt etc.) and the like.
X3 and X4 are particularly preferably identical or different and are selected from the group which consists of hydrogen, sodium, potassium, methyl, ethyl.
A is preferably selected such that a three-membered linking chain is formed between the phosphorus atom and the nitrogen atom of the heterocycle. A is for example advantageously a methylene, hydroxymethylene, ethylene, ethenylene, hydroxyethylene and may in particular also be substituted with an oxo group.
The carbon chain of A with the formula (II) preferably also links, together with the atoms of the heterocycle, the nitrogen and phosphorus atom via three atoms. If the carbon atom arranged in a position relative to the nitrogen or phosphorus atom is substituted with an oxo group in the linking chain, linking chains having four carbon atoms are also preferred. If both an oxo group is in a position relative to the nitrogen atom and another oxo group is in a position relative to the phosphorus atom in this linking chain, a linking chain with five carbon atoms is also preferred. If the carbon atom arranged in a position relative to the phosphorus atom is substituted with a hydroxy group, linking chains having four carbon atoms are preferred. In this case, methylene groups are also preferred for R3 and R4.
Very particularly preferred groups of compounds are listed below:
X3 and X4 are preferably a metal of main groups I, II or III of the periodic system, ammonium, substituted ammonium or ammonium compounds derived from ethylenediamine or amino acids. In other words, the salt compounds of the organophosphorus compounds are formed with organic or inorganic bases (for example sodium salt, potassium salt, calcium salt, aluminium salt, ammonium salt, magnesium salt, triethylamine salt, ethanolamine salt, dicyclohexylamine salt, ethylenediamine salt. N,N'-dibenzylethylenediamine salts) as well as salts with amino acids (for example arginine salt, aspartic acid salt, glutamic acid salt etc.) and the like.
X3 and X4 are particularly preferably identical or different and are selected from the group which consists of hydrogen, sodium, potassium, methyl, ethyl.
A is preferably selected such that a three-membered linking chain is formed between the phosphorus atom and the nitrogen atom of the heterocycle. A is for example advantageously a methylene, hydroxymethylene, ethylene, ethenylene, hydroxyethylene and may in particular also be substituted with an oxo group.
The carbon chain of A with the formula (II) preferably also links, together with the atoms of the heterocycle, the nitrogen and phosphorus atom via three atoms. If the carbon atom arranged in a position relative to the nitrogen or phosphorus atom is substituted with an oxo group in the linking chain, linking chains having four carbon atoms are also preferred. If both an oxo group is in a position relative to the nitrogen atom and another oxo group is in a position relative to the phosphorus atom in this linking chain, a linking chain with five carbon atoms is also preferred. If the carbon atom arranged in a position relative to the phosphorus atom is substituted with a hydroxy group, linking chains having four carbon atoms are preferred. In this case, methylene groups are also preferred for R3 and R4.
Very particularly preferred groups of compounds are listed below:
-5-O/ Rs ~ Rs ~ Rs I ~ I
s A-P032- A-P03z-I II III
~ Rs ~ Rs / Rs O O
O N O N A-P03z- O N
A-P03z- A-P03a-IV V VI
~ Rs O/ Rs ~ Rs I I O
I
p N A-P032- O N O N
A-P03z- A-P03z VII VIII IX
~ Rs ~ Rs O O
I I
O N O O N O
A-PO32- A-P03z_ X XI
s A-P032- A-P03z-I II III
~ Rs ~ Rs / Rs O O
O N O N A-P03z- O N
A-P03z- A-P03a-IV V VI
~ Rs O/ Rs ~ Rs I I O
I
p N A-P032- O N O N
A-P03z- A-P03z VII VIII IX
~ Rs ~ Rs O O
I I
O N O O N O
A-PO32- A-P03z_ X XI
-6-A-P03z-A-PO3z.
O N O N ~ A_P03z- O N J
I
Ow Ow Oo Rs Rs ORs XII XIII
XIV
A-PO z- , A-P032-J~ J
p N O N A_pp3z- O N
O O~ O
\Rs Rs Rs XV XVI XVII
A-P032- A-PO z_ O N O N A_P03z_ O N ~ I
O
O ERs Rs \Rs XIX XX
XVIII
A-P03z-A-PO z-\ ~ A-Pp3z- \
O~ N p N O N
t I
O
\Rs p \Rs O \Rs X~ XXII XXIII
O N O N ~ A_P03z- O N J
I
Ow Ow Oo Rs Rs ORs XII XIII
XIV
A-PO z- , A-P032-J~ J
p N O N A_pp3z- O N
O O~ O
\Rs Rs Rs XV XVI XVII
A-P032- A-PO z_ O N O N A_P03z_ O N ~ I
O
O ERs Rs \Rs XIX XX
XVIII
A-P03z-A-PO z-\ ~ A-Pp3z- \
O~ N p N O N
t I
O
\Rs p \Rs O \Rs X~ XXII XXIII
7 PCT/EP99/10274 A-PO a_ / / / , A-P032-I I
O \Rs O \Rs O Rs XXIV XXV XXVI
/ /
O N O N A_p032-t t O \Rs O \Rs XXVII XXVIII
A-P03z-A-PO z.
~ A-P03z-O N O N J O N
O
O \Rs \Rs O \Rs XXIX ~ XXXI
_g_ N - OH N - OH
A ~ A i ~XB XXXIB
N - ORs N - ORs A A PO32 ~V
mcxxt v O O
/ ORs , ORs J N
A-P03z- ' ~ A-P032- ..
XXXVI XXXVII
ORs I
'N
N
s A-YU3= O
XXXVIII
_g_ and the corresponding phosphinic acid and phosphinoyl derivatives.
Special features of the above definitions and suitable examples thereof are given below:
"Acyl" is a substituent which originates from an acid, such as from an organic carboxylic acid, carbonic acid, carbamic acid or the thio acid or imidic acid corresponding to the above individual acids, or from an organic sulfonic acid, wherein these acids in each case comprise aliphatic, aromatic and/or heterocyclic groups in the molecule together with carbamoyl or carbamimidoyl.
Suitable examples of these acyl groups are given below.
Aliphatic acyl groups are defined as acyl residues originating from an aliphatic acid and include the following:
alkanoyl (for example formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl etc.); alkenoyl (for example acryloyl, methacryloyl, crotonoyl etc.);
alkylthioalkanoyl (for example methylthioacetyl, ethylthioacetyl etc.);
alkanesulfonyl (for example mesyl, ethanesulfonyl, propanesulfonyl etc.); alkoxycarbonyl (for example methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl etc.); alkylcarbamoyl (for example methylcarbamoyl etc.); (N-alkyl)thiocarbamoyl (for example (N-methyl)thiocarbamoyl etc.);
alkylcarbamimidoyl (for example methylcarbamimidoyl etc.); oxalo; alkoxalyl (for example methoxalyl, ethoxalyl, propoxalyl etc.).
In the above examples of aliphatic acyl groups, the aliphatic hydrocarbon moiety, in particular the alkyl group or alkane residue, may optionally have one or more suitable substituents, such as amino, halogen (for example fluorine, chlorine, bromine etc.), hydroxy, hydroxyimino, carboxy, alkoxy (for example methoxy, ethoxy, propoxy etc.), alkoxycarbonyl, acylamino (for example benzyloxycarbonylamino etc.), acyloxy (for example acetoxy, benzoyloxy etc.) and the like; preferred aliphatic acyl residues with such substituents which may be mentioned are, for example, alkanoyls substituted with amino, carboxy, amino and carboxy, halogen, acylamino or the like.
Aromatic acyl residues are defined as those acyl residues which originate from an acid with a substituted or unsubstituted aryl group, wherein the aryl group may comprise phenyl, toluyl, xylyl, naphthyl and the like; suitable examples are stated below:
aroyl (for example benzoyl, toluoyl, xyloyl, naphthoyl, phthaloyl etc.);
aralkanoyl (for example phenylacetyl etc.); aralkenoyl (for example cinnamoyl etc.);
aryloxyalkanoyl (for example phenoxyacetyl etc.); arylthioalkanoyl (for example phenylthioacetyl etc.);
arylaminoalkanoyl (for example N-phenylglycyl, etc.); arenesulfonyl (for example benzenesulfonyl, tosyl or toluenesulfonyl, naphthalenesulfonyl etc.);
aryloxycarbonyl (for example phenoxycarbonyl, naphthyloxycarbonyl etc.); aralkoxycarbonyl (for example benzyloxycarbonyl etc.); arylcarbamoyl (for example phenylcarbamoyl, naphthylcarbamoyl etc.); arylglyoxyloyl (for example phenylglyoxyloyl etc.).
In the above-stated examples of aromatic acyl residues, the aromatic hydrocarbon moiety (in particular the aryl residue) and/or the aliphatic hydrocarbon moiety (in particular the alkane residue) may optionally have one or more suitable substituents, such as those which have already been stated as suitable substituents for the alkyl group or the alkane residue.
Examples of preferred aromatic acyl residues with specific substituents which may in particular be mentioned are aroyl substituted with halogen and hydroxy or with halogen and acyloxy, and aralkanoyl substituted with hydroxy, hydroxyimino, dihaloalkanoyloxyimino, together with arylthiocarbamoyl (for example phenylthiocarbamoyl etc.);
arylcarbamimidoyl (for example phenylcarbamimidoyl etc.).
A heterocyclic acyl residue is taken to mean an acyl residue which originates from an acid with a heterocyclic group; such residues include:
heterocyclic carbonyl, in which the heterocyclic residue is an aromatic or aliphatic 5- to 6-membered heterocycle with at least one heteroatom from the group nitrogen, oxygen and sulfur (for example thiophenyl, furoyl, pyrrolecarbonyl, nicotinyl etc.);
heterocycle-alkanoyl, in which the heterocyclic residue is 5- to 6-membered and comprises at least one heteroatom from the group nitrogen, oxygen and sulfur (for example thiophenylacetyl, furylacetyl, imidazolylpropionyl, tetrazolylacetyl, 2-(2-amino-4-thiazolyl)-2-methoxyiminoacetyl etc.) and the like.
In the above Examples of heterocyclic acyl residues, the heterocycle and/or the aliphatic hydrocarbon moiety may optionally comprise one or more suitable substituents, such as the same as were stated to be suitable for alkyl and alkane groups.
"Alkyl" is a linear or branched alkyl residue, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, pentyl, hexyl and the like.
"Hydroxyalkyl" is a linear or branched alkyl residue which comprises at least one hydroxyl group, preferably one or two hydroxyl groups.
"Alkenyl" includes linear or branched alkenyl groups, such as for example vinyl, propenyl (for example 1-propenyl, 2-propenyl), 1-methylpropenyl, 2-methylpropenyl, butenyl, 2-ethylpropenyl, pentenyl, hexenyl.
"Alkynyl" includes linear or branched alkynyl groups.
Cycloalkyl preferably.denotes an optionally substituted C3_8 cycloalkyl;
possible substituents are inter alia alkyl, alkenyl, alkynyl, alkoxy (for example methoxy, ethoxy etc.), halogen (for example fluorine, chlorine, bromine etc.), nitro and the like.
Aryl is an aromatic hydrocarbon residue, such as phenyl, naphthyl etc., which may optionally comprise one or more suitable substituents, such as alkyl, alkenyl, alkynyl, alkoxy (for example methoxy, ethoxy etc.), halogen (for example fluorine, chlorine, bromine etc.), nitro and the like.
"Aralkyl" includes mono-, di-, triphenylalkyls such as benzoyl, phenethyl, benzhydryl, trityl and the like, wherein the aromatic moiety may optionally comprise one or more suitable substituents, such as alkoxy (for example methoxy, ethoxy etc.), halogen (for example fluorine, chlorine, bromine etc.), nitro and the like.
The residues X3 and X4 may preferably be selected such that esters are formed on the phosphino group or phosphono group. Suitable examples of such esters according to the formulae (I), (III) and (IV) include suitable mono- and diesters, and preferred examples of such esters include alkyl esters (for example hexadecanyl ester, octadecanyl ester etc.);
aralkyl esters (benzyl ester, phenethyl ester, benzhydryl ester, trityl ester etc.); aryl esters (for example phenyl ester, tolyl ester, naphthyl ester etc.); aroylalkyl esters (for example phenacyl ester etc.); and silyl esters (for example of trialkylhalosilyl, dialkyldihalosilyl, alkyltrihalosilyl, dialkylarylhalosilyl, trialkoxyhalosilyl, dialkylaralkylhalosilyl, dialkoxydihalosilyl, trialkoxyhalosilyl etc.) and the like.
In the above esters, the alkane and/or arene moiety may optionally comprise at least one suitable substituent, such as halogen, alkoxy, hydroxy, nitro or the like.
The compounds used according to the invention according to the formulae (I), (III) and (IV) may be present in the protonated form thereof as an ammonium salt of organic or inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, acetic acid, lactic acid, malefic acid, fumaric acid, oxalic acid, tartaric acid, benzoic acid etc..
The compounds used according to the invention of the formulae (I), (III) and (IV) permit, for example for groups Rl, R3, R4, X3, X4 or A which contain double bonds or are chiral, the occurrence of steric isomers. The use according to the invention of the compounds includes all steric isomers, both as pure substances and in the form of mixtures.
The organophosphorus compounds are suitable for the therapeutic and prophylactic treatment of infections in humans and animals caused by viruses, bacteria, uni- and multicellular parasites and fungi.
The compounds are active against unicellular parasites (protozoa), in particular against the causative organisms of malaria and sleeping sickness and of Chagas' disease, toxoplasmosis, amoebic dysentery, leishmaniases, trichomoniasis, pneumocystosis, balantidiasis, cryptosporidiosis, sarcocytosis, acanthamoebosis, naeglerosis, coccidiosis, giardiasis and lambliasis.
They are accordingly in particular suitable for the prophylactic treatment of malaria and of sleeping sickness and of Chagas' disease, of toxoplasmosis, amoebic dysentery, leishmaniases, trichomoniasis, pneumocystosis, balantidiasis, cryptosporidiosis, sarcocytosis, acanthamoebosis, naeglerosis, coccidiosis, giardiasis and lambliasis.
The active substances according to the invention may in particular be used against the following bacteria:
bacteria of the family Propionibacteriaceae, in particular of the genus Propionibacterium, in particular the species Propionibacterium acnes, bacteria of the family Actinomycetaceae, in particular of the genus Actinomyces, bacteria of the genus Cornynebacterium, in particular the species Corynebacterium diphtheriae and Corynebacterium pseudotuberculosis, bacteria of the family Mycobacteriaceae, of the genus Mycobacterium, in particular the species Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium, bacteria of the family Chlamydiaceae, in particular the species Chlamydia trachomatis and Chlamydia psittaci, bacteria of the genus Listeria, in particular the species Listeria monocytogenes, bacteria of the species Erysipelthrix rhusiopathiae, bacteria of the genus Clostridium, bacteria of the genus Yersinia, the species Yersinia pestis, Yersinia pseudotuberculosis, Yersinia enterocolitica and Yersinia ruckeri, bacteria of the family Mycoplasmataceae, of the genera Mycoplasma and Ureaplasma, in particular the species Mycoplasma pneumoniae, bacteria of the genus Brucella, bacteria of the genus Bordetella, bacteria of the family Neisseriaceae, in particular of the genera Neisseria and Moraxella, in particular the species Neisseria meningitides, Neisseria gonorrhoeae and Moraxella bovis, bacteria of the family Vibrionaceae, in particular of the genera Vibrio, Aeromonas, Plesiomonas and Photobacterium, in particular the species Vibrio cholerae, Vibrio anguillarum and Aeromonas salmonicidas, bacteria of the genus Campylobacter, in particular the species Campylobacter jejuni, Campylobacter coli and Campylobacter fetus, bacteria of the genus Helicobacter, in particular the species Helicobacter pylori, bacteria of the families Spirochaetaceae and Leptospiraceae, in particular of the genera Treponema, Borrelia and Leptospira, in particular Borrelia burgdorferi, bacteria of the genus Actinobacillus, bacteria of the family Legionellaceae, of the genus Legionella, bacteria of the family Rickettsiaceae and family Bartonellaceae, bacteria of the genera Nocardia and Rhodococcus, bacteria of the genus Dermatophilus, bacteria of the family Pseudomonadaceae, in particular of the genera Pseudomonas and Xanthomonas, bacteria of the family Enterobacteriaceae, in particular of the genera Escherichia, Klebsiella, Proteus, Providencia, Salmonella, Serratia and Shigella, bacteria of the family Pasteurellaceae, in particular of the genus Haemophilus, bacteria of the family Micrococcaceae, in particular of the genera Micrococcus and Staphylococcus, bacteria of the family Streptococcaceae, in particular of the genera Streptococcus and Enterococcus and bacteria of the family Bacillaceae, in particular of the genera Bacillus and Clostridium.
The organophosphorus compounds and the derivatives thereof are consequently suitable for treating diphtheria, acne vulgaris, listerioses, swine erysipelas in animals, gas gangrene in humans and animals, malignant oedema in humans and animals, tuberculosis in humans and animals, leprosy and further mycobacterioses in humans and animals, paratuberculosis in animals, plague, mesenterial lymphadenitis and pseudotuberculosis in humans and animals, cholera, legionnaires' disease, borreliosis in humans and animals, leptospiroses in humans and animals, syphilis, Campylobacter enteritis infections in humans and animals, Moraxella keratoconjunctivitis and serositis in animals, brucellosis of animals and humans, anthrax in humans and animals, actinomycosis in humans and animals, streptotrichoses, psittacosis/ortnithosis in animals, Q fever, ehrlichiosis.
Use is furthermore in particular preferred in the eradication of Helicobacter in ulcers of the gastrointestinal tract.
Combinations with another antibiotic may also be used to treat the above-stated diseases.
Isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, protionamide and dapsone are in particular suitable for combination preparations with other antiinfective agents for the treatment of tuberculosis.
The active substances according to the invention are furthermore in particular usable in infections with the following viruses:
Paxvoviridae: parvoviruses, dependoviruses, densoviruses, Adenoviridae:
adenoviruses, mastadenoviruses, aviadenoviruses, Papovaviridae: papovaviruses, in particular papillomaviruses ("wart" viruses), polyomaviruses, in particular JC virus, BK
virus and miopapovaviruses, Herpesviridae: all herpesviruses, in particular herpes simplex viruses, varicella-zoster viruses, human cytomegalovirus, Epstein-Barr viruses, all human herpesviruses, human herpesvirus 6, human herpesvirus 7, human herpesvirus 8, Poxiviridae: poxviruses, orthopoxviruses, parapoxviruses, molluscum contagiosum virus, aviviruses, capriviruses, leporipoxviruses, all primarily hepatotropic viruses, hepatitisviruses: hepatitis A viruses, hepatitis B viruses, hepatitis C viruses, hepatitis D viruses, hepatitis E viruses, hepatitis F
viruses, hepatitis G
viruses, hepadnaviruses: all hepatitisviruses, hepatitis B virus, hepatitis D
viruses, Picornaviridae: picornaviruses, all enteroviruses, all polioviruses, all coxsackie-viruses, all echoviruses, all rhinoviruses, hepatitis A virus, aphthoviruses, Calciviridae:
hepatitis E
viruses, Reoviridae: reoviruses, orbiviruses, rotaviruses, Togaviridae:
togaviruses, alphaviruses, rubiviruses, pestiviruses, rubellavirus, Flaviviridae:
flaviviruses, FSME virus, hepatitis C virus, Orthomyxoviridae: all influenza viruses, Paramyxoviridae:
paramyxoviruses, morbillivirus, pneumovirus, measles virus, mumps virus, Rhabdoviridae:
rhabdoviruses, rabies virus, lyssavirus, vascular stomatitisvirus, Coronaviridae: coronaviruses, Bunyaviridae: bunyaviruses, nairovirus, phlebovirus, uukuvirus, hantavirus, hantaan virus, Arenaviridae: arenaviruses, lymphocytic choriomeningitis virus, Retroviridae:
retroviruses, all HTL viruses, human T-cell leukaemia virus, oncornaviruses, spumaviruses, lentiviruses, all HI viruses, Filoviridae: Marburg and Ebola virus, slow-virus infections, prions, oncoviruses and leukaemia viruses.
The organophosphorus compounds used according to the invention are consequently suitable for combating the following viral infections:
eradication of papillomaviruses to prevent tumours, in particular tumours of the reproductive organs caused by papillomaviruses in humans, eradication of JC viruses and BK
viruses, eradication of herpesviruses, eradication of human herpesvirus 8 to treat Kaposi's sarcoma, eradication of cytomegaloviruses before transplantations, eradication of Epstein-Barr viruses before transplantation and to prevent tumours associated with Epstein-Barr viruses, eradication of hepatitis viruses to treat chronic liver disease and to prevent liver tumours and cirrhosis of the liver, eradication of coxsackie-viruses in cardiomyopathy, eradication of coxsackie-viruses in diabetes mellitus patients, eradication of immunodeficiency viruses in humans and animals, treatment of accompanying infections in AIDS patients, treatment of respiratory tract inflammation of viral causation (laryngeal papilloma, hyperplasia, rhinitis, pharyngitis, bronchitis, pneumonia), of the sensory organs (keratoconjunctivitis), of the nervous system (poliomyelitis, meningoencephalitis, encephalitis, subacute sclerosing panencephalitis, SSPE, progressive multifocal leukoencephalopathy, lymphocytic choriomeningitis), of the gastrointestinal tract (stomatitis, gingivostomatitis, oesophagitis, gastritis, gastroenteritis, diarrhoea), of the liver and gall system (hepatitis, cholangitis, hepatocellular carcinoma), of the lymphatic tissue (mononucleosis, lymphadenitis), of the haemopoietic system, of the reproductive organs (mumps orchitis), of the skin (warts, dermatitis, herpes labialis, herpes febrilis, herpes zoster, shingles), of the mucous membranes (papillomas, conjunctiva) papillomas, hyperplasia, dysplasia), of the cardiovascular system (arteriitis, myocarditis, endocarditis, pericarditis), of the kidney/urinary system, of the reproductive organs (anogenital lesions, warts, genital warts, sharp condylomas, dysplasia, papillomas, cervical dysplasia, condyloma acuminatum, epidermodysplasia verruciformis), of the locomotory organs (myositis, myalgia), treatment of foot-and-mouth disease in cloven-hoofed animals, of Colorado tick fever, Dengue syndrome, of haemorrhagic fever, of early summer meningoencephalitis (FSME) and of yellow fever.
The described compounds, i.e. the organophosphorus compounds of the formulae (I), (III) and (IV) and esters and amides thereof on the phosphino group and salts thereof exhibit strong cytotoxic activity against uni- and multicellular parasites, in particular against the causative organisms of malaria and sleeping sickness. The compounds according to the invention are accordingly usable for the treatment of infective diseases which are caused in humans and animals by viruses, bacteria, parasites and fungi. The compounds are also suitable for the prevention of diseases which are caused by viruses, bacteria, parasites and fungi, in particular for the prophylactic treatment of malaria and of sleeping sickness.
The organophosphorus compounds used according to the invention, which generally include for this purpose pharmaceutically acceptable salts, amides, esters, a salt of such an ester or also compounds which, on administration, provide the compounds used according to the invention as metabolites or breakdown products (also known as "prodrugs"), may be formulated for administration in any suitable manner analogous to known agents having an antiinfective action (mixed with a non-toxic, pharmaceutically acceptable excipient).
Pharmaceutically acceptable salts of the compounds include salts which the compounds of the formulae (I), (III) and (IV) according to the invention form in their protonated form as an ammonium salt of inorganic or organic acids, such as hydrochloric acid, sulfuric acid, citric acid, malefic acid, fiunaric acid, tartaric acid, p-toluenesulfonic acid.
Particularly pharmaceutically suitable salts are also those formed by suitable selection of X3 and X4, such as sodium salt, potassium salt, calcium salt, ammonium salt, ethanolamine salt, triethylamine salt, dicyclohexylamine salt and salts of an amino acid such as arginine salt, aspartic acid salt, glutamic acid salt.
The activity of the substances is determined using a test system. This system is based upon in vitro measurement of the inhibition of growth of bacteria, parasites, viruses, fungi or plants.
Test methods known to the person skilled in the art are in part used for this purpose.
For example, antimalarial activity is determined by measuring the inhibition of the growth of malaria parasites in blood cultures.
Antibacterial activity is determined on the basis of measuring the inhibition of bacterial growth on nutrient media and in liquid cultures.
Antiviral activity is determined on the basis of the formation of viral elements in cell cultures.
Fungicidal activity is determined on the basis of inhibition of fungal growth on nutrient media and in liquid cultures.
Some of the microorganisms which are to be investigated may only be investigated in animal models. In this case, the appropriate models will then be used.
Substances which exhibit activity in in vitro measurement systems are then further investigated in in vivo models. Antiparasitic, antiviral, fungicidal or antibacterial activity is further evaluated in the appropriate animal models.
Screening for herbicidal activity is determined by means of algal systems and measurement of isoprene emissions from plants under standard conditions.
The pharmaceutically active agents may be prepared in dosage units in the form of pharmaceutical preparations. This means that the preparation is in the form of individual components, for example tablets, coated tablets, capsules, pills, suppositories and ampoules, the active substance content of which corresponds to a fraction or multiple of an individual dose. The dosage units may contain, for example 1, 2, 3 or 4 individual doses or 1/2, 1/3 or 1/4 of an individual dose. An individual dose preferably contains the quantity of active substance which is administered at one time and usually corresponds to a whole, half, third or quarter of a daily dose.
Non-toxic, inert, pharmaceutically suitable excipients should be taken to mean solid, semi-solid or liquid diluents, fillers and formulation auxiliaries of all kinds.
Preferred pharmaceutical preparations which may be mentioned are tablets, coated tablets, capsules, pills, granules, suppositories, solutions, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders and sprays. Tablets, coated tablets;
capsules, pills and granules may contain the active substances together with conventional excipients, such as (a) fillers and extenders, for example starches, lactose, cane sugar, glucose, mannitol and silica, (b) binders, for example carboxymethylcellulose, alginates, gelatine, polyvinylpyrrolidone, (c) humectants, for example glycerol, (d) suspending agents, for example agar-agar, calcium carbonate and sodium carbonate, (e) dissolution retardants, for example paraffin and (f) resorption accelerators, for example quaternary ammonium compounds, (g) wetting agents, for example cetyl alcohol, glycerol monostearate, (h) adsorbents, for example kaolin and bentonite and (i) lubricants, for example talcum, calcium and magnesium stearate and solid polyethylene glycols or mixtures of the substances stated in (a) to (i).
The tablets, coated tablets, capsules, pills and granules may be provided with conventional coatings and shells optionally containing opacifying agents and may also be composed such that they release the active substances only with a delay or preferably in a particular part of the intestinal tract, wherein polymeric substances and waxes may, for example, be used as the matrices.
The active substance or substances, optionally together with one or more of the above-stated excipients, may also be present in microencapsulated form.
In addition to the active substance or substances, suppositories may contain conventional water-soluble or water-insoluble excipients, for example polyethylene glycols, fats, for example cocoa butter and higher esters (for example C 14 alcohol with C 16 fatty acid) or mixtures of these substances.
In addition to the active substance or substances, ointments, pastes, creams and gels may contain conventional excipients, for example animal and vegetable fats, waxes, paraffins, starch, gum tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talcum and zinc oxide or mixtures of these substances.
In addition to the active substance or substances, powders and sprays may contain conventional excipients, for example lactose, talcum, silica, aluminium hydroxide, calcium silicate and polyamide powder or mixtures of these substances. Sprays may additionally contain conventional propellants, for example chlorofluorocarbons.
In addition to the active substance or substances, solutions and emulsions may contain conventional excipients, such as solvents, solubilising agents and emulsifiers, for example water; ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol, glycerol formal, tetrahydrofurfuryl alcohol, polyethylene glycols and sorbitan fatty acid esters or mixtures of these substances.
For paxenteral administration, the solutions and emulsions may also be present in sterile, isotonic form.
In addition to the active substance or substances, suspensions may contain conventional excipients, such as liquid diluents, for example water, ethyl alcohol, propylene glycol, suspending agents, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar and gum tragacanth or mixtures of these substances.
The stated formulations may also contain colorants, preservatives and odour-or flavour-enhancing additives, for example peppermint oil and eucalyptus oil, and sweeteners, for example saccharin.
The active substances of the formulae (I), (III) and (IV) should preferably be present in the pharmaceutical preparations listed above in a concentration of approx. 0.1 to 99.5 wt.%, preferably from approx. 0.5 to 95 wt.%, of the complete mixture.
Apart from the compounds of the formulae (I), (III) and (IV), the pharmaceutical preparations may also contain further pharmaceutical active substances.
The compounds may be used together with hitherto described substances having antibacterial, antiviral, antimycotic and antiparasitic properties. Such substances in particular include compounds which have already been used in therapeutic applications or are still used.
Substances which are suitable for this purpose are in particular those listed in the Red List or in Simon/Stille, Antibiokia-Therapie in Klinik and Praxis, 9th edition, 1998, Schatauer Verlag, or on the Internet at htt~://www.customs treas gov/imn-exp/rulin~s/harmoniz/hrml29 html. The derivatives may in particular be present with penicillins, benzylpenicillin (penicillin G), phenoxypenicillins, isoxazolylpenicillins, aminopenicillins, ampicillin, amoxicillin, bacampicillin, carboxypenicillin, ticarcillin, temocillin, acylaminopenicillins, azlocillin, mezlocillin, piperacillin, apalcillin, mecillinam, cephalosporins, cefazolin group, cefuroxime group, cefoxitin group, cefoxitin, cefotetan, cefmetazole, latamoxef, flomoxef, cefotaxime group, cefozidime, ceftazidime group, ceftazidime, cefpirome, cefepime, conventional cephalosporins, cefsulodin, cefoperazone, oral cephalosporins of the cephalexin group, loracarbef, cefprozil, new broad-spectrum oral cephalosporins, cefixime, cefpodoxime-proxetil, cefuroxime-axetil, cefetamet, cefotiam-hexetil, cefdinir, ceftibuten, other 13-lactam antibiotics, carbapenem, imipenem/cilastatin, meropenem, biapenem, aztreonam,13-lactamase inhibitors, clavulanic acid/amoxicillin, clavulanic acid/ticarcillin, sulbactam/ampicillin, tazobactam/piperacillin, tetracyclines, oxytetracycline, rolitetracycline, doxycycline, minocycline, chloramphenicol, aminoglycosides, gentamicin, tobramycin, netilmicin, amikacin, spectinomycin, macrolides, erythromycin, clarithromycin, roxithromycin, azithromycin, dirithromycin, spiramycin, josamycin, lincosamides, clindamycin, fusidic acid, glycopeptide antibiotics, vancomycin, teicoplanin, pristinamycin derivatives, fosfomycin, antimicrobial folic acid antagonists, sulfonamides, co-trimoxazole, trimethoprim, other diaminopyrimidine-sulfonamide combinations, nitrofurans, nitrofurantoin, nitrofurazone, gyrase inhibitors (quinolones), norfloxacin, ciprofloxacin, ofloxacin, sparfloxacin, enoxacin, fleroxacin, pefloxacin, lomefloxacin, Bay Y3118, nitroimidazoles, antimycobacterial agents, isoniazid, rifampicin, rifabutin, ethambutol, pyrazinamide, streptomycin, capreomycin, prothionamide, terizidone, dapsone, clofazimine, topical antibiotics, bacitracin, tyrothricin, polymyxins, neomycin, kanamycin, paromomycin, mupirocin, antiviral agents, acyclovir, ganciclovir, azidothymidine, didanosine, zalcitabine, thiacytidine, stavudine, ribavirin, idoxuridine, trifluridine, foscarnet, amantadine, interferons, tibol derivatives, proteinase inhibitors, antimycotics, polyenes, amphotericin B, nystatin, natamycin, azoles, azoles for septic therapy, miconazole, ketoconazole, itraconazole, fluconazole, UK-109,496, azoles for topical use, clotrimazole, econazole, isoconazole, oxiconazole, bifonazole, flucytosine, griseofulvin, ciclopirox olamine, tolnafnate, naftifme, terbinafine, amorolfme, anthraquinones, betulinic acid, semianthraquinones, xanthones, naphthoquinones, arylamino alcohols, quinine, quinidines, mefloquine, halofantrine, chloroquine, amodiaquine, acridine, benzonaphthyridine, mepacrine, pyronaridine, dapsone, sulfonamides, sulfadoxine, sulfalenes, trimethoprim, proguanil, chlorproguanil, diaminopyrimidines, pyrimethamine, primaquine, aminoquinolines, WR 238,605, tetracycline, doxycycline, clindamycin, norfloxacin, ciprofloxacin, ofloxaein, artemisinin, dihydroartemisinin, lOb artemether, arteether, atresunate, atovaquone, suramin, melarsoprol, nifurtimox, stibogluconate sodium, pentamidine, amphotericin B, metronidazole, clioquinol, mebendazole, niclosamide, praziquantel, pyrantel, tiabendazole, diethylcarbamazine, ivermectin, bithionol, oxamniquine, metrifonate, piperazine, embonate.
The organophosphorus compounds may furthermore be present in the pharmaceutical preparations in combination with sulfonamide, sulfadoxine, artemisinin, atovaquone, quinine, chloroquine, hydroxychloroquine, mefloquine, halofantrine, pyrimethamine, armesin, tetracyclines, doxycycline, proguanil, metronidazole, praziquantel, niclosamide, mebendazole, pyrantel, tiabendazole, diethylcarbazine, piperazine, pyrivinium, metrifonate, oxamniquine, bithionol or suramin or two or more of these substances.
The above-stated pharmaceutical preparations are produced in the conventional manner using known methods, for example by mixing the active substance or substances with the excipient or excipients.
The stated preparations maybe administered to humans and animals orally, rectally, parenterally (intravenously, intramuscularly, subcutaneously), intracisternally, intravaginally, intraperitoneally, topically (powders, ointments, drops) and for the treatment of infections in cavities, body cavities. Suitable preparations which may be considered are solutions for injections, solutions and suspensions for oral therapy, gels, infusion formulations, emulsions, ointments or drops. Topical treatment may be performed using ophthalmological and dermatological formulations, silver and other salts, ear drops, eye ointments, powders or solutions. Administration to animals may also be achieved via the feed or drinking water in suitable formulations. Gels, pulverulent formulations, powders, tablets, controlled-release tablets, premixes, concentrates, granules, pellets, tablets, boli, capsules, aerosols, sprays, inhalation formulations may also be used in humans and animals. The compounds according to the invention may also be incorporated into other supports, such as for example plastics (plastic chains for topical treatment), collagen or bone cement.
It has in general proved advantageous in both human and veterinary medicine to administer the active substances of the formula (I), (III) and (IV) in total quantities of approx. 0.05 to approx. 600, preferably of 0.5 to 200 mg/kg body weight per 24 hours, optionally in the form of two or more individual doses in order to achieve the desired results. An individual dose preferably contains the active substance or substances in quantities of approx. 1 to approx.
200, in particular of 1 to 60 mg/kg body weight. It may, however, be necessary to deviate from the stated dosages, in particular as a function of the nature and body weight of the patient to be treated, the nature and severity of the disease, the nature of the preparations and the route of administration of the pharmaceutical preparation and the period of time over which administration is performed.
In some cases, it may accordingly be sufficient to use less than the above-stated quantity of active substance, while in other cases more than the above-stated quantity of active substance must be used. The person skilled in the art will use his/her skill to determine the optimum dosage and route of administration required in each particular case.
The compounds according to the invention may be given to animals in conventional concentrations and preparations together with feed or feed preparations or with drinking water.
The compounds according to the invention are furthermore ideally usable as bactericides, fungicides and herbicides in plants.
If the structure of the compound is known, it is generally possible for the person skilled in the art to develop a production process by analogy with known processes. The production of some compounds according to the invention is stated below by way of example:
Example 1' S-j2-lPhosnhono)ethyl)-N-hvdroxy~vrrolidin 2 one~ll N-Fluorenylmethoxycarbonyl-pvrrolidin-2-vl-methanol Vila A solution of 476 g (1.85 mol) of chloroformic acid 1-(9-fluorenylmethyl) ester (F-MOC) in 1 1 of dioxane is slowly added dropwise with ice cooling to a solution of 182 g (1.8 mol) of pyrrolidin-2-yl-methanol in 1200 ml of dioxane and 1800 ml of a 10% sodium carbonate solution. The mixture is stirred for 4 h at this temperature and for 8 h at room temperature, poured into 1.5 1 of ice water and extracted with diethyl ether. The ice-cooled aqueous phase is weakly acidified with dilute HCI, left to stand overnight at 0°C and the product la is then filtered with good purity and yield.
O-~Methanesulfon l~methyl)-N-fluorenvlmetho~carbon ~~1-~yrrolidine (lb) 470 g (1.4 mol) of la are redissolved in 300 ml of absolute pyridine and combined while cold with 400 g (3.5 mol) of methanesulfonyl chloride. The mixture is stirred under argon initially for 16 h at 0°C and then for a further 3 h at RT. Once the mixture has been poured onto ice, extraction is performed repeatedly with diethyl ether and the organic phase is washed in succession with ice-cold dilute HCI, NaHC03 and water. After drying over M,gS04 and evaporation, lb is obtained, which may be purified by recrystallisation from acetone/petroleum ether.
2-lIodomethvl)-N-fluorenylmethoxycarbon~l-pvrrolidine~l c~
3 equivalents (359.7 g) of NaI in acetone are added to a solution of 331 g (0.8 mol) of lb in acetone. After 12 hours' stirring at RT, the mixture is filtered, the filtrate added to 800 ml of water, which had been combined with sodium thiosulfate. After repeated extraction with diethyl ether, the extracts were combined, washed with water, dried over MgS04 and evaporated under reduced pressure. Leaving the mixture to stand at low temperature initially yields an oil, which may be recrystallised from petroleum ether.
2-f2-lDimethyl__phos~hono)eth~]-~yrrolidine (ld) 190 ml of a 1.6 M solution of n-butyllithium in hexane (corresponding to 0.30 mol) were added dropwise at -78°C under argon to 37.2 g (0.3 mol) of methanephosphonic acid dimethyl ester in 900 ml of dry THF. Stirring is continued for a further 15 minutes at this temperature to permit complete formation of the carbanion.
133.9 g (0.3 mol) of lc in 300 ml of dry THF were added dropwise to this solution at -78°C
with stirring. Once the temperature has risen to room temperature, stirnng is continued for a further 4 h. 85.15 g (1 mol) of piperidine is then added and the mixture stirred overnight. The mixture is filtered, the filtrate is poured into 21 of water, the organic phase separated and the aqueous phase extracted 4 times with 100 ml portions of dichloromethane. Once the combined organic phases have been dried over MgS04, the solvent is removed and the residue fractionally distilled under a vacuum. 2-[2-(Dimethylphosphono)ethyl]-pyrrolidine (ld) is obtained as a colourless oil at yields of 30-40%.
5-f2-(Dimethvlphosphono)ether]pvrrolidinone~le) A solution of 60 mmol of dimethyldioxirane in 120 ml of dry acetone is added dropwise to a solution, cooled to 0°C, of 3.32 g (15 mmol) of ld in 50 ml of dry acetone. The mixture is stirred for 30 min at 0°C and the solvent is then stripped out under a vacuum. The resultant crude product is recrystallised from isopropanol. 5-[2-(Dimethylphosphono)ethyl]pyrrolidinone (le) is obtained in moderate yield as colourless crystals.
Dimethyldioxirane is produced in accordance with a method in Org. Syntheses IX, 288.
5-f2-lPhosphonolethvl]-N-hvdrox~pvrrolidin-2-one (lf~
3.06 g (20 mmol) of trimethylbromosilane are added dropwise to a solution, cooled to 0°C, of 1.19 g (5 mmol) of le in 50 ml of dry acetonitrile. The mixture is stirred for 3 h at RT, then the solvent is stripped out under a vacuum, the residue is redissolved with 20 ml of ice water, the mixture is stirred for 1 h at room temperature, extracted twice with 20 ml portions of ether, a pH value of 4.5 is established with 2 M NaOH and the water is then stripped out in a Rotavapor rotary evaporator at a maximum of 50°C. The solid residue is crystallised from methanol/ethyl acetate. 5-[2-(Phosphono)ethyl]-N-hydroxy-pyrrolidin-2-one (lf7 is obtained in good yield in the form of yellowish microcrystals.
Examble 2: 3-(PhosnhonomethYl)-N-h~rdrox~pvrrolidin-2-one~21 3-Meth(2-trimethylsilvlethoxy)-pvrrolidin-2-one ~2a1 A solution of 120 mmol of sodium ethanolate in 50 ml of absolute ethanol is added dropwise at 0°C with exclusion of moisture to a solution of 20.37 g (120 mmol) of O-(2-trimethylsilyethyl)hydroxylamine hydrochloride in 100 ml of absolute ethanol.
Any precipitated NaCI is filtered out with an argon sintered glass filter. The ethanol is removed from the filtrate under reduced pressure and, once argon has been passed through the residue, the latter is redissolved with absolute toluene. 1 mol% of RhCl3*3 H20, 5 mol%
of DMAP
and, dropwise, 5.01 g (50 mmol) of 2-methylbutyrolactone are added thereto at 0°C. The mixture is allowed to thaw and is stirred overnight while being refluxed on the water separator. After cooling, volatile constituents are stripped out under a vacuum at 50°C in a Rotavapor rotary evaporator, a weakly yellow coloured oil being left behind.
Redissolution in 50 ml of ether, filtration through a short Si02 column and stripping of the solvent gives rise to 3-methyl-N-(2-trimethylsilylethoxy)-pyrrolidin-2-one (2a) in moderate yield as a virtually colourless oil, which is obtained in good purity.
3-Bromometh~N-(2-trimethvlsil lethoxy)~yrrolidin-2-one (2b) 50 mmol of 2a, dissolved in 30 ml of absolute carbon tetrachloride, are combined with 1.2 equivalents of N-bromosuccinimide and refluxed for 12 h. Small quantities of azobisisobutyronitrile (AIBN) are added at hourly intervals. After cooling, the product is filtered from succinimide, the latter is washed with CCl4 and the combined CC14 phases are evaporated under reduced pressure. The resultant oil may be chromatographed on Si02, 2b being obtained in poor yield.
3-(Diethvlnhosphonometh~l-N-f2-trimeth~vlethoxvl pyrrolidin 2 one l2cl 100 mmol (17.3 ml) of triethyl phosphite are combined with 100 mmol of 2b and heated to 150°C for 0.5 h without solvent. After cooling, the mixture is evaporated under reduced pressure and the yellowish brown oil is chromatographed on Si02 with chloroform/methanol in a 25:1 ratio. Once volatile constituents have been stripped out, 2c is obtained in moderate yield as a yellow oil.
3-(Phosphonomethvl~ N-~2-trimeth~i_l lethoxyl pvrrolidin 2 one~2d) 4 equivalents (120 mmol, 15.4 ml) of trimethylbromosilane are added dropwise with ice cooling to 30 mmol of 2c in 50 ml of absoluted acetonitrile, the mixture is stirred for 15 min at the same temperature, then for 2 h at RT, evaporated under reduced pressure until a yellowish oil is obtained, the product is redissolved in 100 ml of water and hydrolysed for 1 h at RT (pH less than 1 ). This solution is extracted twice with CHCl3, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at 45°C. The resultant yellow-brown oil is redissolved in water and a pH of 4.5 to 5.0 is established. After washing with ice water, 2d is obtained as a virtually colourless sodium salt at a yield of 50%.
3-fPhosnhonometh~~hvdroxy-pvrrolidin-2-one (2e) 5.3 mmol of BF3 etherate are added to a solution of 2.65 mmol of 2d in absoluted acetonitrile and stirred for 0.5 h at room temperature. Once the solution has been evaporated under reduced pressure, it is redissolved in 40 ml of ethyl acetate, washed with 3%
common salt solution, dried over MgS04, filtered through a membrane filter and the solvent is stripped out under reduced pressure. The crude product may be recrystallised from MeOH/EtOH, the product being obtained in pure form and good yield.
Example 3: 4-lPhos~honomethyll-N-hvdrox~nvrrolidin-2-one (31 4-Methyl-2(5Hl-furanone ~3a1 g of 3-methylglutaric acid monoethyl ester and 31 g of lead tetraacetate dissolved in 400 ml of absolute CC14 are heated to boiling under argon. After 10 minutes' illumination by means of a tungsten daylight lamp, 23.1 g of iodine are added within 45 min while illumination is continued. After cooling, the mixture is filtered, the filtrate washed with aqueous sodium thiosulfate solution, soda solution and water, dried over MgS04 and evaporated under reduced pressure. The gamma-iodine ester 3a' is obtained as a oil which may be further reacted without further purification. 18.4 g of freshly precipitated silver acetate and 24 g of acetic anhydride are heated to 120°C in 82 ml of glacial acetic acid for 1 hour, 19.1 g of the gamma-iodine ester 3a' are added and the mixture refluxed for a further 2 hours.
The mixture is then kept for 15 h at R'r, combined with 300 ml of ether and filtered. Once the filtrate has been washed with water and aqueous soda solution, the aqueous phase is extracted again with ether, the combined organic extracts are dried over MgS04 and evaporated under reduced pressure. Once this oil has been redissolved in 70 ml of 2 N NaOH, 10 ml of EtOH
and 50 ml of water, the mixture is repeatedly extracted with ether, the ether phases being quantitatively discarded. The aqueous phase, acidified with 150 ml of 6 N HC1, is continuously extracted with ether and, after drying over MgS04 and evaporation under reduced pressure, is distilled (102-105°C at 34 Torr). 4.4 g of 4-methyl-2[5H]-furanone (3a) are obtained.
The remaining steps for preparing 3 follow the synthesis sequence described in 2 by the introduction of O-(2-trimethylsilylethyl)-hydroxylamine hydrochloride, NBS, triethyl phosphate and the hydrolyses of phosphonic acid esters by trimethylbromosilane and the liberation of the cyclic hydroxamic acid by BF3 etherate. Reference may also be made to T.Sakamoto, Y.Kikugawa J. Org. Chem. 1994, 59, 929-931 with regard to the synthesis sequence.
Example 4: N-Hvdroxv-3-amino-4-lphosphon-omethyll pvrrolidin 2 one (4) 2-Phenyl-4-(2-acetoxy-1-acetox~ yl-eth laden 1 2 oxazolin 5 one ~4a1_ 0.2 mol of hippuric acid, 0.6 mol of acetic anhydride, 0.24 mol of 1,3-diacetoxyacetone and 0.1 mol of anhydrous lead(II) acetate are initially introduced into 500 ml of THF and refluxed for 16 h under argon. After cooling to RT, inorganic salts are filtered out, the mixture is evaporated under reduced pressure, redissolved in 500 ml of toluene, gaseous hydrogen sulfide is introduced until PbS ceases to precipitate and, after filtration, the mixture is reevaporated. The product is chromatographed on Si02 with hexane/chloroform as the solvent mixture, 4b being obtained at a yield of 73%.
Diacetoxyacetone is synthesised in accordance with a method of A.O.L. Fischer, H.
Mildbrand Ber. Dt, them. Ges. 57, 707, 1924.
2-Amino-3-methox -v butyric acid l4bl A solution of 31.8 mol of 4a in 150 ml of dioxane is combined with 1 g of Pd/C
and hydrogenated at standard pressure until 10 mol of hydrogen have been absorbed (4-6 h). Once the catalyst has been filtered out, the mixture is evaporated to dryness, redissolved in 40 ml of water and 60 ml of coot. HCI, refluxed for 4 h and kept overnight in the refrigerator. The filtered solution is evaporated, redissolved in 50 ml of water and purified on Amberlite IR
120, H+ ion exchanger by elution with 300 ml of aqueous ammonia solution. The mixture is boiled until no ammonia is any longer detectable, reevaporated under reduced pressure and recrystallised.
Aloha-amino-beta-methox~garmsna-butvrolactone (4c) 25 mmol of 4b are stirred for 15 min at RT with 20 ml of 2.5% HCI. The solution is evaporated to dryness and extracted overnight with chloroform in a Soxhlet apparatus. Once the solvent has been stripped out under reduced pressure, the lactone 4c is obtained in virtually quantitative yield.
N.N-Dibenzvla_mino-beta-methox~-gamma butvrolactone ~4d1 0.2 mol of 4c, 72 g of KZC03 and 300 mg of tetrabutylammonium iodide and 500 mg of 18-crown-6 are suspended in 100 ml of ethanol and heated to 40°C. 0.65 mol of benzyl bromide are added dropwise within 15 min, the mixture is stirred for 12 h at RT, the phases are separated, the aqueous phase washed twice with 75 ml portions of ether, the organic phases are combined, washed with saturated NaCI solution and dried over MgS04. After evaporation under reduced pressure, the mixture is chromatographed on a short silica gel column.
N.N-Dibenzylamino-beta~bromomethvll-butyrolactone~4e~
2.23 g (6.18 mmol) of CBr4 are added to a mixture of 4.12 mmol of 4d, 6.18 mmol of PPh3 and 20 ml of absolute acetonitrile. The mixture is stirred for 20 h at RT, the solvent removed under reduced pressure and chromatographed on silica gel with ethyl acetate/n-hexane as solvent. 4e is obtained in variable yield as a yellowish oil.
N.N-Dibenzvlamino-beta-ldimeth~phosphonomethylLutyrolactone (4f1 40 mmol of 4e are refluxed for 0.5 to 1 h with 1 equivalent of trimethyl phosphite in toluene.
After cooling, the mixture is evaporated under reduced pressure and the remaining oil is chromatographed on Si02 with chloroform/methanol as the mobile solvent. Once volatile constituents have been stripped out, 4f is obtained in moderate yield.
N N-Dibenzvlamino-beta~dimet Yl hosnhonometh l~) butvrolactam (4~) A solution of 100 ml of sodium ethanolate in 50 ml of absolute ethanol is added dropwise at 0°C with exclusion of moisture to a solution of 120 mmol of O-benzylhydroxylamine hydrochloride in 100 ml of absolute ethanol. Any precipitated NaCI is filtered out with an argon sintered glass filter. The ethanol is removed from the filtrate under reduced pressure and, once argon has been passed through the residue, the latter is redissolved with absolute toluene. 1 mol% of RhCl3 3 H20, 5 mol% DMAP and, dropwise, 50 mmol of 4f are added thereto at 0°C. The mixture is allowed to thaw and is stirred overnight while being refluxed on the water separator. After cooling, volatile constituents are stripped out under a vacuum at 50°C in a Rotavapor rotary evaporator, an oil being left behind.
Redissolution in 40 ml of ethyl acetate, filtration through a short Si02 column and stripping of the solvent gives rise to (4g) in moderate yield as a yellow oil, which is obtained in good purity.
N-Hvdroxy-3-amino-4-(dimeth~phosphonometh~l ~vrrolidin 2 one (4hl 30 mmol of 4g in 60 ml of methanol and 10 ml of formic acid are hydrogenated with 5 mol%
Pd/C (10-20%) under standard pressure at RT for 13 h. Once the catalyst has been filtered out, the mixture is evaporated under reduced pressure and reacted without further purification.
N-H~xv-3-amino-4~Phosnhonomethyl~pvrrolidin-2-one~4il 35 mmol of trimethylbromosilane are added dropwise with ice cooling to 10 mmol of 4h in 20 ml of absoluted acetonitrile, the mixture is stirred for 15 min at the same temperature, then for 2 h at RT, evaporated under reduced pressure until a yellowish oil is obtained, the product is redissolved in 100 ml of water and hydrolysed for 1 h at RT. This solution is extracted twice with CHC13, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at 45°C. The resultant dark oil is redissolved in water and a pH of 6.0 is established. Precipitating 4i is filtered out and washed with ice water. 4i is obtained as the sodium salt in the form of beige crystals at a yield of 35-40%.
Example 5: N.2-Dihvdrox~~2~hosphonoethvl~~vrrole (5) N-Benz~~[2-(dimeth~pho~honoZth~7pvrrolidin-2-one (Sad 20 mmol of 5-[2-(dimethylphosphono)ethyl]pyrrolidinone (le) are stirred overnight at room temperature with 1.2 equivalents of benzyl bromide, 10 mg of tetrabutylammonium iodide and 1.3 equivalents of triethylamine in 30 ml of THF, are then poured into ice water, repeatedly extracted with small quantities of ether, the diethyl ether phase is washed with cold dilute HC1 and with saturated common salt solution, dried over MgS04, evaporated and the crude product chromatographed on silica gel with chloroform/methanol 25:1. Sa is obtained in good yield.
N-Benz~~ henylseleno-5-~2-(dimeth~phos honoleth~l_~pvrrolidin-2-one (5b) 2.0 mmol of Sa, which is dissolved in 1 ml of absolute THF and stirred for 20 min at -78°C, is added at the same temperature to 2.4 mmol of diisopropylamide in 3 ml of THF (LDA, produced from 0.35 ml of diisopropylamine and 1.6 ml of 1.65 M n-BuLi in hexane under argon at -78°C). 2.4 mmol of diphenyl diselenide, dissolved in 1 ml of THF and 1.2 mmol of HMPT, are added at -78°C to the enolate of 5a. The reaction mixture is stirred for 40 min at -78°C and for 1.5 h at -40°C. Quenching with 0.1 N HC1 and subsequent repeated extraction with ether yields, after chromatography on silica gel, a yellowish oil Sb of a characteristic odour.
N-Benz -~ drox~[2-(dimeth~phosphonoleth~~vrrole (Sc) 0.2 mmol of the phenylseleno compound 5b, dissolved in 1 ml of absolute THF, is combined with 30 ~,l of glacial acetic acid, 140 ~l of Perhydrol (30% hydrogen peroxide solution) are added dropwise with ice cooling and the mixture stirred for 30 min at the same temperature.
The solution is poured into cold, saturated aqueous sodium hydrogen carbonate solution, the mixture extracted with ether, dried over MgS04, evaporated under reduced pressure and the crude product chromatographed on silica gel. Sc is obtained in good yield as a yellowish oil.
N.2-Dihvdroxv-4-[2-(dimethvlphos hono)ethvl]pvrrole (Sdl 0.15 mmol of Sc is placed in 50 ml of absolute EtOH, a spatula-tipfull of 10%
Pd on activated carbon is added and the mixture hydrogenated for 1 h at RT in a standard pressure hydrogenation apparatus with vigorous stirring. Once the catalyst has been filtered out, the mixture is evaporated and the crude product is reacted without further purification.
N.2-Dihydrox ~-~5-J2-phos~honoethL~ll-pyrrole (5e) 4 equivalents (60 mmol, 8 ml) of trimethylbromosilane are added dropwise with ice cooling to 15 mmol of Sd in 50 ml of absoluted acetonitrile, the mixture is stirred for 15 min at the same temperature, then for 2 h at RT, evaporated under reduced pressure until a yellowish oil is obtained, the product is redissolved in 80 ml of water and hydrolysed for 1 h at RT (pH <
1). This solution is extracted twice with CHC13, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at a maximum of 45°C. The resultant oil is redissolved in water and a pH of 4.5 to 5.0 is established with NaHC03. Se is removed by suction filtration and, after washing with iced water, 5e is obtained as a virtually colourless sodium salt at a yield of 40%.
Example 6: N-H~xv-3-[2 ~phosnhonolethyl~-1H-~,vridone~61 2-Bromo-3-(bromometh,~lpvridine (6a~
g (58.1 mmol) of 2-bromo-3-methylpyridine and 11.4 g (64 mmol) of [sic] are refluxed for 24 h in 250 ml of CC14. The succinimide is separated by filtration and the organic phase is washed twice with water. After evaporation under reduced pressure, 6a is obtained as a colourless liquid by fractional distillation (bp: 90°C, 1 Torr).
2-Bromo-3-[2-(dimeth~nhosphonoleth~]pyridine fhb) 0.21 mol of MeLi in ether is added dropwise to 100 ml of absolute THF, 0.1 mol of trimethyl phosphite, dissolved in 50 ml of THF, is added dropwise within 15 min in such a manner that the internal temperature slowly reaches 0°C. 0.107 mol of 6a in 20 ml of THF is then added dropwise at a temperature of -78°C, stirring is continued for a further 30 min at the same temperature, the mixture is allowed to thaw and quenched at 0°C by dropwise addition of 80 ml of 3 M HCI. The organic phase is separated, the aqueous phase extracted three times with 40 ml portions of dichloromethane and, after drying over MgS04, the combined organic phases are evaporated. The yellow crude product may be purified in a short column on Si02.
2-Bromo-3-[2-(dimeth~nhos~nhono)ethy~pyridine N-oxide (6c) 100 mmol of 6b in 60 ml of glacial acetic acid are combined with 2 equivalents of a 40%
peracetic acid solution, wherein the temperature should not exceed 50°C. After 5 hours' heating to 50°C and 12 hours' heating to 70°C, the solution is evaporated to half its volume under reduced pressure, poured onto ice and made highly alkaline with 40%
aqueous KOH.
Triple extraction with chloroform yields, after drying over KzC03 and evaporation under reduced pressure, an N-oxide oil 6c, which was reacted without further purification.
N-Hvdroxv-3-f2-~dimethYlphosphonolet_hvl~-1H-pvridone~6d~
6c is heated in a glass autoclave for 3 h to 120°C in absolute MeOH
together with mortar-ground potassium hydroxide, potassium carbonate and tris(3,6-dioxaheptyl)amine. After cooling, the reaction mixture is poured into water, a pH value of 6 is established, the mixture evaporated under a vacuum and, after addition of ethanol, a crude product is obtained which may be recrystallised in moderate yield from ethanol/toluene.
N-H droxv-3-~2~fphos~hono)eth~]-1H-~vridone (6e) 40 mmol of trimethylbromosilane are added dropwise with ice cooling to 10 mmol of 6d in 30 ml of absolute acetonitrile, the mixture is stirred for 15 min at the same temperature, then for 2 h at RT, evaporated under reduced pressure until an oil is obtained, the product is redissolved in 20 ml of water and hydrolysed for 1 h at RT (acidic pH). This solution is extracted twice with CHCl3, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at 45°C. The resultant brown oil is redissolved in water, stirred twice with activated carbon, filtered therefrom and a pH of 5 is established.
As a result, 6e precipitates out, is filtered, washed with ice water and may be recrystallised from MeOH/EtOH.
Example 7: N-Hvdroxv-6-(2-lphosphono~ethvl]-1H-pyridone l7~
2-Bromo-6-bromomethvlpyridine ) 10.1 g (58.7 mmol) of 2-bromo-6-methylpyridine, 11.1 g (62.4 mmol) of N-bromosuccinimide (NBS) and 0.1 g (0.6 mmol) of AIBN are heated under argon for 6 h to 110°C in 150 ml of toluene, the mixture simultaneously being illuminated with a tungsten daylight lamp (150 W, >320 nm). After cooling, succinimide is filtered out and the solution evaporated under reduced pressure. Chromatography on silica gel (mobile solvent:
hexane/dichloromethane) at first yields 2-bromo-6-dibromomethylpyridine, while 7a may subsequently be eluted at a yield of up to 45% (mp: 138°C).
2-Bromo-6-[2-(dimeth~pho h~ono_leth~~~ ridine~7b~
0.21 mol of MeLi in ether is added dropwise to 100 ml of absolute THF, 0.1 mol of trimethyl phosphite, dissolved in 50 ml of THF, is added dropwise within 15 min in such a manner that the internal temperature slowly reaches 0°C. 0.107 mol of 7a in 15 ml of THF is then added dropwise at a temperature of -78°C, stirring is continued for a further 30 min at the same temperature, the mixture is allowed to thaw and quenched at 0°C by dropwise addition of 80 ml of 3 M HCI. The organic phase is separated, the aqueous phase extracted repeatedly with 40 ml portions of dichloromethane and, after drying over MgS04, the combined organic phases are evaporated. The yellow crude product may be chromatographically purified on SiOZ, 7b being obtained at a yield of 47%.
2-Bromo-6-(2-(dimethyl hosphonoleth ~~ll~yridine N-oxide~7c~
50 mmol of 7b in 50 ml of glacial acetic acid are combined with 2 equivalents of a 40%
peracetic acid solution, the temperature varying between 25 and 45°C.
After 5 hours' heating to 50°C and 12 hours' heating to 70°C, the solution is poured onto ice and made highly alkaline with 40% aqueous KOH. Triple extraction with chloroform yields, after drying over KZC03 and evaporation under reduced pressure, an N-oxide oil 7c, which may be recrystallised from ether/ethanol.
N-Hvdroxv-6-~~dimethvlphos honoleth l~pyridone (7dl 7c is heated in a glass autoclave for 2.5 h to 100°C in absolute MeOH
together with mortar-ground potassium hydroxide, potassium carbonate and tris(3,6-dioxaheptyl)amine. After cooling, the reaction mixture is poured into water, a pH value of 6 is established, the mixture evaporated under a vacuum and, after addition of ethanol, a crude product is obtained which, similarly to 6d, may be recrystallised in moderate yield.
N-H drox~[2-(~ho~honolet~vl]-1H ~vridone (7el 40 mmol of trimethylbromosilane axe added dropwise with ice cooling to 10 mmol of 7d in 25 ml of absolute acetonitrile, the mixture is stirred for 10 min at the same temperature, then for 2 h at RT, evaporated under reduced pressure at 45°C until an oil is obtained, the product is redissolved in 20 ml of water and hydrolysed for 1 h at RT. This solution is extracted twice with CHCl3, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at 45°C. The resultant dark-coloured oil is redissolved in water and a pH of 4.8 is established. As a result, 7e precipitates out as the sodium salt.
After filtration and washing with ice water, 7e is obtained as a crude product, which may be recrystallised from MeOH/toluene.
Example 8: N-Hvdrox~j2-phosphono-2-hvdroxylethvllpvrrolidin-2-one Ll_ N-Benzyl-2-(1.3-dithio lmeth~ly-pYrrolidine (,8a) 100 mmol (12.0 g) of 1,3-dithiane are weighed out under protective gas, 250 ml of absolute THF are added thereto and a 5% excess of n-BuLi in hexane is added dropwise thereto within 3-5 min at ~.0°C. The mixture is stirred for 2 h at -25 to -15°C, the temperature is reduced to -60 to -78°C and 100 mmol of 2-iodomethyl-N-benzyloxy-pyrrolidine are slowly added thereto under protective gas. After 5-6 hours' stirring at -20 to -10°C, the temperature is allowed to rise to 0°C and the reaction mixture is placed in the refrigerator for three days.
After evaporation to approx. 20 ml, the mixture is poured into three times its volume of water, extraction performed three to five times with chloroform, the organic phases are combined, washed in succession with water, 6% KOH and again with water and the chloroform phase is dried over KZC03. The residue obtained after evaporation under reduced pressure is reacted without further purification.
N-Benzyl_2-lformylmethYl)-nvrrolidine~8b) 1.1 g of CaC03 and 2.5 ml of Hg(C104)2 of a 4 M aqueous solution are added to a solution of 9 mmol of 8a in 30 ml of THF and 6 ml of water, stirring is continued for a further 5 to 10 min, 150 ml of ether are added thereto and inorganic salts are filtered out.
Once the solution has been evaporated under reduced pressure, a coloured crude product remains, which is purified by flash chromatography.
N-Benzyl-2-[2-ldiethylphosphono)-2-hvdroxv]pyrrolidine (8c) 20 g (145 mmol) of diethyl phosphonate and 140 mmol of 8b are heated under argon to 80 to 85°C for 8 h. After cooling, the mixture is evaporated under reduced pressure and the product 8c is purified chromatographically on silica gel.
N-Benz[2-(diethyl_phosphonol-2-acetox~lpvrrolidine ~8d) A mixture of 50 mmol of 1-hydroxyphosphonic acid ester 8c, 75 mmol of triethylamine, 75 mmol of acetic anhydride and 4 mmol of dimethylaminopyridine (DMAP) is left to stand for 14 h at RT and, after addition of 100 ml of ether and 2 N HCI, the etheric phase is washed with saturated aqueous NaHC03 solution, dried over MgS04, evaporated and purified on a short ALOX column.
2-f2-(N-Benzyl-2-[8-ldiethylphosphono)-2-acetoxy~pvrrolidine 1,8e) After addition of 400 mg of PtO2, a solution of 40 mmol of 8d in 30 ml of glacial acetic acid is hydrogenated at 70°C for 6 h at standard pressure. Once the catalyst has been filtered out, the mixture is repeatedly extracted with ether in a strongly alkaline medium, the combined ether extracts are dried over MgS04, evaporated and the product 8e, which is obtained in good yield, is directly further reacted.
N-H drox ~-~5-[2-phosnhono-2-h~X)eth~~pvrrolidin-2-one~8f~
A solution of 70 mmol of dimethyldioxirane in 110 ml of dry acetone is added dropwise to a solution, cooled to 0°C, of 20 mmol of 8e in 50 ml of dry acetone. The mixture is stirred for 30 min at 0°C and the solvent is then stripped out under a vacuum. A
yellow oil is obtained, which may be purified on silica gel with a chloroform/methanol mobile solvent mixture.
N-H~~[(2-dieth~phosnhono-2-hvdrox~ -ethyl]~vrrolidin-2 one (~~l The yellow oil 8f is stirred overnight with 5 M aqueous KOH in MeOH at RT, then neutralised, MeOH is removed under reduced pressure and the mixture extracted with ether.
The combined organic phases were dried over MgS04 and evaporated to dryness.
The resultant 8g is used for the subsequent reactions without further purification.
N-H derv-5-[(2-nhosphono-2-h~xl-ethyl~pvrrolidin-2-one ~8h~
80 mmol of trimethylbromosilane are added dropwise to a solution, cooled to 0°C, of 20 mmol of 8g in 50 ml of dry acetonitrile. The mixture is stirred for 3 h at RT, then the solvent is stripped out under a vacuum, the residue is redissolved with 60 ml of iced water, the mixture is stirred for 1 h at room temperature, extracted three times with 60 ml portions of ether, a pH value of 5.5 to 6.0 is established with 2 M NaOH and the water is then stripped out in a Rotavapor rotary evaporator at a maximum of 45°C. The solid residue is crystallised from methanol/ethyl acetate. N-Hydroxy-5-[(2-phosphono-2-hydroxy)-ethyl]pyrrolidin-2-one (8h) is obtained in good yield in the form of yellowish-white microcrystals.
Example 9: 3-(Methvlphosphono)-N-hvdroxv-succinimide~91 3-(Bromomethyl-succinic anh, d~(9a) In a similar manner to the preparation of N-(2-trimethylsilylethoxy)-pyrrolidin-2-one (2b) 50 mmol of 2-methylsuccinic anhydride, dissolved in 30 ml of absoluted carbon tetrachloride, are reacted with 1.2 equivalents of N-bromosuccinimide by refluxing the mixture for 12 h.
Small quantities of azobisisobutyronitrile (AIBN) are added at hourly intervals. After cooling, the product is filtered from succinimide, the latter is washed with CC14 and the combined CC14 phases are evaporated under reduced pressure. The resultant oil may be chromatographed on Si02, 9a being obtained in low yield.
3-[2-(Dimeth~rlhosnhono~ethyl]-succinic anh_ dv ride (2b) 40 mmol of 9a are refluxed for 0.5 to 1 h with 1 equivalent of trimethyl phosphite in toluene.
After cooling, the mixture is evaporated under reduced pressure and the yellowish oil is chromatographed on Si02. Once volatile constituents have been stripped out, 9b is obtained in low yield.
3-[~Dimeth~phosphonolmethvll-N-benzyloxy-succinimide~9c) 1.0 g of benzyloxyamine is heated in a glass autoclave with 1.0 equivalent of 9b to 180°C for 30 min. After cooling, the oil is evaporated under reduced pressure, a poor crude product yield being observed, and 9c is further reacted without purification.
3-[2-(Dimeth~phosphono)meths]-N-h~droxv-succinimide (9dl 9.28 mmol of the benzyloxy compound 9c dissolved in 60 ml of ethanol are combined with 700 mg of Pd/C and hydrogenated at standard pressure for 4 h at RT. Once hydrogen absorption has ceased, the catalyst is filtered out, the mixture evaporated under reduced pressure and recrystallised from ethyl acetate/hexane, 9d being obtained in good yield.
3-(2-Phosnhonomethvl]-N-hydroxy-succinimide ~9e1 110 mmol of trimethylbromosilane are added dropwise to a solution, cooled to 0°C, of 30 mmol of 9g in 70 ml of dry acetonitrile. The mixture is stirred for 3 h at RT, then the solvent is stripped out under a vacuum, the residue is redissolved with 80 ml of iced water, the mixture is stirred for 1 h at room temperature, extracted three times with 50 ml portions of ether, a pH value of 5.5 to 6.0 is established with NaHC03 and the water is then stripped out in a Rotavapor rotary evaporator at a maximum of 45°C. The solid residue is crystallised from methanol/acetone. 9e is obtained in the form of beige crystals in good yield.
Example 10: 1-N-l2-Phosphonoethyll-3-hvdroxy-7-meth~rl-xanthine f101 1-N-(2-Dimethylnhosnhono-eth~,i-7-methylxanthine~l0a) 50 g of 7-methylxanthine (2,6-dihydroxy-7-methylpurine) are dissolved in 1 1 of boiling ethanol and 38 g of 50% potassium hydroxide solution are added thereto. Once the mixture has cooled to 15 to 20°C, the potassium salt of 7-methylxanthine precipitates out, is filtered out and decocted with boiling acetone and boiling absolute ethanol.
A solution of 20 mmol of 2-bromomethylphosphonic acid dimethyl ester and 2 mmol of hexadecyltributyl-phosphonium bromide in 10 ml of toluene is combined with 25 mmol of the potassium salt of 7-methylxanthine and the mixture heated to 100°C for 2 h. Once the reaction mixture has cooled, undissolved fractions are filtered out and the evaporated organic phase is chromatographed on silica gel with ether/chloroform as mobile solvent. In this manner, both the desired 1-N-(2-dimethylphosphono-ethyl)-7-methylxanthine (l0a) and, at lower yield, 3-N-(2-dimethylphosphono-ethyl)-7-methylxanthine (l0a') are obtained.
1-N-f2-Dimeth~phosnhono-ethyll-3-h droxy-7-met~yl-xanthine ~(lObl A solution of 60 mmol of dimethyldioxirane in 120 ml of dry acetone is added dropwise to a solution, cooled to 0°C, of 25 mmol of l0a in 50 ml of dry acetone. The mixture is stirred for 30 min at 0°C and the solvent is then stripped out under reduced pressure. The resultant crude product is chromatographed on silica gel, 1-N-(2-dimethylphosphono-ethyl)-3-hydroxy-7-methyl-xanthine (lOb) being obtained in poor yield.
In a similar manner, 3-N-(2-dimethylphosphonoethyl)-7-methylxanthine (l0a') may be converted into 3-N-(2-dimethylphosphono-ethyl)-1-hydroxy-7-methylxanthine (lOb').
1-N-(2-Phosphono-ethyll-3-hydroxy-7-methyl-xanthine (lOc~
4 equivalents (100 mmol) of trimethylbromosilane are added dropwise with ice cooling to 25 mmol of lOb in 50 ml of absoluted acetonitrile, the mixture is stirred for 15 min at the same temperature, then for 2 h at RT', evaporated under reduced pressure until an oil is obtained, the product is redissolved in 100 ml of water and hydrolysed for 1 h at RT. In order to remove hexamethyldisiloxane, this solution is extracted twice with CHC13, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at 45°C. The resultant beige oil is redissolved in water and a pH of 6.5 to 7.0 is established. After washing with iced water, lOc is obtained as a virtually colourless sodium salt at a yield of SS%.
In a similar manner, 3-N-(2-dimethylphosphono-ethyl)-1-hydroxy-7-methyl-xanthine (lOb') is reacted with trimethylbromosilane to yield 3-N-(2-phosphono-ethyl)-1-hydroxy-7-methyl-xanthine (lOc').
Example 11: N-Hvdroxv-1,2,3 4-tetrahvdro-1-oxo-3-~2-nhos~honoethyl)1-iso~uinoline 3-Phenyl-2-amino~ropanol (lla~
3.0 mol of LiAlH4 are suspended in 900 ml of anhydrous tetrahydrofuran in a heat-treated and argon-flooded three-necked flask fitted with a KPG stirrer and 1.5 mol of phenylalanine are added in portions with ice cooling. The mixture is then refluxed for 6 h, allowed to cool and hydrolysed with crushed ice. The mixture is filtered and the solvent removed under a vacuum.
The filtrate is redissolved with CH2Cl2, washed with saturated NaCI solution and dried with Na2S04. Vacuum distillation is then performed. 3-Phenyl-2-aminopropanol lla is obtained at a yield of 76%.
1-Phen,~(tetrahvdro-2-~~,~Xl-2-aminopropane (llb) 2.5 mol of dihydropyran and 5.3 g of p-toluenesulfonic acid are added to 1.4 mol of 3-phenyl-2-aminopropanol 1 and the mixture then stirred for 20 h at RT. The excess dihydropyran is then removed under a vacuum, the residue redissolved with 700 ml of ethyl acetate and washed with 300 ml portions of saturated NaHC03 solution and saturated NaCI
solution. The mixture is then dried with MgS04, filtered and the solvent removed under a vacuum. 1-Phenyl-3-(tetrahydro-2-pyranyloxy)-2-aminopropane (1lb) is obtained at a yield of 63%.
1-Phen,~(tetrahydro-2-pyr~,~~l-2-isocyanopropane fllc) 0.88 mol of 1-phenyl-3-(tetrahydro-2-pyranyloxy)-2-aminopropane llb are added dropwise to a solution of 3.52 mol of phosgene in 1.5 1 of toluene and the mixture then boiled for 3 h at 80°C. The solvent is then removed under a vacuum. The desired product 1-phenyl-3-(tetrahydro-2-pyranyloxy)-2-isocyanopropane llc is obtained at a yield of 83%.
This is used without further purification.
1.2,3~4-Tetrahydro-1-oxo-3-h~droxymeth,1-~quinoline (lld) A solution of 0.72 mol of 1-phenyl-3-(tetrahydro-2-pyranyloxy)-2-isocyanopropane llc in 80 ml of anhydrous acetone is slowly added dropwise to 100 ml of ice-cooled phosphoric acid and stirred for 3 h at RT. Ice water is then added, the mixture stirred for 0.5 h and then extracted with CH2Cl2. The organic phase is washed with water, saturated NaZC03 solution, again with water and with saturated NaCI solution and dried with MgS04. After filtration and removal of the solvent under a vacuum, the product is recrystallised from hexane/benzene, 28% of 1,2,3,4-tetrahydro-1-oxo-3-hydroxymethyl-isoquinoline (lld) being obtained.
1 2,3.4-Tetrahydro-1-oxo-3-bromomethyl-isoquinoline (lle) A solution of 180 mmol of PPh3 in 120 ml of CH2C12 is added to a solution of 150 mmol of 1,2,3,4-tetrahydro-1-oxo-3-hydroxymethyl-isoquinoline llc and 210 mmol of CBr4 in 150 ml of CHZCl2 and stirred for 20 h at RT. The solvent is then removed under a vacuum and the residue repeatedly recrystallised from benzene. The product 1,2,3,4-tetrahydro-1-oxo-3-bromomethyl-isoquinoline lle is obtained at a yield of 31%.
1.2.3.4-Tetrahvdro-1-oxo-3-(2-dieth, l~bhosnhonoeth,~ll-isoauinoline ,llf) 66.2 mmol of solution of n-butyllithium (1.15 M) in hexane are added dropwise at -78°C to a solution of 75 mmol of dimethyl methylphosphonate in 120 ml of absolute THF
under argon and the mixture stirred for 1.5 h at this temperature. 46.5 mmol of 1,2,3,4-tetrahydro-1-oxo-3-bromomethyl-isoquinoline lle in 50 ml of absolute THF are added dropwise to this solution at -78°C, the mixture stirred for a further 1 h at -78°C and then allowed to rise to RT
overnight. 100 ml of water are then added, the aqueous phase separated and extracted 3 times with 50 ml portions of ethyl acetate. The combined organic phases are dried with MgS04, filtered and the solvent removed under a vacuum. The residue is purified chromatographically (silica gel, hexane/ethyl acetate 5:1). 24% of the desired product 1,2,3,4-tetrahydro-1-oxo-3-(2-diethylphosphonoethyl)-isoquinoline llf are obtained.
N-H, d~,~ 2,3.4-tetrah~dro-1-oxo-3-~2-dieth, ly~hosnhonoethy~-isoduinoline~llg) 5.36 mmol of 1,2,3,4-tetrahydro-1-oxo-3-(2-diehtylphosphonoethyl)-isoquinoline 6 are dissolved in 30 ml of absolute acetone and cooled to 0°C. A solution of 17.15 mmol of dimethyldioxirane is then added dropwise and the mixture stirred for 30 min at 0°C. The solvent is removed under a vacuum and the residue purified chromatographically (silica gel, hexane/ethyl acetate 4:1). 33% of the product N-hydroxy-1,2,3,4-tetrahydro-1-oxo-3-(2-diethylphosphonoethyl)-isoquinoline llg are obtained.
N-Hydrox,~.2.3.4-tetrahvdro-1-oxo-3-(2-phosphonoeth_ lv_l-isoduinoline f,llh) 1.77 mmol ofN-hydroxy-1,2,3,4-tetrahydro-1-oxo-3-(2-diethylphosphonoethyl)-isoquinoline llg are dissolved in 15 ml of absolute CHZCl2 under argon and cooled to 0°C. 10 mmol of trimethylbromosilane are then added dropwise from a syringe, the mixture stirred for a further 1 h at 0°C and then overnight at RT. The solvent is then removed under a vacuum, the residue redissolved in 20 ml of water and stirred for 1 h at RT. 15 ml of CHC13 are then added and the organic phase separated. The aqueous phase is extracted twice more with 10 ml portions of CHC13 and the mixture evaporated under a vacuum. The residue is purified chromatographically (silica gel, H20/methanol 1:1). The desired product is obtained at a yield of 54%.
Example 12:
The antimalarial activity of the substances stated in Table I was determined using in vitro cultures of the causative organism of malaria, Plasmodium falciparum. The roman numerals refer to the particularly preferred compounds stated on pages [sic] to [sic].
200 ~l of an asynchronous Plasmodium falciparum culture with a 0.4% blood parasite content and a haematocrit of 2% were loaded into each of the wells of a 96 well microtitre plate. A serial dilution series of the compounds was then prepared in steps of three between concentrations of 100 and 1 ~mol 1-1. The plates are incubated at 37°C, 3% C02 and 5%
02 over a period of 48 hours. 30 pl of medium supplemented with 27 ~Ci ml-1 of [3H]-hypoxanthine were then added to each well. After 24 hours' incubation, the parasites were harvested by filtration through glass fibre filters and the incorporated radioactivity was measured.
Inhibition of parasite growth was measured as the percentage inhibition of tritium incorporation relative to a comparison without the substance. The results for the three different concentrations are stated in Table I.
Ta le I
SubstanceR5 A Form used 100 wM 10 p,M 1 ~.M
inhibitioninhibitioninhibition (%) (%) (%) I H C2H4 Na salt 98 98 98 III H CHZ Na salt 96 98 63 II H CHZ Na salt 98 87 59 I H CH2CHOH Na salt 98 97 78 X H CHZ Na salt 89 80 0 X H CHZ Na salt 98 97 98 III H CHZ Na salt 98 98 82 pyrrole ring is NH2-substituted in osition VII H CZH4 Na salt 98 98 98 ~:XXI H CZH4 Na salt 97 73 53 XXVIII H CZH4 Na salt 98 97 82 ~!:XXVIIIH CZH4 Na salt 92 78 30 N-substituted in osition XXXVI H C2H4 Na salt 95 80 37 in position Example 13 The antibacterial action of the substances stated in Table II was determined.
The roman numerals refer to the particularly preferred compounds stated on pages 5 to 8.
A dilution series comprising the concentrations 500, 100, 50 and 10 ~,mol l~l of the individual compounds in LB medium is introduced into 5 culture microtubes in a volume of 0.5 ml. Each of the microtubes was inoculated with 10 ~1 of an overnight culture of E. coli K12 and shaken overnight at 37°C. Bacterial growth was assessed on the basis of the turbidity of the medium.
The minimum concentration causing inhibition of bacterial growth was determined (minimum inhibition concentration, MIC).
Antibacterial activity with regard to P. aeruginosa was determined in the same manner. The results are shown in Table II.
Table II
SubstanceR5 A Form used E. coli P. aeruginosa MIC (m ) 10 m /1 I H C2H4 Na salt 2.5 5 III H CH2 Na salt 5 5 pyrrole ring is NH2-substituted in osition 3 II H CH2 Na salt 10 5 I H CHZCHOH Na salt 2.5 1.25 X H CH2 Na salt 1.25 1.25 X ~ H CH2 Na salt 10 20 III i H CHz Na salt 1.25 10 VII H CZH4 Na salt 10 40 I~:XXI H C2H4 Na salt 10 1.25 XXVIII H CzH4 Na salt 5 5 XXXVIII H C2H4 Na salt 20 80 N-substituted in osition 5 XXXVI H CZH4 Na salt 40 20 in position
O \Rs O \Rs O Rs XXIV XXV XXVI
/ /
O N O N A_p032-t t O \Rs O \Rs XXVII XXVIII
A-P03z-A-PO z.
~ A-P03z-O N O N J O N
O
O \Rs \Rs O \Rs XXIX ~ XXXI
_g_ N - OH N - OH
A ~ A i ~XB XXXIB
N - ORs N - ORs A A PO32 ~V
mcxxt v O O
/ ORs , ORs J N
A-P03z- ' ~ A-P032- ..
XXXVI XXXVII
ORs I
'N
N
s A-YU3= O
XXXVIII
_g_ and the corresponding phosphinic acid and phosphinoyl derivatives.
Special features of the above definitions and suitable examples thereof are given below:
"Acyl" is a substituent which originates from an acid, such as from an organic carboxylic acid, carbonic acid, carbamic acid or the thio acid or imidic acid corresponding to the above individual acids, or from an organic sulfonic acid, wherein these acids in each case comprise aliphatic, aromatic and/or heterocyclic groups in the molecule together with carbamoyl or carbamimidoyl.
Suitable examples of these acyl groups are given below.
Aliphatic acyl groups are defined as acyl residues originating from an aliphatic acid and include the following:
alkanoyl (for example formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl etc.); alkenoyl (for example acryloyl, methacryloyl, crotonoyl etc.);
alkylthioalkanoyl (for example methylthioacetyl, ethylthioacetyl etc.);
alkanesulfonyl (for example mesyl, ethanesulfonyl, propanesulfonyl etc.); alkoxycarbonyl (for example methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl etc.); alkylcarbamoyl (for example methylcarbamoyl etc.); (N-alkyl)thiocarbamoyl (for example (N-methyl)thiocarbamoyl etc.);
alkylcarbamimidoyl (for example methylcarbamimidoyl etc.); oxalo; alkoxalyl (for example methoxalyl, ethoxalyl, propoxalyl etc.).
In the above examples of aliphatic acyl groups, the aliphatic hydrocarbon moiety, in particular the alkyl group or alkane residue, may optionally have one or more suitable substituents, such as amino, halogen (for example fluorine, chlorine, bromine etc.), hydroxy, hydroxyimino, carboxy, alkoxy (for example methoxy, ethoxy, propoxy etc.), alkoxycarbonyl, acylamino (for example benzyloxycarbonylamino etc.), acyloxy (for example acetoxy, benzoyloxy etc.) and the like; preferred aliphatic acyl residues with such substituents which may be mentioned are, for example, alkanoyls substituted with amino, carboxy, amino and carboxy, halogen, acylamino or the like.
Aromatic acyl residues are defined as those acyl residues which originate from an acid with a substituted or unsubstituted aryl group, wherein the aryl group may comprise phenyl, toluyl, xylyl, naphthyl and the like; suitable examples are stated below:
aroyl (for example benzoyl, toluoyl, xyloyl, naphthoyl, phthaloyl etc.);
aralkanoyl (for example phenylacetyl etc.); aralkenoyl (for example cinnamoyl etc.);
aryloxyalkanoyl (for example phenoxyacetyl etc.); arylthioalkanoyl (for example phenylthioacetyl etc.);
arylaminoalkanoyl (for example N-phenylglycyl, etc.); arenesulfonyl (for example benzenesulfonyl, tosyl or toluenesulfonyl, naphthalenesulfonyl etc.);
aryloxycarbonyl (for example phenoxycarbonyl, naphthyloxycarbonyl etc.); aralkoxycarbonyl (for example benzyloxycarbonyl etc.); arylcarbamoyl (for example phenylcarbamoyl, naphthylcarbamoyl etc.); arylglyoxyloyl (for example phenylglyoxyloyl etc.).
In the above-stated examples of aromatic acyl residues, the aromatic hydrocarbon moiety (in particular the aryl residue) and/or the aliphatic hydrocarbon moiety (in particular the alkane residue) may optionally have one or more suitable substituents, such as those which have already been stated as suitable substituents for the alkyl group or the alkane residue.
Examples of preferred aromatic acyl residues with specific substituents which may in particular be mentioned are aroyl substituted with halogen and hydroxy or with halogen and acyloxy, and aralkanoyl substituted with hydroxy, hydroxyimino, dihaloalkanoyloxyimino, together with arylthiocarbamoyl (for example phenylthiocarbamoyl etc.);
arylcarbamimidoyl (for example phenylcarbamimidoyl etc.).
A heterocyclic acyl residue is taken to mean an acyl residue which originates from an acid with a heterocyclic group; such residues include:
heterocyclic carbonyl, in which the heterocyclic residue is an aromatic or aliphatic 5- to 6-membered heterocycle with at least one heteroatom from the group nitrogen, oxygen and sulfur (for example thiophenyl, furoyl, pyrrolecarbonyl, nicotinyl etc.);
heterocycle-alkanoyl, in which the heterocyclic residue is 5- to 6-membered and comprises at least one heteroatom from the group nitrogen, oxygen and sulfur (for example thiophenylacetyl, furylacetyl, imidazolylpropionyl, tetrazolylacetyl, 2-(2-amino-4-thiazolyl)-2-methoxyiminoacetyl etc.) and the like.
In the above Examples of heterocyclic acyl residues, the heterocycle and/or the aliphatic hydrocarbon moiety may optionally comprise one or more suitable substituents, such as the same as were stated to be suitable for alkyl and alkane groups.
"Alkyl" is a linear or branched alkyl residue, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, pentyl, hexyl and the like.
"Hydroxyalkyl" is a linear or branched alkyl residue which comprises at least one hydroxyl group, preferably one or two hydroxyl groups.
"Alkenyl" includes linear or branched alkenyl groups, such as for example vinyl, propenyl (for example 1-propenyl, 2-propenyl), 1-methylpropenyl, 2-methylpropenyl, butenyl, 2-ethylpropenyl, pentenyl, hexenyl.
"Alkynyl" includes linear or branched alkynyl groups.
Cycloalkyl preferably.denotes an optionally substituted C3_8 cycloalkyl;
possible substituents are inter alia alkyl, alkenyl, alkynyl, alkoxy (for example methoxy, ethoxy etc.), halogen (for example fluorine, chlorine, bromine etc.), nitro and the like.
Aryl is an aromatic hydrocarbon residue, such as phenyl, naphthyl etc., which may optionally comprise one or more suitable substituents, such as alkyl, alkenyl, alkynyl, alkoxy (for example methoxy, ethoxy etc.), halogen (for example fluorine, chlorine, bromine etc.), nitro and the like.
"Aralkyl" includes mono-, di-, triphenylalkyls such as benzoyl, phenethyl, benzhydryl, trityl and the like, wherein the aromatic moiety may optionally comprise one or more suitable substituents, such as alkoxy (for example methoxy, ethoxy etc.), halogen (for example fluorine, chlorine, bromine etc.), nitro and the like.
The residues X3 and X4 may preferably be selected such that esters are formed on the phosphino group or phosphono group. Suitable examples of such esters according to the formulae (I), (III) and (IV) include suitable mono- and diesters, and preferred examples of such esters include alkyl esters (for example hexadecanyl ester, octadecanyl ester etc.);
aralkyl esters (benzyl ester, phenethyl ester, benzhydryl ester, trityl ester etc.); aryl esters (for example phenyl ester, tolyl ester, naphthyl ester etc.); aroylalkyl esters (for example phenacyl ester etc.); and silyl esters (for example of trialkylhalosilyl, dialkyldihalosilyl, alkyltrihalosilyl, dialkylarylhalosilyl, trialkoxyhalosilyl, dialkylaralkylhalosilyl, dialkoxydihalosilyl, trialkoxyhalosilyl etc.) and the like.
In the above esters, the alkane and/or arene moiety may optionally comprise at least one suitable substituent, such as halogen, alkoxy, hydroxy, nitro or the like.
The compounds used according to the invention according to the formulae (I), (III) and (IV) may be present in the protonated form thereof as an ammonium salt of organic or inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, acetic acid, lactic acid, malefic acid, fumaric acid, oxalic acid, tartaric acid, benzoic acid etc..
The compounds used according to the invention of the formulae (I), (III) and (IV) permit, for example for groups Rl, R3, R4, X3, X4 or A which contain double bonds or are chiral, the occurrence of steric isomers. The use according to the invention of the compounds includes all steric isomers, both as pure substances and in the form of mixtures.
The organophosphorus compounds are suitable for the therapeutic and prophylactic treatment of infections in humans and animals caused by viruses, bacteria, uni- and multicellular parasites and fungi.
The compounds are active against unicellular parasites (protozoa), in particular against the causative organisms of malaria and sleeping sickness and of Chagas' disease, toxoplasmosis, amoebic dysentery, leishmaniases, trichomoniasis, pneumocystosis, balantidiasis, cryptosporidiosis, sarcocytosis, acanthamoebosis, naeglerosis, coccidiosis, giardiasis and lambliasis.
They are accordingly in particular suitable for the prophylactic treatment of malaria and of sleeping sickness and of Chagas' disease, of toxoplasmosis, amoebic dysentery, leishmaniases, trichomoniasis, pneumocystosis, balantidiasis, cryptosporidiosis, sarcocytosis, acanthamoebosis, naeglerosis, coccidiosis, giardiasis and lambliasis.
The active substances according to the invention may in particular be used against the following bacteria:
bacteria of the family Propionibacteriaceae, in particular of the genus Propionibacterium, in particular the species Propionibacterium acnes, bacteria of the family Actinomycetaceae, in particular of the genus Actinomyces, bacteria of the genus Cornynebacterium, in particular the species Corynebacterium diphtheriae and Corynebacterium pseudotuberculosis, bacteria of the family Mycobacteriaceae, of the genus Mycobacterium, in particular the species Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium, bacteria of the family Chlamydiaceae, in particular the species Chlamydia trachomatis and Chlamydia psittaci, bacteria of the genus Listeria, in particular the species Listeria monocytogenes, bacteria of the species Erysipelthrix rhusiopathiae, bacteria of the genus Clostridium, bacteria of the genus Yersinia, the species Yersinia pestis, Yersinia pseudotuberculosis, Yersinia enterocolitica and Yersinia ruckeri, bacteria of the family Mycoplasmataceae, of the genera Mycoplasma and Ureaplasma, in particular the species Mycoplasma pneumoniae, bacteria of the genus Brucella, bacteria of the genus Bordetella, bacteria of the family Neisseriaceae, in particular of the genera Neisseria and Moraxella, in particular the species Neisseria meningitides, Neisseria gonorrhoeae and Moraxella bovis, bacteria of the family Vibrionaceae, in particular of the genera Vibrio, Aeromonas, Plesiomonas and Photobacterium, in particular the species Vibrio cholerae, Vibrio anguillarum and Aeromonas salmonicidas, bacteria of the genus Campylobacter, in particular the species Campylobacter jejuni, Campylobacter coli and Campylobacter fetus, bacteria of the genus Helicobacter, in particular the species Helicobacter pylori, bacteria of the families Spirochaetaceae and Leptospiraceae, in particular of the genera Treponema, Borrelia and Leptospira, in particular Borrelia burgdorferi, bacteria of the genus Actinobacillus, bacteria of the family Legionellaceae, of the genus Legionella, bacteria of the family Rickettsiaceae and family Bartonellaceae, bacteria of the genera Nocardia and Rhodococcus, bacteria of the genus Dermatophilus, bacteria of the family Pseudomonadaceae, in particular of the genera Pseudomonas and Xanthomonas, bacteria of the family Enterobacteriaceae, in particular of the genera Escherichia, Klebsiella, Proteus, Providencia, Salmonella, Serratia and Shigella, bacteria of the family Pasteurellaceae, in particular of the genus Haemophilus, bacteria of the family Micrococcaceae, in particular of the genera Micrococcus and Staphylococcus, bacteria of the family Streptococcaceae, in particular of the genera Streptococcus and Enterococcus and bacteria of the family Bacillaceae, in particular of the genera Bacillus and Clostridium.
The organophosphorus compounds and the derivatives thereof are consequently suitable for treating diphtheria, acne vulgaris, listerioses, swine erysipelas in animals, gas gangrene in humans and animals, malignant oedema in humans and animals, tuberculosis in humans and animals, leprosy and further mycobacterioses in humans and animals, paratuberculosis in animals, plague, mesenterial lymphadenitis and pseudotuberculosis in humans and animals, cholera, legionnaires' disease, borreliosis in humans and animals, leptospiroses in humans and animals, syphilis, Campylobacter enteritis infections in humans and animals, Moraxella keratoconjunctivitis and serositis in animals, brucellosis of animals and humans, anthrax in humans and animals, actinomycosis in humans and animals, streptotrichoses, psittacosis/ortnithosis in animals, Q fever, ehrlichiosis.
Use is furthermore in particular preferred in the eradication of Helicobacter in ulcers of the gastrointestinal tract.
Combinations with another antibiotic may also be used to treat the above-stated diseases.
Isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, protionamide and dapsone are in particular suitable for combination preparations with other antiinfective agents for the treatment of tuberculosis.
The active substances according to the invention are furthermore in particular usable in infections with the following viruses:
Paxvoviridae: parvoviruses, dependoviruses, densoviruses, Adenoviridae:
adenoviruses, mastadenoviruses, aviadenoviruses, Papovaviridae: papovaviruses, in particular papillomaviruses ("wart" viruses), polyomaviruses, in particular JC virus, BK
virus and miopapovaviruses, Herpesviridae: all herpesviruses, in particular herpes simplex viruses, varicella-zoster viruses, human cytomegalovirus, Epstein-Barr viruses, all human herpesviruses, human herpesvirus 6, human herpesvirus 7, human herpesvirus 8, Poxiviridae: poxviruses, orthopoxviruses, parapoxviruses, molluscum contagiosum virus, aviviruses, capriviruses, leporipoxviruses, all primarily hepatotropic viruses, hepatitisviruses: hepatitis A viruses, hepatitis B viruses, hepatitis C viruses, hepatitis D viruses, hepatitis E viruses, hepatitis F
viruses, hepatitis G
viruses, hepadnaviruses: all hepatitisviruses, hepatitis B virus, hepatitis D
viruses, Picornaviridae: picornaviruses, all enteroviruses, all polioviruses, all coxsackie-viruses, all echoviruses, all rhinoviruses, hepatitis A virus, aphthoviruses, Calciviridae:
hepatitis E
viruses, Reoviridae: reoviruses, orbiviruses, rotaviruses, Togaviridae:
togaviruses, alphaviruses, rubiviruses, pestiviruses, rubellavirus, Flaviviridae:
flaviviruses, FSME virus, hepatitis C virus, Orthomyxoviridae: all influenza viruses, Paramyxoviridae:
paramyxoviruses, morbillivirus, pneumovirus, measles virus, mumps virus, Rhabdoviridae:
rhabdoviruses, rabies virus, lyssavirus, vascular stomatitisvirus, Coronaviridae: coronaviruses, Bunyaviridae: bunyaviruses, nairovirus, phlebovirus, uukuvirus, hantavirus, hantaan virus, Arenaviridae: arenaviruses, lymphocytic choriomeningitis virus, Retroviridae:
retroviruses, all HTL viruses, human T-cell leukaemia virus, oncornaviruses, spumaviruses, lentiviruses, all HI viruses, Filoviridae: Marburg and Ebola virus, slow-virus infections, prions, oncoviruses and leukaemia viruses.
The organophosphorus compounds used according to the invention are consequently suitable for combating the following viral infections:
eradication of papillomaviruses to prevent tumours, in particular tumours of the reproductive organs caused by papillomaviruses in humans, eradication of JC viruses and BK
viruses, eradication of herpesviruses, eradication of human herpesvirus 8 to treat Kaposi's sarcoma, eradication of cytomegaloviruses before transplantations, eradication of Epstein-Barr viruses before transplantation and to prevent tumours associated with Epstein-Barr viruses, eradication of hepatitis viruses to treat chronic liver disease and to prevent liver tumours and cirrhosis of the liver, eradication of coxsackie-viruses in cardiomyopathy, eradication of coxsackie-viruses in diabetes mellitus patients, eradication of immunodeficiency viruses in humans and animals, treatment of accompanying infections in AIDS patients, treatment of respiratory tract inflammation of viral causation (laryngeal papilloma, hyperplasia, rhinitis, pharyngitis, bronchitis, pneumonia), of the sensory organs (keratoconjunctivitis), of the nervous system (poliomyelitis, meningoencephalitis, encephalitis, subacute sclerosing panencephalitis, SSPE, progressive multifocal leukoencephalopathy, lymphocytic choriomeningitis), of the gastrointestinal tract (stomatitis, gingivostomatitis, oesophagitis, gastritis, gastroenteritis, diarrhoea), of the liver and gall system (hepatitis, cholangitis, hepatocellular carcinoma), of the lymphatic tissue (mononucleosis, lymphadenitis), of the haemopoietic system, of the reproductive organs (mumps orchitis), of the skin (warts, dermatitis, herpes labialis, herpes febrilis, herpes zoster, shingles), of the mucous membranes (papillomas, conjunctiva) papillomas, hyperplasia, dysplasia), of the cardiovascular system (arteriitis, myocarditis, endocarditis, pericarditis), of the kidney/urinary system, of the reproductive organs (anogenital lesions, warts, genital warts, sharp condylomas, dysplasia, papillomas, cervical dysplasia, condyloma acuminatum, epidermodysplasia verruciformis), of the locomotory organs (myositis, myalgia), treatment of foot-and-mouth disease in cloven-hoofed animals, of Colorado tick fever, Dengue syndrome, of haemorrhagic fever, of early summer meningoencephalitis (FSME) and of yellow fever.
The described compounds, i.e. the organophosphorus compounds of the formulae (I), (III) and (IV) and esters and amides thereof on the phosphino group and salts thereof exhibit strong cytotoxic activity against uni- and multicellular parasites, in particular against the causative organisms of malaria and sleeping sickness. The compounds according to the invention are accordingly usable for the treatment of infective diseases which are caused in humans and animals by viruses, bacteria, parasites and fungi. The compounds are also suitable for the prevention of diseases which are caused by viruses, bacteria, parasites and fungi, in particular for the prophylactic treatment of malaria and of sleeping sickness.
The organophosphorus compounds used according to the invention, which generally include for this purpose pharmaceutically acceptable salts, amides, esters, a salt of such an ester or also compounds which, on administration, provide the compounds used according to the invention as metabolites or breakdown products (also known as "prodrugs"), may be formulated for administration in any suitable manner analogous to known agents having an antiinfective action (mixed with a non-toxic, pharmaceutically acceptable excipient).
Pharmaceutically acceptable salts of the compounds include salts which the compounds of the formulae (I), (III) and (IV) according to the invention form in their protonated form as an ammonium salt of inorganic or organic acids, such as hydrochloric acid, sulfuric acid, citric acid, malefic acid, fiunaric acid, tartaric acid, p-toluenesulfonic acid.
Particularly pharmaceutically suitable salts are also those formed by suitable selection of X3 and X4, such as sodium salt, potassium salt, calcium salt, ammonium salt, ethanolamine salt, triethylamine salt, dicyclohexylamine salt and salts of an amino acid such as arginine salt, aspartic acid salt, glutamic acid salt.
The activity of the substances is determined using a test system. This system is based upon in vitro measurement of the inhibition of growth of bacteria, parasites, viruses, fungi or plants.
Test methods known to the person skilled in the art are in part used for this purpose.
For example, antimalarial activity is determined by measuring the inhibition of the growth of malaria parasites in blood cultures.
Antibacterial activity is determined on the basis of measuring the inhibition of bacterial growth on nutrient media and in liquid cultures.
Antiviral activity is determined on the basis of the formation of viral elements in cell cultures.
Fungicidal activity is determined on the basis of inhibition of fungal growth on nutrient media and in liquid cultures.
Some of the microorganisms which are to be investigated may only be investigated in animal models. In this case, the appropriate models will then be used.
Substances which exhibit activity in in vitro measurement systems are then further investigated in in vivo models. Antiparasitic, antiviral, fungicidal or antibacterial activity is further evaluated in the appropriate animal models.
Screening for herbicidal activity is determined by means of algal systems and measurement of isoprene emissions from plants under standard conditions.
The pharmaceutically active agents may be prepared in dosage units in the form of pharmaceutical preparations. This means that the preparation is in the form of individual components, for example tablets, coated tablets, capsules, pills, suppositories and ampoules, the active substance content of which corresponds to a fraction or multiple of an individual dose. The dosage units may contain, for example 1, 2, 3 or 4 individual doses or 1/2, 1/3 or 1/4 of an individual dose. An individual dose preferably contains the quantity of active substance which is administered at one time and usually corresponds to a whole, half, third or quarter of a daily dose.
Non-toxic, inert, pharmaceutically suitable excipients should be taken to mean solid, semi-solid or liquid diluents, fillers and formulation auxiliaries of all kinds.
Preferred pharmaceutical preparations which may be mentioned are tablets, coated tablets, capsules, pills, granules, suppositories, solutions, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders and sprays. Tablets, coated tablets;
capsules, pills and granules may contain the active substances together with conventional excipients, such as (a) fillers and extenders, for example starches, lactose, cane sugar, glucose, mannitol and silica, (b) binders, for example carboxymethylcellulose, alginates, gelatine, polyvinylpyrrolidone, (c) humectants, for example glycerol, (d) suspending agents, for example agar-agar, calcium carbonate and sodium carbonate, (e) dissolution retardants, for example paraffin and (f) resorption accelerators, for example quaternary ammonium compounds, (g) wetting agents, for example cetyl alcohol, glycerol monostearate, (h) adsorbents, for example kaolin and bentonite and (i) lubricants, for example talcum, calcium and magnesium stearate and solid polyethylene glycols or mixtures of the substances stated in (a) to (i).
The tablets, coated tablets, capsules, pills and granules may be provided with conventional coatings and shells optionally containing opacifying agents and may also be composed such that they release the active substances only with a delay or preferably in a particular part of the intestinal tract, wherein polymeric substances and waxes may, for example, be used as the matrices.
The active substance or substances, optionally together with one or more of the above-stated excipients, may also be present in microencapsulated form.
In addition to the active substance or substances, suppositories may contain conventional water-soluble or water-insoluble excipients, for example polyethylene glycols, fats, for example cocoa butter and higher esters (for example C 14 alcohol with C 16 fatty acid) or mixtures of these substances.
In addition to the active substance or substances, ointments, pastes, creams and gels may contain conventional excipients, for example animal and vegetable fats, waxes, paraffins, starch, gum tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talcum and zinc oxide or mixtures of these substances.
In addition to the active substance or substances, powders and sprays may contain conventional excipients, for example lactose, talcum, silica, aluminium hydroxide, calcium silicate and polyamide powder or mixtures of these substances. Sprays may additionally contain conventional propellants, for example chlorofluorocarbons.
In addition to the active substance or substances, solutions and emulsions may contain conventional excipients, such as solvents, solubilising agents and emulsifiers, for example water; ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol, glycerol formal, tetrahydrofurfuryl alcohol, polyethylene glycols and sorbitan fatty acid esters or mixtures of these substances.
For paxenteral administration, the solutions and emulsions may also be present in sterile, isotonic form.
In addition to the active substance or substances, suspensions may contain conventional excipients, such as liquid diluents, for example water, ethyl alcohol, propylene glycol, suspending agents, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar and gum tragacanth or mixtures of these substances.
The stated formulations may also contain colorants, preservatives and odour-or flavour-enhancing additives, for example peppermint oil and eucalyptus oil, and sweeteners, for example saccharin.
The active substances of the formulae (I), (III) and (IV) should preferably be present in the pharmaceutical preparations listed above in a concentration of approx. 0.1 to 99.5 wt.%, preferably from approx. 0.5 to 95 wt.%, of the complete mixture.
Apart from the compounds of the formulae (I), (III) and (IV), the pharmaceutical preparations may also contain further pharmaceutical active substances.
The compounds may be used together with hitherto described substances having antibacterial, antiviral, antimycotic and antiparasitic properties. Such substances in particular include compounds which have already been used in therapeutic applications or are still used.
Substances which are suitable for this purpose are in particular those listed in the Red List or in Simon/Stille, Antibiokia-Therapie in Klinik and Praxis, 9th edition, 1998, Schatauer Verlag, or on the Internet at htt~://www.customs treas gov/imn-exp/rulin~s/harmoniz/hrml29 html. The derivatives may in particular be present with penicillins, benzylpenicillin (penicillin G), phenoxypenicillins, isoxazolylpenicillins, aminopenicillins, ampicillin, amoxicillin, bacampicillin, carboxypenicillin, ticarcillin, temocillin, acylaminopenicillins, azlocillin, mezlocillin, piperacillin, apalcillin, mecillinam, cephalosporins, cefazolin group, cefuroxime group, cefoxitin group, cefoxitin, cefotetan, cefmetazole, latamoxef, flomoxef, cefotaxime group, cefozidime, ceftazidime group, ceftazidime, cefpirome, cefepime, conventional cephalosporins, cefsulodin, cefoperazone, oral cephalosporins of the cephalexin group, loracarbef, cefprozil, new broad-spectrum oral cephalosporins, cefixime, cefpodoxime-proxetil, cefuroxime-axetil, cefetamet, cefotiam-hexetil, cefdinir, ceftibuten, other 13-lactam antibiotics, carbapenem, imipenem/cilastatin, meropenem, biapenem, aztreonam,13-lactamase inhibitors, clavulanic acid/amoxicillin, clavulanic acid/ticarcillin, sulbactam/ampicillin, tazobactam/piperacillin, tetracyclines, oxytetracycline, rolitetracycline, doxycycline, minocycline, chloramphenicol, aminoglycosides, gentamicin, tobramycin, netilmicin, amikacin, spectinomycin, macrolides, erythromycin, clarithromycin, roxithromycin, azithromycin, dirithromycin, spiramycin, josamycin, lincosamides, clindamycin, fusidic acid, glycopeptide antibiotics, vancomycin, teicoplanin, pristinamycin derivatives, fosfomycin, antimicrobial folic acid antagonists, sulfonamides, co-trimoxazole, trimethoprim, other diaminopyrimidine-sulfonamide combinations, nitrofurans, nitrofurantoin, nitrofurazone, gyrase inhibitors (quinolones), norfloxacin, ciprofloxacin, ofloxacin, sparfloxacin, enoxacin, fleroxacin, pefloxacin, lomefloxacin, Bay Y3118, nitroimidazoles, antimycobacterial agents, isoniazid, rifampicin, rifabutin, ethambutol, pyrazinamide, streptomycin, capreomycin, prothionamide, terizidone, dapsone, clofazimine, topical antibiotics, bacitracin, tyrothricin, polymyxins, neomycin, kanamycin, paromomycin, mupirocin, antiviral agents, acyclovir, ganciclovir, azidothymidine, didanosine, zalcitabine, thiacytidine, stavudine, ribavirin, idoxuridine, trifluridine, foscarnet, amantadine, interferons, tibol derivatives, proteinase inhibitors, antimycotics, polyenes, amphotericin B, nystatin, natamycin, azoles, azoles for septic therapy, miconazole, ketoconazole, itraconazole, fluconazole, UK-109,496, azoles for topical use, clotrimazole, econazole, isoconazole, oxiconazole, bifonazole, flucytosine, griseofulvin, ciclopirox olamine, tolnafnate, naftifme, terbinafine, amorolfme, anthraquinones, betulinic acid, semianthraquinones, xanthones, naphthoquinones, arylamino alcohols, quinine, quinidines, mefloquine, halofantrine, chloroquine, amodiaquine, acridine, benzonaphthyridine, mepacrine, pyronaridine, dapsone, sulfonamides, sulfadoxine, sulfalenes, trimethoprim, proguanil, chlorproguanil, diaminopyrimidines, pyrimethamine, primaquine, aminoquinolines, WR 238,605, tetracycline, doxycycline, clindamycin, norfloxacin, ciprofloxacin, ofloxaein, artemisinin, dihydroartemisinin, lOb artemether, arteether, atresunate, atovaquone, suramin, melarsoprol, nifurtimox, stibogluconate sodium, pentamidine, amphotericin B, metronidazole, clioquinol, mebendazole, niclosamide, praziquantel, pyrantel, tiabendazole, diethylcarbamazine, ivermectin, bithionol, oxamniquine, metrifonate, piperazine, embonate.
The organophosphorus compounds may furthermore be present in the pharmaceutical preparations in combination with sulfonamide, sulfadoxine, artemisinin, atovaquone, quinine, chloroquine, hydroxychloroquine, mefloquine, halofantrine, pyrimethamine, armesin, tetracyclines, doxycycline, proguanil, metronidazole, praziquantel, niclosamide, mebendazole, pyrantel, tiabendazole, diethylcarbazine, piperazine, pyrivinium, metrifonate, oxamniquine, bithionol or suramin or two or more of these substances.
The above-stated pharmaceutical preparations are produced in the conventional manner using known methods, for example by mixing the active substance or substances with the excipient or excipients.
The stated preparations maybe administered to humans and animals orally, rectally, parenterally (intravenously, intramuscularly, subcutaneously), intracisternally, intravaginally, intraperitoneally, topically (powders, ointments, drops) and for the treatment of infections in cavities, body cavities. Suitable preparations which may be considered are solutions for injections, solutions and suspensions for oral therapy, gels, infusion formulations, emulsions, ointments or drops. Topical treatment may be performed using ophthalmological and dermatological formulations, silver and other salts, ear drops, eye ointments, powders or solutions. Administration to animals may also be achieved via the feed or drinking water in suitable formulations. Gels, pulverulent formulations, powders, tablets, controlled-release tablets, premixes, concentrates, granules, pellets, tablets, boli, capsules, aerosols, sprays, inhalation formulations may also be used in humans and animals. The compounds according to the invention may also be incorporated into other supports, such as for example plastics (plastic chains for topical treatment), collagen or bone cement.
It has in general proved advantageous in both human and veterinary medicine to administer the active substances of the formula (I), (III) and (IV) in total quantities of approx. 0.05 to approx. 600, preferably of 0.5 to 200 mg/kg body weight per 24 hours, optionally in the form of two or more individual doses in order to achieve the desired results. An individual dose preferably contains the active substance or substances in quantities of approx. 1 to approx.
200, in particular of 1 to 60 mg/kg body weight. It may, however, be necessary to deviate from the stated dosages, in particular as a function of the nature and body weight of the patient to be treated, the nature and severity of the disease, the nature of the preparations and the route of administration of the pharmaceutical preparation and the period of time over which administration is performed.
In some cases, it may accordingly be sufficient to use less than the above-stated quantity of active substance, while in other cases more than the above-stated quantity of active substance must be used. The person skilled in the art will use his/her skill to determine the optimum dosage and route of administration required in each particular case.
The compounds according to the invention may be given to animals in conventional concentrations and preparations together with feed or feed preparations or with drinking water.
The compounds according to the invention are furthermore ideally usable as bactericides, fungicides and herbicides in plants.
If the structure of the compound is known, it is generally possible for the person skilled in the art to develop a production process by analogy with known processes. The production of some compounds according to the invention is stated below by way of example:
Example 1' S-j2-lPhosnhono)ethyl)-N-hvdroxy~vrrolidin 2 one~ll N-Fluorenylmethoxycarbonyl-pvrrolidin-2-vl-methanol Vila A solution of 476 g (1.85 mol) of chloroformic acid 1-(9-fluorenylmethyl) ester (F-MOC) in 1 1 of dioxane is slowly added dropwise with ice cooling to a solution of 182 g (1.8 mol) of pyrrolidin-2-yl-methanol in 1200 ml of dioxane and 1800 ml of a 10% sodium carbonate solution. The mixture is stirred for 4 h at this temperature and for 8 h at room temperature, poured into 1.5 1 of ice water and extracted with diethyl ether. The ice-cooled aqueous phase is weakly acidified with dilute HCI, left to stand overnight at 0°C and the product la is then filtered with good purity and yield.
O-~Methanesulfon l~methyl)-N-fluorenvlmetho~carbon ~~1-~yrrolidine (lb) 470 g (1.4 mol) of la are redissolved in 300 ml of absolute pyridine and combined while cold with 400 g (3.5 mol) of methanesulfonyl chloride. The mixture is stirred under argon initially for 16 h at 0°C and then for a further 3 h at RT. Once the mixture has been poured onto ice, extraction is performed repeatedly with diethyl ether and the organic phase is washed in succession with ice-cold dilute HCI, NaHC03 and water. After drying over M,gS04 and evaporation, lb is obtained, which may be purified by recrystallisation from acetone/petroleum ether.
2-lIodomethvl)-N-fluorenylmethoxycarbon~l-pvrrolidine~l c~
3 equivalents (359.7 g) of NaI in acetone are added to a solution of 331 g (0.8 mol) of lb in acetone. After 12 hours' stirring at RT, the mixture is filtered, the filtrate added to 800 ml of water, which had been combined with sodium thiosulfate. After repeated extraction with diethyl ether, the extracts were combined, washed with water, dried over MgS04 and evaporated under reduced pressure. Leaving the mixture to stand at low temperature initially yields an oil, which may be recrystallised from petroleum ether.
2-f2-lDimethyl__phos~hono)eth~]-~yrrolidine (ld) 190 ml of a 1.6 M solution of n-butyllithium in hexane (corresponding to 0.30 mol) were added dropwise at -78°C under argon to 37.2 g (0.3 mol) of methanephosphonic acid dimethyl ester in 900 ml of dry THF. Stirring is continued for a further 15 minutes at this temperature to permit complete formation of the carbanion.
133.9 g (0.3 mol) of lc in 300 ml of dry THF were added dropwise to this solution at -78°C
with stirring. Once the temperature has risen to room temperature, stirnng is continued for a further 4 h. 85.15 g (1 mol) of piperidine is then added and the mixture stirred overnight. The mixture is filtered, the filtrate is poured into 21 of water, the organic phase separated and the aqueous phase extracted 4 times with 100 ml portions of dichloromethane. Once the combined organic phases have been dried over MgS04, the solvent is removed and the residue fractionally distilled under a vacuum. 2-[2-(Dimethylphosphono)ethyl]-pyrrolidine (ld) is obtained as a colourless oil at yields of 30-40%.
5-f2-(Dimethvlphosphono)ether]pvrrolidinone~le) A solution of 60 mmol of dimethyldioxirane in 120 ml of dry acetone is added dropwise to a solution, cooled to 0°C, of 3.32 g (15 mmol) of ld in 50 ml of dry acetone. The mixture is stirred for 30 min at 0°C and the solvent is then stripped out under a vacuum. The resultant crude product is recrystallised from isopropanol. 5-[2-(Dimethylphosphono)ethyl]pyrrolidinone (le) is obtained in moderate yield as colourless crystals.
Dimethyldioxirane is produced in accordance with a method in Org. Syntheses IX, 288.
5-f2-lPhosphonolethvl]-N-hvdrox~pvrrolidin-2-one (lf~
3.06 g (20 mmol) of trimethylbromosilane are added dropwise to a solution, cooled to 0°C, of 1.19 g (5 mmol) of le in 50 ml of dry acetonitrile. The mixture is stirred for 3 h at RT, then the solvent is stripped out under a vacuum, the residue is redissolved with 20 ml of ice water, the mixture is stirred for 1 h at room temperature, extracted twice with 20 ml portions of ether, a pH value of 4.5 is established with 2 M NaOH and the water is then stripped out in a Rotavapor rotary evaporator at a maximum of 50°C. The solid residue is crystallised from methanol/ethyl acetate. 5-[2-(Phosphono)ethyl]-N-hydroxy-pyrrolidin-2-one (lf7 is obtained in good yield in the form of yellowish microcrystals.
Examble 2: 3-(PhosnhonomethYl)-N-h~rdrox~pvrrolidin-2-one~21 3-Meth(2-trimethylsilvlethoxy)-pvrrolidin-2-one ~2a1 A solution of 120 mmol of sodium ethanolate in 50 ml of absolute ethanol is added dropwise at 0°C with exclusion of moisture to a solution of 20.37 g (120 mmol) of O-(2-trimethylsilyethyl)hydroxylamine hydrochloride in 100 ml of absolute ethanol.
Any precipitated NaCI is filtered out with an argon sintered glass filter. The ethanol is removed from the filtrate under reduced pressure and, once argon has been passed through the residue, the latter is redissolved with absolute toluene. 1 mol% of RhCl3*3 H20, 5 mol%
of DMAP
and, dropwise, 5.01 g (50 mmol) of 2-methylbutyrolactone are added thereto at 0°C. The mixture is allowed to thaw and is stirred overnight while being refluxed on the water separator. After cooling, volatile constituents are stripped out under a vacuum at 50°C in a Rotavapor rotary evaporator, a weakly yellow coloured oil being left behind.
Redissolution in 50 ml of ether, filtration through a short Si02 column and stripping of the solvent gives rise to 3-methyl-N-(2-trimethylsilylethoxy)-pyrrolidin-2-one (2a) in moderate yield as a virtually colourless oil, which is obtained in good purity.
3-Bromometh~N-(2-trimethvlsil lethoxy)~yrrolidin-2-one (2b) 50 mmol of 2a, dissolved in 30 ml of absolute carbon tetrachloride, are combined with 1.2 equivalents of N-bromosuccinimide and refluxed for 12 h. Small quantities of azobisisobutyronitrile (AIBN) are added at hourly intervals. After cooling, the product is filtered from succinimide, the latter is washed with CCl4 and the combined CC14 phases are evaporated under reduced pressure. The resultant oil may be chromatographed on Si02, 2b being obtained in poor yield.
3-(Diethvlnhosphonometh~l-N-f2-trimeth~vlethoxvl pyrrolidin 2 one l2cl 100 mmol (17.3 ml) of triethyl phosphite are combined with 100 mmol of 2b and heated to 150°C for 0.5 h without solvent. After cooling, the mixture is evaporated under reduced pressure and the yellowish brown oil is chromatographed on Si02 with chloroform/methanol in a 25:1 ratio. Once volatile constituents have been stripped out, 2c is obtained in moderate yield as a yellow oil.
3-(Phosphonomethvl~ N-~2-trimeth~i_l lethoxyl pvrrolidin 2 one~2d) 4 equivalents (120 mmol, 15.4 ml) of trimethylbromosilane are added dropwise with ice cooling to 30 mmol of 2c in 50 ml of absoluted acetonitrile, the mixture is stirred for 15 min at the same temperature, then for 2 h at RT, evaporated under reduced pressure until a yellowish oil is obtained, the product is redissolved in 100 ml of water and hydrolysed for 1 h at RT (pH less than 1 ). This solution is extracted twice with CHCl3, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at 45°C. The resultant yellow-brown oil is redissolved in water and a pH of 4.5 to 5.0 is established. After washing with ice water, 2d is obtained as a virtually colourless sodium salt at a yield of 50%.
3-fPhosnhonometh~~hvdroxy-pvrrolidin-2-one (2e) 5.3 mmol of BF3 etherate are added to a solution of 2.65 mmol of 2d in absoluted acetonitrile and stirred for 0.5 h at room temperature. Once the solution has been evaporated under reduced pressure, it is redissolved in 40 ml of ethyl acetate, washed with 3%
common salt solution, dried over MgS04, filtered through a membrane filter and the solvent is stripped out under reduced pressure. The crude product may be recrystallised from MeOH/EtOH, the product being obtained in pure form and good yield.
Example 3: 4-lPhos~honomethyll-N-hvdrox~nvrrolidin-2-one (31 4-Methyl-2(5Hl-furanone ~3a1 g of 3-methylglutaric acid monoethyl ester and 31 g of lead tetraacetate dissolved in 400 ml of absolute CC14 are heated to boiling under argon. After 10 minutes' illumination by means of a tungsten daylight lamp, 23.1 g of iodine are added within 45 min while illumination is continued. After cooling, the mixture is filtered, the filtrate washed with aqueous sodium thiosulfate solution, soda solution and water, dried over MgS04 and evaporated under reduced pressure. The gamma-iodine ester 3a' is obtained as a oil which may be further reacted without further purification. 18.4 g of freshly precipitated silver acetate and 24 g of acetic anhydride are heated to 120°C in 82 ml of glacial acetic acid for 1 hour, 19.1 g of the gamma-iodine ester 3a' are added and the mixture refluxed for a further 2 hours.
The mixture is then kept for 15 h at R'r, combined with 300 ml of ether and filtered. Once the filtrate has been washed with water and aqueous soda solution, the aqueous phase is extracted again with ether, the combined organic extracts are dried over MgS04 and evaporated under reduced pressure. Once this oil has been redissolved in 70 ml of 2 N NaOH, 10 ml of EtOH
and 50 ml of water, the mixture is repeatedly extracted with ether, the ether phases being quantitatively discarded. The aqueous phase, acidified with 150 ml of 6 N HC1, is continuously extracted with ether and, after drying over MgS04 and evaporation under reduced pressure, is distilled (102-105°C at 34 Torr). 4.4 g of 4-methyl-2[5H]-furanone (3a) are obtained.
The remaining steps for preparing 3 follow the synthesis sequence described in 2 by the introduction of O-(2-trimethylsilylethyl)-hydroxylamine hydrochloride, NBS, triethyl phosphate and the hydrolyses of phosphonic acid esters by trimethylbromosilane and the liberation of the cyclic hydroxamic acid by BF3 etherate. Reference may also be made to T.Sakamoto, Y.Kikugawa J. Org. Chem. 1994, 59, 929-931 with regard to the synthesis sequence.
Example 4: N-Hvdroxv-3-amino-4-lphosphon-omethyll pvrrolidin 2 one (4) 2-Phenyl-4-(2-acetoxy-1-acetox~ yl-eth laden 1 2 oxazolin 5 one ~4a1_ 0.2 mol of hippuric acid, 0.6 mol of acetic anhydride, 0.24 mol of 1,3-diacetoxyacetone and 0.1 mol of anhydrous lead(II) acetate are initially introduced into 500 ml of THF and refluxed for 16 h under argon. After cooling to RT, inorganic salts are filtered out, the mixture is evaporated under reduced pressure, redissolved in 500 ml of toluene, gaseous hydrogen sulfide is introduced until PbS ceases to precipitate and, after filtration, the mixture is reevaporated. The product is chromatographed on Si02 with hexane/chloroform as the solvent mixture, 4b being obtained at a yield of 73%.
Diacetoxyacetone is synthesised in accordance with a method of A.O.L. Fischer, H.
Mildbrand Ber. Dt, them. Ges. 57, 707, 1924.
2-Amino-3-methox -v butyric acid l4bl A solution of 31.8 mol of 4a in 150 ml of dioxane is combined with 1 g of Pd/C
and hydrogenated at standard pressure until 10 mol of hydrogen have been absorbed (4-6 h). Once the catalyst has been filtered out, the mixture is evaporated to dryness, redissolved in 40 ml of water and 60 ml of coot. HCI, refluxed for 4 h and kept overnight in the refrigerator. The filtered solution is evaporated, redissolved in 50 ml of water and purified on Amberlite IR
120, H+ ion exchanger by elution with 300 ml of aqueous ammonia solution. The mixture is boiled until no ammonia is any longer detectable, reevaporated under reduced pressure and recrystallised.
Aloha-amino-beta-methox~garmsna-butvrolactone (4c) 25 mmol of 4b are stirred for 15 min at RT with 20 ml of 2.5% HCI. The solution is evaporated to dryness and extracted overnight with chloroform in a Soxhlet apparatus. Once the solvent has been stripped out under reduced pressure, the lactone 4c is obtained in virtually quantitative yield.
N.N-Dibenzvla_mino-beta-methox~-gamma butvrolactone ~4d1 0.2 mol of 4c, 72 g of KZC03 and 300 mg of tetrabutylammonium iodide and 500 mg of 18-crown-6 are suspended in 100 ml of ethanol and heated to 40°C. 0.65 mol of benzyl bromide are added dropwise within 15 min, the mixture is stirred for 12 h at RT, the phases are separated, the aqueous phase washed twice with 75 ml portions of ether, the organic phases are combined, washed with saturated NaCI solution and dried over MgS04. After evaporation under reduced pressure, the mixture is chromatographed on a short silica gel column.
N.N-Dibenzylamino-beta~bromomethvll-butyrolactone~4e~
2.23 g (6.18 mmol) of CBr4 are added to a mixture of 4.12 mmol of 4d, 6.18 mmol of PPh3 and 20 ml of absolute acetonitrile. The mixture is stirred for 20 h at RT, the solvent removed under reduced pressure and chromatographed on silica gel with ethyl acetate/n-hexane as solvent. 4e is obtained in variable yield as a yellowish oil.
N.N-Dibenzvlamino-beta-ldimeth~phosphonomethylLutyrolactone (4f1 40 mmol of 4e are refluxed for 0.5 to 1 h with 1 equivalent of trimethyl phosphite in toluene.
After cooling, the mixture is evaporated under reduced pressure and the remaining oil is chromatographed on Si02 with chloroform/methanol as the mobile solvent. Once volatile constituents have been stripped out, 4f is obtained in moderate yield.
N N-Dibenzvlamino-beta~dimet Yl hosnhonometh l~) butvrolactam (4~) A solution of 100 ml of sodium ethanolate in 50 ml of absolute ethanol is added dropwise at 0°C with exclusion of moisture to a solution of 120 mmol of O-benzylhydroxylamine hydrochloride in 100 ml of absolute ethanol. Any precipitated NaCI is filtered out with an argon sintered glass filter. The ethanol is removed from the filtrate under reduced pressure and, once argon has been passed through the residue, the latter is redissolved with absolute toluene. 1 mol% of RhCl3 3 H20, 5 mol% DMAP and, dropwise, 50 mmol of 4f are added thereto at 0°C. The mixture is allowed to thaw and is stirred overnight while being refluxed on the water separator. After cooling, volatile constituents are stripped out under a vacuum at 50°C in a Rotavapor rotary evaporator, an oil being left behind.
Redissolution in 40 ml of ethyl acetate, filtration through a short Si02 column and stripping of the solvent gives rise to (4g) in moderate yield as a yellow oil, which is obtained in good purity.
N-Hvdroxy-3-amino-4-(dimeth~phosphonometh~l ~vrrolidin 2 one (4hl 30 mmol of 4g in 60 ml of methanol and 10 ml of formic acid are hydrogenated with 5 mol%
Pd/C (10-20%) under standard pressure at RT for 13 h. Once the catalyst has been filtered out, the mixture is evaporated under reduced pressure and reacted without further purification.
N-H~xv-3-amino-4~Phosnhonomethyl~pvrrolidin-2-one~4il 35 mmol of trimethylbromosilane are added dropwise with ice cooling to 10 mmol of 4h in 20 ml of absoluted acetonitrile, the mixture is stirred for 15 min at the same temperature, then for 2 h at RT, evaporated under reduced pressure until a yellowish oil is obtained, the product is redissolved in 100 ml of water and hydrolysed for 1 h at RT. This solution is extracted twice with CHC13, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at 45°C. The resultant dark oil is redissolved in water and a pH of 6.0 is established. Precipitating 4i is filtered out and washed with ice water. 4i is obtained as the sodium salt in the form of beige crystals at a yield of 35-40%.
Example 5: N.2-Dihvdrox~~2~hosphonoethvl~~vrrole (5) N-Benz~~[2-(dimeth~pho~honoZth~7pvrrolidin-2-one (Sad 20 mmol of 5-[2-(dimethylphosphono)ethyl]pyrrolidinone (le) are stirred overnight at room temperature with 1.2 equivalents of benzyl bromide, 10 mg of tetrabutylammonium iodide and 1.3 equivalents of triethylamine in 30 ml of THF, are then poured into ice water, repeatedly extracted with small quantities of ether, the diethyl ether phase is washed with cold dilute HC1 and with saturated common salt solution, dried over MgS04, evaporated and the crude product chromatographed on silica gel with chloroform/methanol 25:1. Sa is obtained in good yield.
N-Benz~~ henylseleno-5-~2-(dimeth~phos honoleth~l_~pvrrolidin-2-one (5b) 2.0 mmol of Sa, which is dissolved in 1 ml of absolute THF and stirred for 20 min at -78°C, is added at the same temperature to 2.4 mmol of diisopropylamide in 3 ml of THF (LDA, produced from 0.35 ml of diisopropylamine and 1.6 ml of 1.65 M n-BuLi in hexane under argon at -78°C). 2.4 mmol of diphenyl diselenide, dissolved in 1 ml of THF and 1.2 mmol of HMPT, are added at -78°C to the enolate of 5a. The reaction mixture is stirred for 40 min at -78°C and for 1.5 h at -40°C. Quenching with 0.1 N HC1 and subsequent repeated extraction with ether yields, after chromatography on silica gel, a yellowish oil Sb of a characteristic odour.
N-Benz -~ drox~[2-(dimeth~phosphonoleth~~vrrole (Sc) 0.2 mmol of the phenylseleno compound 5b, dissolved in 1 ml of absolute THF, is combined with 30 ~,l of glacial acetic acid, 140 ~l of Perhydrol (30% hydrogen peroxide solution) are added dropwise with ice cooling and the mixture stirred for 30 min at the same temperature.
The solution is poured into cold, saturated aqueous sodium hydrogen carbonate solution, the mixture extracted with ether, dried over MgS04, evaporated under reduced pressure and the crude product chromatographed on silica gel. Sc is obtained in good yield as a yellowish oil.
N.2-Dihvdroxv-4-[2-(dimethvlphos hono)ethvl]pvrrole (Sdl 0.15 mmol of Sc is placed in 50 ml of absolute EtOH, a spatula-tipfull of 10%
Pd on activated carbon is added and the mixture hydrogenated for 1 h at RT in a standard pressure hydrogenation apparatus with vigorous stirring. Once the catalyst has been filtered out, the mixture is evaporated and the crude product is reacted without further purification.
N.2-Dihydrox ~-~5-J2-phos~honoethL~ll-pyrrole (5e) 4 equivalents (60 mmol, 8 ml) of trimethylbromosilane are added dropwise with ice cooling to 15 mmol of Sd in 50 ml of absoluted acetonitrile, the mixture is stirred for 15 min at the same temperature, then for 2 h at RT, evaporated under reduced pressure until a yellowish oil is obtained, the product is redissolved in 80 ml of water and hydrolysed for 1 h at RT (pH <
1). This solution is extracted twice with CHC13, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at a maximum of 45°C. The resultant oil is redissolved in water and a pH of 4.5 to 5.0 is established with NaHC03. Se is removed by suction filtration and, after washing with iced water, 5e is obtained as a virtually colourless sodium salt at a yield of 40%.
Example 6: N-H~xv-3-[2 ~phosnhonolethyl~-1H-~,vridone~61 2-Bromo-3-(bromometh,~lpvridine (6a~
g (58.1 mmol) of 2-bromo-3-methylpyridine and 11.4 g (64 mmol) of [sic] are refluxed for 24 h in 250 ml of CC14. The succinimide is separated by filtration and the organic phase is washed twice with water. After evaporation under reduced pressure, 6a is obtained as a colourless liquid by fractional distillation (bp: 90°C, 1 Torr).
2-Bromo-3-[2-(dimeth~nhosphonoleth~]pyridine fhb) 0.21 mol of MeLi in ether is added dropwise to 100 ml of absolute THF, 0.1 mol of trimethyl phosphite, dissolved in 50 ml of THF, is added dropwise within 15 min in such a manner that the internal temperature slowly reaches 0°C. 0.107 mol of 6a in 20 ml of THF is then added dropwise at a temperature of -78°C, stirring is continued for a further 30 min at the same temperature, the mixture is allowed to thaw and quenched at 0°C by dropwise addition of 80 ml of 3 M HCI. The organic phase is separated, the aqueous phase extracted three times with 40 ml portions of dichloromethane and, after drying over MgS04, the combined organic phases are evaporated. The yellow crude product may be purified in a short column on Si02.
2-Bromo-3-[2-(dimeth~nhos~nhono)ethy~pyridine N-oxide (6c) 100 mmol of 6b in 60 ml of glacial acetic acid are combined with 2 equivalents of a 40%
peracetic acid solution, wherein the temperature should not exceed 50°C. After 5 hours' heating to 50°C and 12 hours' heating to 70°C, the solution is evaporated to half its volume under reduced pressure, poured onto ice and made highly alkaline with 40%
aqueous KOH.
Triple extraction with chloroform yields, after drying over KzC03 and evaporation under reduced pressure, an N-oxide oil 6c, which was reacted without further purification.
N-Hvdroxv-3-f2-~dimethYlphosphonolet_hvl~-1H-pvridone~6d~
6c is heated in a glass autoclave for 3 h to 120°C in absolute MeOH
together with mortar-ground potassium hydroxide, potassium carbonate and tris(3,6-dioxaheptyl)amine. After cooling, the reaction mixture is poured into water, a pH value of 6 is established, the mixture evaporated under a vacuum and, after addition of ethanol, a crude product is obtained which may be recrystallised in moderate yield from ethanol/toluene.
N-H droxv-3-~2~fphos~hono)eth~]-1H-~vridone (6e) 40 mmol of trimethylbromosilane are added dropwise with ice cooling to 10 mmol of 6d in 30 ml of absolute acetonitrile, the mixture is stirred for 15 min at the same temperature, then for 2 h at RT, evaporated under reduced pressure until an oil is obtained, the product is redissolved in 20 ml of water and hydrolysed for 1 h at RT (acidic pH). This solution is extracted twice with CHCl3, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at 45°C. The resultant brown oil is redissolved in water, stirred twice with activated carbon, filtered therefrom and a pH of 5 is established.
As a result, 6e precipitates out, is filtered, washed with ice water and may be recrystallised from MeOH/EtOH.
Example 7: N-Hvdroxv-6-(2-lphosphono~ethvl]-1H-pyridone l7~
2-Bromo-6-bromomethvlpyridine ) 10.1 g (58.7 mmol) of 2-bromo-6-methylpyridine, 11.1 g (62.4 mmol) of N-bromosuccinimide (NBS) and 0.1 g (0.6 mmol) of AIBN are heated under argon for 6 h to 110°C in 150 ml of toluene, the mixture simultaneously being illuminated with a tungsten daylight lamp (150 W, >320 nm). After cooling, succinimide is filtered out and the solution evaporated under reduced pressure. Chromatography on silica gel (mobile solvent:
hexane/dichloromethane) at first yields 2-bromo-6-dibromomethylpyridine, while 7a may subsequently be eluted at a yield of up to 45% (mp: 138°C).
2-Bromo-6-[2-(dimeth~pho h~ono_leth~~~ ridine~7b~
0.21 mol of MeLi in ether is added dropwise to 100 ml of absolute THF, 0.1 mol of trimethyl phosphite, dissolved in 50 ml of THF, is added dropwise within 15 min in such a manner that the internal temperature slowly reaches 0°C. 0.107 mol of 7a in 15 ml of THF is then added dropwise at a temperature of -78°C, stirring is continued for a further 30 min at the same temperature, the mixture is allowed to thaw and quenched at 0°C by dropwise addition of 80 ml of 3 M HCI. The organic phase is separated, the aqueous phase extracted repeatedly with 40 ml portions of dichloromethane and, after drying over MgS04, the combined organic phases are evaporated. The yellow crude product may be chromatographically purified on SiOZ, 7b being obtained at a yield of 47%.
2-Bromo-6-(2-(dimethyl hosphonoleth ~~ll~yridine N-oxide~7c~
50 mmol of 7b in 50 ml of glacial acetic acid are combined with 2 equivalents of a 40%
peracetic acid solution, the temperature varying between 25 and 45°C.
After 5 hours' heating to 50°C and 12 hours' heating to 70°C, the solution is poured onto ice and made highly alkaline with 40% aqueous KOH. Triple extraction with chloroform yields, after drying over KZC03 and evaporation under reduced pressure, an N-oxide oil 7c, which may be recrystallised from ether/ethanol.
N-Hvdroxv-6-~~dimethvlphos honoleth l~pyridone (7dl 7c is heated in a glass autoclave for 2.5 h to 100°C in absolute MeOH
together with mortar-ground potassium hydroxide, potassium carbonate and tris(3,6-dioxaheptyl)amine. After cooling, the reaction mixture is poured into water, a pH value of 6 is established, the mixture evaporated under a vacuum and, after addition of ethanol, a crude product is obtained which, similarly to 6d, may be recrystallised in moderate yield.
N-H drox~[2-(~ho~honolet~vl]-1H ~vridone (7el 40 mmol of trimethylbromosilane axe added dropwise with ice cooling to 10 mmol of 7d in 25 ml of absolute acetonitrile, the mixture is stirred for 10 min at the same temperature, then for 2 h at RT, evaporated under reduced pressure at 45°C until an oil is obtained, the product is redissolved in 20 ml of water and hydrolysed for 1 h at RT. This solution is extracted twice with CHCl3, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at 45°C. The resultant dark-coloured oil is redissolved in water and a pH of 4.8 is established. As a result, 7e precipitates out as the sodium salt.
After filtration and washing with ice water, 7e is obtained as a crude product, which may be recrystallised from MeOH/toluene.
Example 8: N-Hvdrox~j2-phosphono-2-hvdroxylethvllpvrrolidin-2-one Ll_ N-Benzyl-2-(1.3-dithio lmeth~ly-pYrrolidine (,8a) 100 mmol (12.0 g) of 1,3-dithiane are weighed out under protective gas, 250 ml of absolute THF are added thereto and a 5% excess of n-BuLi in hexane is added dropwise thereto within 3-5 min at ~.0°C. The mixture is stirred for 2 h at -25 to -15°C, the temperature is reduced to -60 to -78°C and 100 mmol of 2-iodomethyl-N-benzyloxy-pyrrolidine are slowly added thereto under protective gas. After 5-6 hours' stirring at -20 to -10°C, the temperature is allowed to rise to 0°C and the reaction mixture is placed in the refrigerator for three days.
After evaporation to approx. 20 ml, the mixture is poured into three times its volume of water, extraction performed three to five times with chloroform, the organic phases are combined, washed in succession with water, 6% KOH and again with water and the chloroform phase is dried over KZC03. The residue obtained after evaporation under reduced pressure is reacted without further purification.
N-Benzyl_2-lformylmethYl)-nvrrolidine~8b) 1.1 g of CaC03 and 2.5 ml of Hg(C104)2 of a 4 M aqueous solution are added to a solution of 9 mmol of 8a in 30 ml of THF and 6 ml of water, stirring is continued for a further 5 to 10 min, 150 ml of ether are added thereto and inorganic salts are filtered out.
Once the solution has been evaporated under reduced pressure, a coloured crude product remains, which is purified by flash chromatography.
N-Benzyl-2-[2-ldiethylphosphono)-2-hvdroxv]pyrrolidine (8c) 20 g (145 mmol) of diethyl phosphonate and 140 mmol of 8b are heated under argon to 80 to 85°C for 8 h. After cooling, the mixture is evaporated under reduced pressure and the product 8c is purified chromatographically on silica gel.
N-Benz[2-(diethyl_phosphonol-2-acetox~lpvrrolidine ~8d) A mixture of 50 mmol of 1-hydroxyphosphonic acid ester 8c, 75 mmol of triethylamine, 75 mmol of acetic anhydride and 4 mmol of dimethylaminopyridine (DMAP) is left to stand for 14 h at RT and, after addition of 100 ml of ether and 2 N HCI, the etheric phase is washed with saturated aqueous NaHC03 solution, dried over MgS04, evaporated and purified on a short ALOX column.
2-f2-(N-Benzyl-2-[8-ldiethylphosphono)-2-acetoxy~pvrrolidine 1,8e) After addition of 400 mg of PtO2, a solution of 40 mmol of 8d in 30 ml of glacial acetic acid is hydrogenated at 70°C for 6 h at standard pressure. Once the catalyst has been filtered out, the mixture is repeatedly extracted with ether in a strongly alkaline medium, the combined ether extracts are dried over MgS04, evaporated and the product 8e, which is obtained in good yield, is directly further reacted.
N-H drox ~-~5-[2-phosnhono-2-h~X)eth~~pvrrolidin-2-one~8f~
A solution of 70 mmol of dimethyldioxirane in 110 ml of dry acetone is added dropwise to a solution, cooled to 0°C, of 20 mmol of 8e in 50 ml of dry acetone. The mixture is stirred for 30 min at 0°C and the solvent is then stripped out under a vacuum. A
yellow oil is obtained, which may be purified on silica gel with a chloroform/methanol mobile solvent mixture.
N-H~~[(2-dieth~phosnhono-2-hvdrox~ -ethyl]~vrrolidin-2 one (~~l The yellow oil 8f is stirred overnight with 5 M aqueous KOH in MeOH at RT, then neutralised, MeOH is removed under reduced pressure and the mixture extracted with ether.
The combined organic phases were dried over MgS04 and evaporated to dryness.
The resultant 8g is used for the subsequent reactions without further purification.
N-H derv-5-[(2-nhosphono-2-h~xl-ethyl~pvrrolidin-2-one ~8h~
80 mmol of trimethylbromosilane are added dropwise to a solution, cooled to 0°C, of 20 mmol of 8g in 50 ml of dry acetonitrile. The mixture is stirred for 3 h at RT, then the solvent is stripped out under a vacuum, the residue is redissolved with 60 ml of iced water, the mixture is stirred for 1 h at room temperature, extracted three times with 60 ml portions of ether, a pH value of 5.5 to 6.0 is established with 2 M NaOH and the water is then stripped out in a Rotavapor rotary evaporator at a maximum of 45°C. The solid residue is crystallised from methanol/ethyl acetate. N-Hydroxy-5-[(2-phosphono-2-hydroxy)-ethyl]pyrrolidin-2-one (8h) is obtained in good yield in the form of yellowish-white microcrystals.
Example 9: 3-(Methvlphosphono)-N-hvdroxv-succinimide~91 3-(Bromomethyl-succinic anh, d~(9a) In a similar manner to the preparation of N-(2-trimethylsilylethoxy)-pyrrolidin-2-one (2b) 50 mmol of 2-methylsuccinic anhydride, dissolved in 30 ml of absoluted carbon tetrachloride, are reacted with 1.2 equivalents of N-bromosuccinimide by refluxing the mixture for 12 h.
Small quantities of azobisisobutyronitrile (AIBN) are added at hourly intervals. After cooling, the product is filtered from succinimide, the latter is washed with CC14 and the combined CC14 phases are evaporated under reduced pressure. The resultant oil may be chromatographed on Si02, 9a being obtained in low yield.
3-[2-(Dimeth~rlhosnhono~ethyl]-succinic anh_ dv ride (2b) 40 mmol of 9a are refluxed for 0.5 to 1 h with 1 equivalent of trimethyl phosphite in toluene.
After cooling, the mixture is evaporated under reduced pressure and the yellowish oil is chromatographed on Si02. Once volatile constituents have been stripped out, 9b is obtained in low yield.
3-[~Dimeth~phosphonolmethvll-N-benzyloxy-succinimide~9c) 1.0 g of benzyloxyamine is heated in a glass autoclave with 1.0 equivalent of 9b to 180°C for 30 min. After cooling, the oil is evaporated under reduced pressure, a poor crude product yield being observed, and 9c is further reacted without purification.
3-[2-(Dimeth~phosphono)meths]-N-h~droxv-succinimide (9dl 9.28 mmol of the benzyloxy compound 9c dissolved in 60 ml of ethanol are combined with 700 mg of Pd/C and hydrogenated at standard pressure for 4 h at RT. Once hydrogen absorption has ceased, the catalyst is filtered out, the mixture evaporated under reduced pressure and recrystallised from ethyl acetate/hexane, 9d being obtained in good yield.
3-(2-Phosnhonomethvl]-N-hydroxy-succinimide ~9e1 110 mmol of trimethylbromosilane are added dropwise to a solution, cooled to 0°C, of 30 mmol of 9g in 70 ml of dry acetonitrile. The mixture is stirred for 3 h at RT, then the solvent is stripped out under a vacuum, the residue is redissolved with 80 ml of iced water, the mixture is stirred for 1 h at room temperature, extracted three times with 50 ml portions of ether, a pH value of 5.5 to 6.0 is established with NaHC03 and the water is then stripped out in a Rotavapor rotary evaporator at a maximum of 45°C. The solid residue is crystallised from methanol/acetone. 9e is obtained in the form of beige crystals in good yield.
Example 10: 1-N-l2-Phosphonoethyll-3-hvdroxy-7-meth~rl-xanthine f101 1-N-(2-Dimethylnhosnhono-eth~,i-7-methylxanthine~l0a) 50 g of 7-methylxanthine (2,6-dihydroxy-7-methylpurine) are dissolved in 1 1 of boiling ethanol and 38 g of 50% potassium hydroxide solution are added thereto. Once the mixture has cooled to 15 to 20°C, the potassium salt of 7-methylxanthine precipitates out, is filtered out and decocted with boiling acetone and boiling absolute ethanol.
A solution of 20 mmol of 2-bromomethylphosphonic acid dimethyl ester and 2 mmol of hexadecyltributyl-phosphonium bromide in 10 ml of toluene is combined with 25 mmol of the potassium salt of 7-methylxanthine and the mixture heated to 100°C for 2 h. Once the reaction mixture has cooled, undissolved fractions are filtered out and the evaporated organic phase is chromatographed on silica gel with ether/chloroform as mobile solvent. In this manner, both the desired 1-N-(2-dimethylphosphono-ethyl)-7-methylxanthine (l0a) and, at lower yield, 3-N-(2-dimethylphosphono-ethyl)-7-methylxanthine (l0a') are obtained.
1-N-f2-Dimeth~phosnhono-ethyll-3-h droxy-7-met~yl-xanthine ~(lObl A solution of 60 mmol of dimethyldioxirane in 120 ml of dry acetone is added dropwise to a solution, cooled to 0°C, of 25 mmol of l0a in 50 ml of dry acetone. The mixture is stirred for 30 min at 0°C and the solvent is then stripped out under reduced pressure. The resultant crude product is chromatographed on silica gel, 1-N-(2-dimethylphosphono-ethyl)-3-hydroxy-7-methyl-xanthine (lOb) being obtained in poor yield.
In a similar manner, 3-N-(2-dimethylphosphonoethyl)-7-methylxanthine (l0a') may be converted into 3-N-(2-dimethylphosphono-ethyl)-1-hydroxy-7-methylxanthine (lOb').
1-N-(2-Phosphono-ethyll-3-hydroxy-7-methyl-xanthine (lOc~
4 equivalents (100 mmol) of trimethylbromosilane are added dropwise with ice cooling to 25 mmol of lOb in 50 ml of absoluted acetonitrile, the mixture is stirred for 15 min at the same temperature, then for 2 h at RT', evaporated under reduced pressure until an oil is obtained, the product is redissolved in 100 ml of water and hydrolysed for 1 h at RT. In order to remove hexamethyldisiloxane, this solution is extracted twice with CHC13, back-extracted once with water and the combined aqueous phases are evaporated under reduced pressure at 45°C. The resultant beige oil is redissolved in water and a pH of 6.5 to 7.0 is established. After washing with iced water, lOc is obtained as a virtually colourless sodium salt at a yield of SS%.
In a similar manner, 3-N-(2-dimethylphosphono-ethyl)-1-hydroxy-7-methyl-xanthine (lOb') is reacted with trimethylbromosilane to yield 3-N-(2-phosphono-ethyl)-1-hydroxy-7-methyl-xanthine (lOc').
Example 11: N-Hvdroxv-1,2,3 4-tetrahvdro-1-oxo-3-~2-nhos~honoethyl)1-iso~uinoline 3-Phenyl-2-amino~ropanol (lla~
3.0 mol of LiAlH4 are suspended in 900 ml of anhydrous tetrahydrofuran in a heat-treated and argon-flooded three-necked flask fitted with a KPG stirrer and 1.5 mol of phenylalanine are added in portions with ice cooling. The mixture is then refluxed for 6 h, allowed to cool and hydrolysed with crushed ice. The mixture is filtered and the solvent removed under a vacuum.
The filtrate is redissolved with CH2Cl2, washed with saturated NaCI solution and dried with Na2S04. Vacuum distillation is then performed. 3-Phenyl-2-aminopropanol lla is obtained at a yield of 76%.
1-Phen,~(tetrahvdro-2-~~,~Xl-2-aminopropane (llb) 2.5 mol of dihydropyran and 5.3 g of p-toluenesulfonic acid are added to 1.4 mol of 3-phenyl-2-aminopropanol 1 and the mixture then stirred for 20 h at RT. The excess dihydropyran is then removed under a vacuum, the residue redissolved with 700 ml of ethyl acetate and washed with 300 ml portions of saturated NaHC03 solution and saturated NaCI
solution. The mixture is then dried with MgS04, filtered and the solvent removed under a vacuum. 1-Phenyl-3-(tetrahydro-2-pyranyloxy)-2-aminopropane (1lb) is obtained at a yield of 63%.
1-Phen,~(tetrahydro-2-pyr~,~~l-2-isocyanopropane fllc) 0.88 mol of 1-phenyl-3-(tetrahydro-2-pyranyloxy)-2-aminopropane llb are added dropwise to a solution of 3.52 mol of phosgene in 1.5 1 of toluene and the mixture then boiled for 3 h at 80°C. The solvent is then removed under a vacuum. The desired product 1-phenyl-3-(tetrahydro-2-pyranyloxy)-2-isocyanopropane llc is obtained at a yield of 83%.
This is used without further purification.
1.2,3~4-Tetrahydro-1-oxo-3-h~droxymeth,1-~quinoline (lld) A solution of 0.72 mol of 1-phenyl-3-(tetrahydro-2-pyranyloxy)-2-isocyanopropane llc in 80 ml of anhydrous acetone is slowly added dropwise to 100 ml of ice-cooled phosphoric acid and stirred for 3 h at RT. Ice water is then added, the mixture stirred for 0.5 h and then extracted with CH2Cl2. The organic phase is washed with water, saturated NaZC03 solution, again with water and with saturated NaCI solution and dried with MgS04. After filtration and removal of the solvent under a vacuum, the product is recrystallised from hexane/benzene, 28% of 1,2,3,4-tetrahydro-1-oxo-3-hydroxymethyl-isoquinoline (lld) being obtained.
1 2,3.4-Tetrahydro-1-oxo-3-bromomethyl-isoquinoline (lle) A solution of 180 mmol of PPh3 in 120 ml of CH2C12 is added to a solution of 150 mmol of 1,2,3,4-tetrahydro-1-oxo-3-hydroxymethyl-isoquinoline llc and 210 mmol of CBr4 in 150 ml of CHZCl2 and stirred for 20 h at RT. The solvent is then removed under a vacuum and the residue repeatedly recrystallised from benzene. The product 1,2,3,4-tetrahydro-1-oxo-3-bromomethyl-isoquinoline lle is obtained at a yield of 31%.
1.2.3.4-Tetrahvdro-1-oxo-3-(2-dieth, l~bhosnhonoeth,~ll-isoauinoline ,llf) 66.2 mmol of solution of n-butyllithium (1.15 M) in hexane are added dropwise at -78°C to a solution of 75 mmol of dimethyl methylphosphonate in 120 ml of absolute THF
under argon and the mixture stirred for 1.5 h at this temperature. 46.5 mmol of 1,2,3,4-tetrahydro-1-oxo-3-bromomethyl-isoquinoline lle in 50 ml of absolute THF are added dropwise to this solution at -78°C, the mixture stirred for a further 1 h at -78°C and then allowed to rise to RT
overnight. 100 ml of water are then added, the aqueous phase separated and extracted 3 times with 50 ml portions of ethyl acetate. The combined organic phases are dried with MgS04, filtered and the solvent removed under a vacuum. The residue is purified chromatographically (silica gel, hexane/ethyl acetate 5:1). 24% of the desired product 1,2,3,4-tetrahydro-1-oxo-3-(2-diethylphosphonoethyl)-isoquinoline llf are obtained.
N-H, d~,~ 2,3.4-tetrah~dro-1-oxo-3-~2-dieth, ly~hosnhonoethy~-isoduinoline~llg) 5.36 mmol of 1,2,3,4-tetrahydro-1-oxo-3-(2-diehtylphosphonoethyl)-isoquinoline 6 are dissolved in 30 ml of absolute acetone and cooled to 0°C. A solution of 17.15 mmol of dimethyldioxirane is then added dropwise and the mixture stirred for 30 min at 0°C. The solvent is removed under a vacuum and the residue purified chromatographically (silica gel, hexane/ethyl acetate 4:1). 33% of the product N-hydroxy-1,2,3,4-tetrahydro-1-oxo-3-(2-diethylphosphonoethyl)-isoquinoline llg are obtained.
N-Hydrox,~.2.3.4-tetrahvdro-1-oxo-3-(2-phosphonoeth_ lv_l-isoduinoline f,llh) 1.77 mmol ofN-hydroxy-1,2,3,4-tetrahydro-1-oxo-3-(2-diethylphosphonoethyl)-isoquinoline llg are dissolved in 15 ml of absolute CHZCl2 under argon and cooled to 0°C. 10 mmol of trimethylbromosilane are then added dropwise from a syringe, the mixture stirred for a further 1 h at 0°C and then overnight at RT. The solvent is then removed under a vacuum, the residue redissolved in 20 ml of water and stirred for 1 h at RT. 15 ml of CHC13 are then added and the organic phase separated. The aqueous phase is extracted twice more with 10 ml portions of CHC13 and the mixture evaporated under a vacuum. The residue is purified chromatographically (silica gel, H20/methanol 1:1). The desired product is obtained at a yield of 54%.
Example 12:
The antimalarial activity of the substances stated in Table I was determined using in vitro cultures of the causative organism of malaria, Plasmodium falciparum. The roman numerals refer to the particularly preferred compounds stated on pages [sic] to [sic].
200 ~l of an asynchronous Plasmodium falciparum culture with a 0.4% blood parasite content and a haematocrit of 2% were loaded into each of the wells of a 96 well microtitre plate. A serial dilution series of the compounds was then prepared in steps of three between concentrations of 100 and 1 ~mol 1-1. The plates are incubated at 37°C, 3% C02 and 5%
02 over a period of 48 hours. 30 pl of medium supplemented with 27 ~Ci ml-1 of [3H]-hypoxanthine were then added to each well. After 24 hours' incubation, the parasites were harvested by filtration through glass fibre filters and the incorporated radioactivity was measured.
Inhibition of parasite growth was measured as the percentage inhibition of tritium incorporation relative to a comparison without the substance. The results for the three different concentrations are stated in Table I.
Ta le I
SubstanceR5 A Form used 100 wM 10 p,M 1 ~.M
inhibitioninhibitioninhibition (%) (%) (%) I H C2H4 Na salt 98 98 98 III H CHZ Na salt 96 98 63 II H CHZ Na salt 98 87 59 I H CH2CHOH Na salt 98 97 78 X H CHZ Na salt 89 80 0 X H CHZ Na salt 98 97 98 III H CHZ Na salt 98 98 82 pyrrole ring is NH2-substituted in osition VII H CZH4 Na salt 98 98 98 ~:XXI H CZH4 Na salt 97 73 53 XXVIII H CZH4 Na salt 98 97 82 ~!:XXVIIIH CZH4 Na salt 92 78 30 N-substituted in osition XXXVI H C2H4 Na salt 95 80 37 in position Example 13 The antibacterial action of the substances stated in Table II was determined.
The roman numerals refer to the particularly preferred compounds stated on pages 5 to 8.
A dilution series comprising the concentrations 500, 100, 50 and 10 ~,mol l~l of the individual compounds in LB medium is introduced into 5 culture microtubes in a volume of 0.5 ml. Each of the microtubes was inoculated with 10 ~1 of an overnight culture of E. coli K12 and shaken overnight at 37°C. Bacterial growth was assessed on the basis of the turbidity of the medium.
The minimum concentration causing inhibition of bacterial growth was determined (minimum inhibition concentration, MIC).
Antibacterial activity with regard to P. aeruginosa was determined in the same manner. The results are shown in Table II.
Table II
SubstanceR5 A Form used E. coli P. aeruginosa MIC (m ) 10 m /1 I H C2H4 Na salt 2.5 5 III H CH2 Na salt 5 5 pyrrole ring is NH2-substituted in osition 3 II H CH2 Na salt 10 5 I H CHZCHOH Na salt 2.5 1.25 X H CH2 Na salt 1.25 1.25 X ~ H CH2 Na salt 10 20 III i H CHz Na salt 1.25 10 VII H CZH4 Na salt 10 40 I~:XXI H C2H4 Na salt 10 1.25 XXVIII H CzH4 Na salt 5 5 XXXVIII H C2H4 Na salt 20 80 N-substituted in osition 5 XXXVI H CZH4 Na salt 40 20 in position
Claims (12)
1. Organophosphorus compounds of the general formula (I) wherein A is selected from the group which consists of a (C1-9) alkylene residue, which may comprise one or more double bonds and may be substituted with hydroxy, halogen, amino, oxo groups with branched or unbranched C1-9 alkyl groups and C2-9 alkenyl groups, wherein the C1-9 alkyl groups and C2-9 alkenyl groups may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, -C-O-C- and -C-N-C-, wherein the carbon atoms of -C-O-C- and -C-N-C- may be substituted with an alkyl having up to 7 carbon atoms or hydroxy groups, or in which A is of the following formula (II):
wherein one or more of the carbon atoms selected from the group C3, C4, C5, together with their substituents, may also be absent, and at least one substituent present in the range from B1 to B10 is a C3-8-cycloalkyl-(C0-9)-alkyl group, wherein both the cycloalkyl group and the C0-9 alkyl group may comprise one or more double bonds and one or two carbon atoms of the cycloalkyl group may be replaced by nitrogen, oxygen or sulfur atoms, and wherein both the cycloalkyl group and the alkyl group may be substituted with hydroxy, halogen, amino, oxo groups with branched or unbranched C1-9 alkyl groups and C2-9 alkenyl groups, wherein the C1-9 alkyl groups and C2-9 alkenyl groups may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, and the remaining substituents B1 to B10 present are selected from the group which consists of hydrogen, hydroxy, halogen, amino groups, C1-26 alkyl residues, C1-26 alkoxy residues, C1-26-alkoxy-C1-26-alkyl residues or both substituents of a C atom together form an oxo group, wherein each C1-26 alkyl residue and each C1-26 alkoxy residue may be branched or unbranched and be saturated or unsaturated with one or more double bonds and may be substituted with hydroxy, amino, halogen and oxo groups, in which R1 is selected from the group which consists of 5- and 6-membered heterocycles with at least one ring nitrogen atom or a polycyclic carbon with at least one of these heterocycles, wherein at least one of these nitrogen atoms belongs to a hydroxamic acid group or a hydroxamic acid ester group, and may be saturated or unsaturated with one or more double or triple bonds and may thus also be aromatic and may be substituted with hydroxy, halogen, amino, oxo groups and with branched or unbranched C1-9 alkyl groups and C2-9 alkenyl groups, wherein the C1-9 alkyl groups and C2-9 alkenyl groups may be saturated or unsaturated with one or more double or triple bonds and may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, wherein the nitrogen atom of the hydroxamic acid group or hydroxamic acid ester group is substituted with OR5 and R5 is selected from the group which consists of hydrogen, substituted and unsubstituted C1-9 alkyl, substituted and unsubstituted hydroxy-C1-9-alkyl, substituted and unsubstituted C1-9 alkenyl, substituted and unsubstituted C1-9 alkynyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic residue, in which R3 and R4 are identical or different and are selected from the group which consists of hydrogen, substituted and unsubstituted C1-26 alkyl, hydroxy-C1-26-alkyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted aralkyl, substituted and unsubstituted C1-26 alkenyl, substituted and unsubstituted C1-26 alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, halogen, OX3 and OX4, wherein X3 and X4 are identical or different and are selected from the group which consists of hydrogen, substituted and unsubstituted C1-26 alkyl, substituted and unsubstituted hydroxy-C1-26-alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted C1-26 alkenyl, substituted and unsubstituted C1-26 alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, a silyl, a canon of an organic and inorganic base, in particular a metal of main groups I, II or III of the periodic system, ammonium, substituted ammonium and ammonium compounds derived from ethylenediamine or amino acids, and the pharmaceutically acceptable salts, esters and amides thereof and salts of the esters.
wherein one or more of the carbon atoms selected from the group C3, C4, C5, together with their substituents, may also be absent, and at least one substituent present in the range from B1 to B10 is a C3-8-cycloalkyl-(C0-9)-alkyl group, wherein both the cycloalkyl group and the C0-9 alkyl group may comprise one or more double bonds and one or two carbon atoms of the cycloalkyl group may be replaced by nitrogen, oxygen or sulfur atoms, and wherein both the cycloalkyl group and the alkyl group may be substituted with hydroxy, halogen, amino, oxo groups with branched or unbranched C1-9 alkyl groups and C2-9 alkenyl groups, wherein the C1-9 alkyl groups and C2-9 alkenyl groups may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, and the remaining substituents B1 to B10 present are selected from the group which consists of hydrogen, hydroxy, halogen, amino groups, C1-26 alkyl residues, C1-26 alkoxy residues, C1-26-alkoxy-C1-26-alkyl residues or both substituents of a C atom together form an oxo group, wherein each C1-26 alkyl residue and each C1-26 alkoxy residue may be branched or unbranched and be saturated or unsaturated with one or more double bonds and may be substituted with hydroxy, amino, halogen and oxo groups, in which R1 is selected from the group which consists of 5- and 6-membered heterocycles with at least one ring nitrogen atom or a polycyclic carbon with at least one of these heterocycles, wherein at least one of these nitrogen atoms belongs to a hydroxamic acid group or a hydroxamic acid ester group, and may be saturated or unsaturated with one or more double or triple bonds and may thus also be aromatic and may be substituted with hydroxy, halogen, amino, oxo groups and with branched or unbranched C1-9 alkyl groups and C2-9 alkenyl groups, wherein the C1-9 alkyl groups and C2-9 alkenyl groups may be saturated or unsaturated with one or more double or triple bonds and may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, wherein the nitrogen atom of the hydroxamic acid group or hydroxamic acid ester group is substituted with OR5 and R5 is selected from the group which consists of hydrogen, substituted and unsubstituted C1-9 alkyl, substituted and unsubstituted hydroxy-C1-9-alkyl, substituted and unsubstituted C1-9 alkenyl, substituted and unsubstituted C1-9 alkynyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic residue, in which R3 and R4 are identical or different and are selected from the group which consists of hydrogen, substituted and unsubstituted C1-26 alkyl, hydroxy-C1-26-alkyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted aralkyl, substituted and unsubstituted C1-26 alkenyl, substituted and unsubstituted C1-26 alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, halogen, OX3 and OX4, wherein X3 and X4 are identical or different and are selected from the group which consists of hydrogen, substituted and unsubstituted C1-26 alkyl, substituted and unsubstituted hydroxy-C1-26-alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted C1-26 alkenyl, substituted and unsubstituted C1-26 alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, a silyl, a canon of an organic and inorganic base, in particular a metal of main groups I, II or III of the periodic system, ammonium, substituted ammonium and ammonium compounds derived from ethylenediamine or amino acids, and the pharmaceutically acceptable salts, esters and amides thereof and salts of the esters.
2. Compound according to claim 1, characterised in that the organophosphorus compounds are of the formula (III) wherein R3 is preferably hydrogen, methyl, ethyl, an amide residue and X4 is selected from the group which consists of hydrogen, sodium, potassium, methyl, ethyl.
3. Compound according to claim 1, characterised in that the organophosphorus compounds are of the formula (IV) wherein X3 and X4 are identical or different and are selected from the group which consists of hydrogen, a (C1-3) alkyl, a metal of main groups I, II or III of the periodic system, ammonium, substituted ammonium, or ammonium compounds derived from ethylenediamine or amino acids.
4. Compound according to claim 3, characterised in that X3 and X4 are identical or different and are selected from the group which consists of hydrogen, sodium, potassium, methyl, ethyl.
5. Compound according to one of the preceding claims, characterised in that A
is selected from the group which consists of alkylene, alkenylene, hydroxyalkylene and oxoalkylene.
is selected from the group which consists of alkylene, alkenylene, hydroxyalkylene and oxoalkylene.
6. Compound according to claim 5, characterised in that A is selected such that three atoms are present between the nitrogen atom of the heterocyclic group and the phosphorus atom, wherein A is preferably a methylene, hydroxymethylene, ethylene, ethenylene or hydroxyethylene.
7. Compound according to one of claims 1 to 3, characterised in that the compound is selected from the group of compounds which consists of and the corresponding phosphinic acid and phosphinoyl derivatives, wherein R5 is defined as in claim 1.
Use of a compound according to one of claims 1 to 7 as a fungicide, bactericide or herbicide in plants.
9. Use according to one of claims 1 to 7 for the treatment of infections caused by bacteria, viruses, fungi or uni- or multicellular parasites.
10. Use according to claim 9 for the prevention and treatment of infections caused by unicellular parasites, namely the causative organisms of malaria, sleeping sickness, Chagas' disease, toxoplasmosis, amoebic dysentery, leishmaniases, trichomoniasis, pneumocystosis, balantidiasis, cryptosporidiosis, sarcocytosis, acanthamoebosis, naeglerosis, coccidiosis, giardiasis and lambliasis.
11. Pharmaceutical preparation for the therapeutic and prophylactic treatment of infectious processes, characterised in that the preparation contains an active content of at least one organophosphorus compound according to one of claims 1 to 7 together with a pharmaceutically acceptable excipient.
12. Pharmaceutical preparation according to claim 11, characterised in that the preparation contains another pharmaceutical active substance.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19859426A DE19859426A1 (en) | 1998-12-22 | 1998-12-22 | Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections |
DE19859426.7 | 1998-12-22 | ||
PCT/EP1999/010274 WO2000037477A1 (en) | 1998-12-22 | 1999-12-22 | Organo-phosphorus compounds and their utilization |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2356289A1 true CA2356289A1 (en) | 2000-06-29 |
Family
ID=7892237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002356289A Abandoned CA2356289A1 (en) | 1998-12-22 | 1999-12-22 | Organophosphorous compounds and use thereof |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1140952B1 (en) |
JP (1) | JP2002533350A (en) |
KR (1) | KR20010089670A (en) |
CN (1) | CN1331695A (en) |
AP (1) | AP2001002168A0 (en) |
AT (1) | ATE248846T1 (en) |
AU (1) | AU2538500A (en) |
BR (1) | BR9916466A (en) |
CA (1) | CA2356289A1 (en) |
CZ (1) | CZ20012284A3 (en) |
DE (2) | DE19859426A1 (en) |
DK (1) | DK1140952T3 (en) |
EA (1) | EA200100689A1 (en) |
ES (1) | ES2204189T3 (en) |
HU (1) | HUP0104866A3 (en) |
IL (1) | IL143470A0 (en) |
MX (1) | MXPA01006456A (en) |
NO (1) | NO20013085L (en) |
OA (1) | OA11730A (en) |
PL (1) | PL349045A1 (en) |
PT (1) | PT1140952E (en) |
SK (1) | SK8892001A3 (en) |
TR (1) | TR200101832T2 (en) |
WO (1) | WO2000037477A1 (en) |
ZA (1) | ZA200104443B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002078714A1 (en) * | 2001-03-30 | 2002-10-10 | Jomaa Pharmaka Gmbh | Formulations which are resistant to gastric juice and are used to apply anti-infective compounds inhibiting the 2-c-methylerythrose-4 metabolic pathway, and the salts and esters of the same |
US8586618B2 (en) | 2006-10-06 | 2013-11-19 | Biosignal Limited | Furanone compounds and lactam analogues thereof |
EP2018864A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
CN101977610B (en) | 2008-01-25 | 2012-05-16 | 奇默里克斯公司 | Methods of treating viral infections |
PT2534150T (en) | 2010-02-12 | 2017-05-02 | Chimerix Inc | Methods of treating viral infection |
CA2797601A1 (en) | 2010-04-26 | 2011-11-10 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
AU2015314287B2 (en) | 2014-09-12 | 2019-04-18 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
EP3268376B1 (en) * | 2015-03-09 | 2022-02-09 | Board of Regents, The University of Texas System | Enolase inhibitors and methods of treatment therewith |
GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4206156A (en) * | 1976-07-27 | 1980-06-03 | Fujisawa Pharmaceutical Company, Limited | Hydroxyaminohydrocarbonphosphonic acids |
US4693742A (en) * | 1983-12-20 | 1987-09-15 | Rohm And Hass Company | Herbicidal hydroxyamino phosphonic acids and derivatives |
JPS61106504A (en) * | 1984-10-30 | 1986-05-24 | Teijin Ltd | Herbicide |
AP2000001942A0 (en) * | 1998-04-14 | 2000-12-31 | Jomaa Hassan | Use of organophosphoric compounds for the therapeutic and preventative treatment of infections. |
-
1998
- 1998-12-22 DE DE19859426A patent/DE19859426A1/en not_active Withdrawn
-
1999
- 1999-12-22 PT PT99968365T patent/PT1140952E/en unknown
- 1999-12-22 JP JP2000589547A patent/JP2002533350A/en active Pending
- 1999-12-22 TR TR2001/01832T patent/TR200101832T2/en unknown
- 1999-12-22 IL IL14347099A patent/IL143470A0/en unknown
- 1999-12-22 SK SK889-2001A patent/SK8892001A3/en unknown
- 1999-12-22 ES ES99968365T patent/ES2204189T3/en not_active Expired - Lifetime
- 1999-12-22 KR KR1020017007908A patent/KR20010089670A/en not_active Application Discontinuation
- 1999-12-22 HU HU0104866A patent/HUP0104866A3/en unknown
- 1999-12-22 DE DE59906907T patent/DE59906907D1/en not_active Expired - Fee Related
- 1999-12-22 WO PCT/EP1999/010274 patent/WO2000037477A1/en not_active Application Discontinuation
- 1999-12-22 PL PL99349045A patent/PL349045A1/en not_active Application Discontinuation
- 1999-12-22 BR BR9916466-3A patent/BR9916466A/en not_active IP Right Cessation
- 1999-12-22 CN CN99814915A patent/CN1331695A/en active Pending
- 1999-12-22 MX MXPA01006456A patent/MXPA01006456A/en unknown
- 1999-12-22 EA EA200100689A patent/EA200100689A1/en unknown
- 1999-12-22 CZ CZ20012284A patent/CZ20012284A3/en unknown
- 1999-12-22 AP APAP/P/2001/002168A patent/AP2001002168A0/en unknown
- 1999-12-22 OA OA00100153A patent/OA11730A/en unknown
- 1999-12-22 AT AT99968365T patent/ATE248846T1/en not_active IP Right Cessation
- 1999-12-22 CA CA002356289A patent/CA2356289A1/en not_active Abandoned
- 1999-12-22 AU AU25385/00A patent/AU2538500A/en not_active Abandoned
- 1999-12-22 DK DK99968365T patent/DK1140952T3/en active
- 1999-12-22 EP EP99968365A patent/EP1140952B1/en not_active Expired - Lifetime
-
2001
- 2001-05-30 ZA ZA200104443A patent/ZA200104443B/en unknown
- 2001-06-21 NO NO20013085A patent/NO20013085L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA01006456A (en) | 2002-04-24 |
NO20013085D0 (en) | 2001-06-21 |
HUP0104866A2 (en) | 2002-06-29 |
NO20013085L (en) | 2001-08-22 |
BR9916466A (en) | 2001-09-25 |
AP2001002168A0 (en) | 2001-06-30 |
ES2204189T3 (en) | 2004-04-16 |
HUP0104866A3 (en) | 2002-08-28 |
DK1140952T3 (en) | 2004-01-12 |
DE59906907D1 (en) | 2003-10-09 |
PT1140952E (en) | 2004-02-27 |
ATE248846T1 (en) | 2003-09-15 |
DE19859426A1 (en) | 2000-07-06 |
CN1331695A (en) | 2002-01-16 |
TR200101832T2 (en) | 2001-12-21 |
IL143470A0 (en) | 2002-04-21 |
EP1140952A1 (en) | 2001-10-10 |
JP2002533350A (en) | 2002-10-08 |
EA200100689A1 (en) | 2001-12-24 |
ZA200104443B (en) | 2002-01-14 |
KR20010089670A (en) | 2001-10-08 |
OA11730A (en) | 2005-05-12 |
PL349045A1 (en) | 2002-07-01 |
AU2538500A (en) | 2000-07-12 |
WO2000037477A1 (en) | 2000-06-29 |
EP1140952B1 (en) | 2003-09-03 |
CZ20012284A3 (en) | 2001-10-17 |
SK8892001A3 (en) | 2001-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002511406A (en) | Use of organophosphorus compounds for the treatment and prevention of infectious diseases | |
AU754165B2 (en) | Phosphorous organic compounds and their use | |
AU771339B2 (en) | Use of compounds with a nitrogen-oxygen heterocycle | |
CA2356289A1 (en) | Organophosphorous compounds and use thereof | |
US6534489B1 (en) | Organophosphorus compounds and the use thereof | |
US6753324B2 (en) | Phosphorous organic compounds and their use | |
AU5981199A (en) | Use of organophosphorous compounds for producing medicaments for the therapeuticand prophylactic treatment of infections or as a fungicide, bactericide or herb icide for plants | |
US20030144249A1 (en) | Use of organophosphorous compounds for producing a medicament for treating infections | |
CA2360661A1 (en) | Use of phosphororganic compounds for the prophylactic and therapeutical treatment of infections | |
WO2000017212A1 (en) | Organophosphorous compounds and use thereof | |
AU2003261554A1 (en) | Organophosphorus containing preparations and applications therefor | |
MXPA01000488A (en) | Phosphorous organic compounds and their use | |
MXPA01005208A (en) | Organophosphorous compounds and the use thereof | |
MXPA01002979A (en) | Use of organophosphorous compounds for producing medicaments for the therapeutic and prophylactic treatment of infections or as a fungicide, bactericide or herbicide for plants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |